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ABSTRACT  
  
The normal physiological response to bacterial infection or wounding with threat 
of infection, termed inflammation, has been shown to be dysregulated in certain 
human diseases including (but not limited to): idiopathic pulmonary fibrosis, acute 
lung injury, arthritis and glomerulonephritis. The earliest arriving and most 
abundant cell responding to an inflammatory stimulus is the neutrophil 
granulocyte. It has been shown that under inflammatory conditions neutrophil 
granulocytes have extended longevity, enhanced responsiveness and upregulated 
activation parameters. In the setting of non-infective, or prolonged, ineffectually-
cleared infective disease where resolution of inflammation does not occur then 
neutrophil granulocytes may cause tissue damage which is mediated by excessive, 
misdirected exocytosis of toxic granule contents or by spillage of the same 
products from necrotic or netotic cell carcasses that have lost membrane integrity. 
A key process in the resolution of inflammation is the induction of apoptosis in 
recruited neutrophils following a successful response to an inflammatory stimulus. 
Cellular signalling from apoptotic cells and from professional phagocytes that have 
ingested apoptotic cells has been shown to favour resolution of inflammation and 
restoration of tissue homeostasis. Additionally, the removal of key inflammatory 
cells in a highly regulated, non-phlogistic fashion robustly assists the resolution 
process. 
 
Cyclin-dependent kinase (CDK) inhibitor drugs are being developed as anti-cancer 
agents as it is hypothesized that they should interfere with the enhanced cell-
cycling ability (increased proliferative capacity and extended longevity) which is 
such a key feature of cancer cell biology. The CDKs that drive the cell cycle are 
CDKs 1, 2, 4 and 6 and consequently agents were designed to have enhanced 
specificity for these targets. CDK inhibitor drugs target the ATP-binding domain 
of CDKs and as a result usually have activity against more than one CDK. The 
CDK inhibitor drug, R-roscovitine which targets CDKs 2, 5, 7 and 9 was shown to 
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promote neutrophil apoptosis and consequently resolution of inflammation. This 
thesis aims to investigate the mechanism by which apoptosis is induced in 
neutrophil granulocytes by CDK inhibitor drugs. 
 
The first experimental chapter of this thesis explores in detail the time-course and 
active concentration range of CDK inhibitor drugs in comparison to known 
promoters and inhibitors of neutrophil apoptosis. It then dissects the apoptotic 
machinery which is responsible for the effects of CDK inhibitor drugs before 
investigating their capacity to promote apoptosis even in the presence of survival 
mediators relevant to the context of inflammatory disease. Flow-cytometry, light 
and confocal microscopy  as well as western blotting for caspases, mitochondrial 
dissipation assay, fluorometric caspase assay and the detection of DNA laddering 
demonstrate that CDK inhibitor drugs promote classical neutrophil apoptosis  by 
the intrinsic pathway  and show similar kinetics of apoptosis induction to drugs 
that inhibit transcription. 
 
The second experimental chapter investigates the key neutrophil survival protein 
and bcl-2 homologue Mcl-1. By flow cytometry, western blotting and RT-PCR it is 
demonstrated that Mcl-1 is down-regulated at the level of transcription and that 
this occurs even in the presence of inflammatory mediators that would normally 
promote neutrophil survival. Additionally, it is shown that pro-apoptotic bcl-2 
homologues are affected to a lesser degree suggesting an imbalance of bcl-2 
proteins is caused by effects at a transcriptional level mediated by CDK inhibitor 
drugs. 
 
The third experimental chapter identifies CDKs and their binding partner cyclins in 
neutrophil granulocytes and investigates the impact of CDK inhibitor drugs on 
CDK protein levels and cellular distribution by differential lysis and western 
blotting as well as by confocal microscopy. The key transcriptional enzyme RNA 
polymerase II is also identified and the effect of CDK inhibitor drugs on 
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phosphorylation of this enzyme is documented. Western blotting and confocal 
microscopy demonstrate the presence of key CDKs 2, 5, 7, 9 and cyclin binding 
partners of CDKs 7 and 9. It is shown that the phosphorylation of RNA 
polymerase II mediated by CDKs 7 and 9 is inhibited by CDK inhibitor drugs. 
This suggests that a key mechanism by which neutrophil apoptosis is induced by 
CDK inhibitor drugs is the inhibition of transcription of key proteins and suggests 
that neutrophils require survival proteins for functional longevity. 
 
The fourth experimental chapter addresses the production and use of HIV-tat 
dominant negative CDK 7 and 9 proteins to knockdown CDKs 7 and 9 in 
neutrophil granulocytes in vitro to provide a molecular biology surrogate for the 
pharmacological data already presented.  The cloning, production, purification and 
use of HIV-tat dominant negative CDK proteins are described. 
 
The final chapter describes the use of a more specific pharmacological inhibitor of 
CDKs 7 and 9, DRB, in the mouse bleomycin lung injury model. Resolution of 
inflammation by a compound specifically targeting CDKs 7 and 9 is described.  
 
This thesis identifies CDKs 7 and 9 as key targets of CDK inhibitor drugs in 
neutrophilic inflammation. It shows these drugs acting at the level of transcription 
to drive neutrophil apoptosis by exploiting the unique dependency of neutrophils 
on the short-lived survival protein Mcl-1. In so doing the presence of functional 
and essential transcriptional machinery is identified in neutrophils and the 
transcriptional profile of resting, stimulated and inhibited neutrophils is delineated. 
These findings suggest novel approaches to the pharmacological promotion of 
resolution of inflammation and indicate key new targets for rational drug design. In 
future, it will be important to further characterize the effects of CDK inhibitor 
drugs on other cell-types including epithelial cells, fibroblasts and mononuclear 
cells. This information should prove important to the continued investigation of 
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CDK inhibitor drugs in resolution of inflammation and also to the ongoing 
experimental trial of these drugs in idiopathic pulmonary fibrosis.   
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1 Introduction 
 
In this chapter I aim to review the published literature on inflammation, granulocytes 
(with specific regard to neutrophils and apoptosis), the survival protein myeloid cell 
leukaemia (Mcl)-1, cyclin dependent kinases (CDKs) and the bleomycin lung injury 
model. This information will provide a background to the major themes investigated in 
the thesis as a whole. 
 
1.1 Lung Inflammation and Immunity 
 
1.1.1 Structural immune defence in the lung 
 
The respiratory mucosa is the largest body surface area to be exposed to and require 
defence from the external environment. It is not surprising, therefore, that a robust, 
vigorous and rapidly responsive immune defence system has evolved over millennia of 
exposure to diverse and increasingly sophisticated microbes. Additionally, air-borne 
irritant particulate matter (PM) such as allergens, biopersistent fibres such as asbestos 
and combustion-derived nanoparticles (e.g. diesel exhaust particles) must be dealt with 
in order to maintain a high level of function (Donaldson et al. 2005). The architecture of 
the respiratory system provides a first layer of defence against air-borne micro-
organisms and PM effectively blocking the lower airways from anything greater than 
5m in diameter (Donaldson et al. 2005). Inhaled air is warmed and filtered through the 
nasal hair and nasopharyngeal passages before negotiating the larynx (which ordinarily 
prevents any intrusion from matter destined for the gastrointestinal system and allows 
phonation) down the large tubular trachea and into the upper bronchi. The initially large 
bronchial airways repeatedly bifurcate until they reach an extremely narrow gauge and 
form alveoli at which point gas exchange with the capillary network that lines the 
alveolar wall becomes possible. Pseudo-stratified columnar ciliated epithelium 
predominates in the trachea and bronchi forming the muco-ciliary escalator. Any 
intruding micro-organism or misplaced particulate matter slipping out of the air-stream 
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in the upper airways is trapped in the muco-ciliary escalator and forced up and out by 
the regular beating motion of the respiratory cilia (Leitch et al. 2008). 
 
1.1.2 Innate immune defence in the lung 
 
Should these initial defences be breached then an intruder must be adapted to survive an 
uninviting but non-specific chemical milieu including lysozyme, endogenous 
antimicrobial agents, adverse pH, Immunoglobulin (Ig) A and surfactants (Seaton 2000). 
Should this fail then a more goal-directed system is brought on-line. The respiratory 
mucosa has developed a sensitive and specific recognition strategy which allows it to 
identify microbe specific molecular patterns such as lipopolysaccharide (LPS), 
lipotechoic acid, formylated peptides, flagellin and non-methylated DNA. Once detected 
these galvanise resident alveolar macrophages and initiate a variety of pro-inflammatory 
pathways that instigate the classical elements of inflammation (calor (heat), rubor 
(redness), dolor (pain), tumor (swelling) and loss of function as described by Celsus and 
Virchow) driven by increased vascular permeability leading to a proteinaceous infiltrate 
and leucocyte recruitment. The Toll-like receptors (TLRs) mediate most of this form of 
recognition and though they each have a specific role TLRs can function in unison to 
expand their powers of recognition (Sabroe et al. 2007b). Resident alveolar macrophages 
deal with the majority of insults that trigger this alert system but if they are 
overwhelmed recruited leucocytes including granulocytes lend assistance. 
 
The invading microbes are rendered highly recognisable to recruited granulocytes by 
comprehensive opsonisation mediated by both complement-dependent and independent 
means. They are then ingested (phagocytosed) by neutrophils or, if they should prove 
resistant to this because of size or learned subversion are subjected to a chemical 
onslaught (exocytosis) as neutrophils forcibly externalize toxic granule substances such 
as lactoferrin and myeloperoxidase (MPO) as well as reactive oxygen species (ROS) 
(Rossi et al. 2007;Serhan et al. 2007). A subset of neutrophils (and other leucocytes 
potentially (von Kockritz-Blickwede et al. 2008)) employ web-like neutrophil extra-
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cellular traps (NETs) to ensnare and kill resistant organisms but must themselves die in 
the process (Brinkmann et al. 2004). In beneficial neutrophil-dominant inflammation the 
organisms or foreign particles are detected and phagocytosed by neutrophils which then 
undergo an organized, non-provocative programmed-cell death (apoptosis) which 
promotes their own recognition and removal by macrophages or dendritic cells. At this 
point the interface between the innate and adaptive immune systems occurs as 
macrophages, which migrate to the lympho-reticular system following ingestion of 
apoptotic neutrophils, act as antigen presenting cells (APCs) allowing the lymphocyte 
population to complete the resolution and remembrance process. The next time that 
particular organism is encountered a pre-prepared, specific response should be available 
to ensure it has less opportunity to make an impact (Nathan 2006).  
 
The lungs are the arena for another type of granulocyte-driven inflammatory response. 
Eosinophils are present in larger numbers within the lungs of asthma sufferers and are 
recruited in greater numbers in response to sensitizing allergens such as pollen, house 
dust mite and animal dander. This response has no obvious beneficial effects and it is 
still unclear why it should occur. The eosinophil is a useful and active defender against 
parasitic infection and has an armament specific to that end. It has been noted that since 
parasitic infections have been largely eradicated in Western society the incidence of this 
abnormal eosinophil response (termed allergy or atopy) has increased and it seems that 
eosinophilic inflammation occurs almost as an outlet for redundancy (Leitch et al. 
2008;Seaton 2000). 
 
1.1.3 Acute and chronic inflammation and disease 
 
Inflammation is part of the beneficial anti-microbial, immune defence system that has 
been honed and conserved by evolution over millions of years (Marchalonis et al. 2002). 
The system has become increasingly sophisticated because of the breadth of micro-
organisms the human body has encountered and because of the mechanisms these 
organisms have evolved to enable evasion of its front-line defences. Ideally, following 
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prompt detection of a micro-organism by immune mechanisms, an inflammatory 
reaction should contain and destroy the organism before it multiplies, spreads, becomes 
established or causes harm.  Streptococcal lobar pneumonia can be paradigmatic of a 
beneficial inflammatory response as despite a massive, neutrophil-dominant 
inflammatory reaction, resolution of inflammation occurs (and did so in the majority of 
cases in the pre-antibiotic era) with no pathological damage (Haslett 1999). Self-
regulation and limitation are the key, final components of the response as the system 
must actively drive resolution of inflammation to restore tissue homeostasis (Bystrom et 
al. 2008;Nathan 2006;Rajakariar et al. 2008). There is now abundant evidence that 
inflammatory cell (especially neutrophil) programmed cell death (or apoptosis, initially 
described by Kerr et al 1972) followed by non-phlogistic clearance of apoptotic cells by 
phagocytes such as macrophages plays a key role in ensuring efficient (and in the 
majority complete) resolution of inflammation. 
 
Inflammatory diseases arise for a number of reasons; some of which are not fully 
understood. If the inflammatory system cannot destroy organisms or foreign particles 
(such as asbestos fibre and silica) it malfunctions, initiating excessive or prolonged 
inflammatory reactions which are likely to lead to irreversible fibrosis and scarring. 
Alternatively, reactions may be sited where none are apparently needed or self-antigens 
become recognised as foreign. In these settings chronic inflammatory and autoimmune 
disease may supervene. The outcome of excessive or persistent (chronic) inflammation 
is tissue damage caused by the secretion or loss of histotoxic products from over-
activated, under-regulated or frankly necrotic inflammatory cells (Fadok et al. 
1998;Rossi et al. 2007;Voll et al. 1997). The spectrum of inflammatory disease includes 
all the major organ systems and, increasingly, we are recognising a role for 
inflammation in other disease processes such as cancer (Coussens et al. 2002;Hussain et 
al. 2007), neurological disorders (Gilgun-Sherki et al. 2006), atheroma (Hansson et al. 
2006) and menstrual dysfunction (Critchley et al. 2001). There are many similarities 
between inflammatory diseases but also important differences which may occur even 
within the same organ system. For example, in lung–based disease, inflammation in 
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subsets of asthma is eosinophil-dominant while in chronic obstructive pulmonary 
disease (COPD) and idiopathic pulmonary fibrosis (IPF) it is arguably neutrophil-
dominant (Barnes 2007;Kinder et al. 2008;Nair et al. 2009;Walsh 2000) (Figure 1). 
 
1.1.4 Resolution of inflammation 
 
The resolution phase of inflammation has emerged as a key target for the development 
of novel anti-inflammatory therapies. The key elements required for resolution of 
inflammation to proceed towards tissue homeostasis have been defined as: removal of 
the inciting stimulus, controlled death (usually by apoptosis) of inflammatory leucocytes 
and removal of dead cells and debris by phagocytic cells (Figure 1) (Rossi et al. 
2008;Serhan et al. 2007). This has led to the redesign of some traditional models of 
inflammation and approaches to their investigation (Navarro-Xavier et al. 
2009;Renshaw et al. 2006). Importantly the first fruits of this movement are beginning to 
appear with the likely translation of the compound RX-10045 (based on the lipid 
mediator resolvin) which has multiple pro-resolution properties to clinical usage for the 
treatment of inflammation related dry-eye (www.resolvyx.com). 
 
Many inflammatory diseases are treated with glucocorticosteroid drugs either 
independently or in combination regimens. Glucocorticosteroids work through a variety 
of effects at the molecular level including enhancement of anti-inflammatory and 
repression of pro-inflammatory gene transcription (Newton 2000). They are very 
successful at treating eosinophil-dominant inflammatory disease such as asthma while 
they have had more modest (possibly arguable) success with neutrophil-dominant 
disease. It is now known that glucocorticoids promote eosinophil apoptosis but actually 
prolong neutrophil survival (Heasman et al. 2003;Sivertson et al. 2007;Ward et al. 
1999). The latter effect is, presumably, partially compensated by glucocorticoid-
mediated, enhanced macrophage phagocytosis of apoptotic neutrophils (Heasman et al. 
2003). The development of non-steroidal anti-inflammatory drugs (NSAIDs) and 
subsequently Cyclo-oygenase (COX)-2 specific NSAIDs demonstrate further the 
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difficulties associated with combating a well-established, integral host response such as 
inflammation. NSAIDs work by inhibiting the COX enzymes 1 and 2. COX-1 is 
constitutively expressed in all tissues while COX-2 is largely an inducible enzyme 
subject to various regulatory factors. These enzymes convert arachidonic acid (AA) to 
prostaglandin (PG)-H2 which can be converted by isomerise enzymes to: PGE2, PGF2, 
PGD2, prostacyclin (PGI2), and thromboxane (TX)A2. PGE2 is responsible for some of 
the classic features of inflammation. Traditional NSAIDs inhibited COX-1 and 2 
resulting in side-effects related to sites where COX-1 has constitutive housekeeping 
duties (such as the gut leading to peptic ulcer disease), COX-2 specific inhibitors were 
an attempt to avoid these side-effects. Unfortunately, this specific inhibition appeared to 
confer a greater risk of vascular thrombotic events (such as heart attack and stroke) 
thought to be related to suppression of  PGI2, an atheroprotective agent, but not COX-1 
derived TXA2, a pro-aggregatory and vasoconstrictor mediator.  However, recent work 
has suggested that it may be possible to exploit the anti-inflammatory and pro-resolution 
effects of PGD2 metabolites (Usually responsible for negative feedback inhibition of the 
inflammatory response) which inhibit nuclear-factor-kappa-B (NF-B) and have been 
shown to resolve inflammation in animal models (Lawrence et al. 2002;Rossi et al. 
2007;Ward et al. 1999). Another significant barrier to the successful design of novel 
anti-inflammatory agents has been the complex, multi-layered structural redundancy that 
characterises the inflammatory system. Where one cytokine pathway is knocked down, 
another may compensate and the whole is maintained. Only the removal of a load-
bearing structure will allow collapse and return to homeostasis.    
 
Recent anti-inflammatory approaches have utilised ‘biological therapies’ in the targeting 
of specific cytokines. Anti-tumour necrosis factor (TNF)- therapy is the stand-out 
success of this genre and there is now considerable evidence that TNF- is the sought 
after load-bearing structure in inflammatory disease though other agents are showing 
promise (Feldmann et al. 2002;Williams et al. 2007). It is clear that with such 
redundancy in the system there will always be room for new pharmacological agents that 
have novel targets within the inflammatory system. 

































































Figure 1: Diagram showing both resolution and failure of resolution of eosinophil and neutrophil 
dominant inflammatory processes. Neutrophilia at the respiratory mucosa is resolved by apoptosis 
of infiltrating neutrophils and phagocytic clearance by macrophages. It fails to resolve where 
neutrophils are in great excess or are not efficiently cleared and undergo secondary necrosis 
following apoptosis. This leads to alveolar damage and destruction followed by fibrotic healing. 
Histology on the right hand side of diagram shows neutrophil-dominant inflammation. Eosinophil-
dominant inflammation is resolved by the same mechanisms and fails to resolve for the same 
reasons. The effects of eosinophil-dominant inflammation in the asthmatic airway are depicted and 
an example of the histology demonstrated on the left-hand side of the diagram. Histology was 
kindly provided by Dr William Wallace (Pathology Dept. Edinburgh Royal Infirmary). 
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A critical step in the development of pro-resolution of inflammation agents is 
demonstrating efficacy in animal models.  Our own work, focused on the use of cyclin-
dependent kinase inhibitors to drive granulocyte apoptosis has utilised several murine 
models of inflammation, including passively-induced arthritis, bleomycin-induced lung 
injury and carrageenan-elicited acute pleurisy. Other strategies that have been shown to 
resolve inflammation in animal models include anti-recruitment agents like 
phosphoinositol-3-kinase (PI3K) inhibitors (Pinho et al. 2005;Pinho et al. 2007)/ anti-
interleukin (IL)-5, multi-effect agents like resolvins/lipoxins (Serhan 2007) and designer 
antibody approaches against cytokines (anti-TNF-, anti-IL-6, anti-IL-33, anti IL-17 
(Feldmann et al. 2002)) and integrins (anti-cluster differentiation (CD)11b). Anti-
cytokine therapies have of course translated to use in inflammatory disease but it is 
unlikely that a single therapy will be totally efficacious as there appears to be 
considerable inter-individual heterogeneity in the inflammatory response mounted to 
similar stimuli. 
 
There have been recent exciting innovations in this area with the characterisation and 
utility of the zebrafish model and the increasingly rapid development of novel imaging 
modalities. It is also clear that researchers are beginning to think from a pro-resolution 
perspective in the development of models so that a more uniform set of read-outs of 
efficacy might be achieved. This is particularly evident in a thoughtful paper by Gilroy 
et al., which encourages the use of a mouse peritonitis model which they have 
extensively characterised (Navarro-Xavier et al. 2010). 
The zebrafish model offers the advantages of a readily available in vivo system that can 
be monitored and modified at organism level and dissected at molecular level. The 
system has obvious experimental advantages but also has potential for use as a high-
throughput  pharmacological screening technique (Barros et al. 2008). Renshaw et al 
(Renshaw et al. 2006;Renshaw et al. 2007) have developed a transgenic zebrafish line 
that expresses green fluorescent protein (GFP) under the myeloperoxidase promoter 
allowing them to track all stages of the inflammatory process. In addition they have 
shown that they can alter the course of resolution by introducing the pan-caspase 
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inhibitor N-Benzyloxycarbonyl-Val-Ala-Asp(O-Me)fluoromethyl ketone (zVAD-fmk) 
to prevent apoptosis and hence resolution. Conversely they have shown resolution of 
inflammation with the CDK inhibitor drug, R-roscovitine. 
 
The benefit of inducing neutrophil apoptosis during pneumococcal meningitis was 
comprehensively shown by Koedel et al (Koedel et al. 2009). Neurological deficits 
caused by brain tissue damage are a common finding in survivors of severe meningitis 
and are linked to increased longevity of the neutrophil population recruited to the brain. 
Inducing neutrophil apoptosis with R-roscovitine in conjunction with antibiotic therapy 
with ceftriaxone reduced markers of neuronal damage in murine models of 
pneumococcal meningitis. This suggests a possible new strategy for the limitation of 
detrimental neurological side-effects of meningeal infection as well as opening up a 
more general approach to the management of severe infective disease where a causative 
role for neutrophils in disease pathology can be demonstrated. A dual strategy directed 
against both the causative organism and the inflammatory response generated toward 
that organism may be more efficacious than traditional microbe-directed treatment. 
 
Imaging the process of inflammation and its resolution is key to understanding the 
pathophysiology involved and to the development of non-invasive screening tools for 
novel resolution agents. In early experiments using rabbits with experimental upper lobe 
pneumonia, Haslett et al (Jones et al. 1994) showed that 18-fluorodeoxyglucose (18FDG) 
uptake detected by positron emission tomography (PET) could be used as a surrogate for 
neutrophil activity. PET is still at the forefront of inflammation imaging but novel 
techniques are emerging. Imaging modalities that have been shown to be of use in the 
assessment of inflammation include magnetic resonance imaging (MRI), computerised 
tomography (CT), fluorescence molecular tomography (FMT) and intravital fibre-optic 
confocal fluorescence microscopy. In particular MRI has been used to show 
inflammatory neutrophilic response in vivo, in stroke models by measuring MPO 
activity (Breckwoldt et al. 2008). This technique utilises an ‘MPO-sensing agent’ which 
gives an enhanced image compared to gadolinium alone. Additionally the same group 
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used fluorescence molecular tomography (FMT) and intravital confocal microscopy to 
monitor allergic airway inflammation in a mouse model (Cortez-Retamozo et al. 2008). 
In these experiments they used a matrix metalloproteinase (MMP)-sensing probe to 
exploit the unique enzymatic activities of eosinophils at the site of inflammation.  
 
 We have mainly focused on models of lung inflammation including: bleomycin (acute 
and chronic), LPS challenge, carrageenan pleurisy, ovalbumin peritonitis and ovalbumin 
airways challenge. These models are now extensively characterised in the literature and 
allow the assessment of classical inflammatory parameters including inflammatory cell 
subset and number, oedema, lavage protein level, cytokine levels and histological 
appearances. We have shown that zVAD-fmk also prevents resolution of these models 
and have demonstrated resolution of inflammation with CDK inhibitor compounds 
(Rossi et al. 2006). These pro-resolution agents have now been shown to selectively 
drive inflammatory cell apoptosis in vitro (Duffin et al. 2009;Leitch et al. 2010b), to 
resolve inflammation in vivo (measured by the parameters discussed above) (Rossi et al. 
2006) and are about to be used in an experimental medicine trial in inflammatory lung 
disease. The key feature of these agents is their selectivity for inflammatory 
granulocytes and their paucity of effect on macrophage phagocytic clearance of 
apoptotic cells. Thus the benefits of driving apoptosis are retained whilst the deleterious 
potential creation of secondarily necrotic cells is avoided. 
 
The apoptotic neutrophil and the process of cell death exert anti-inflammatory effects 
that have been shown to be of therapeutic value in inflammatory disease models. Our 
own work on the pharmacological manipulation of the apoptotic pathway (e.g., by using 
CDK inhibitor drugs) has resulted in improved disease scores in murine lung fibrosis, 
arthritis and pleurisy models (Rossi et al. 2006). The endogenous inhibitors of CDKs 
have also been a recent focus in macrophage inflammatory responses that have 
demonstrated a role for the endogenous CDK inhibitor p21 (waf1/CIP1) in attenuation 
of LPS-induced cytokine production by murine macrophages in sepsis models (Lloberas 
et al. 2009;Scatizzi et al. 2009). Recently, in a rather radical but nonetheless elegant 
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approach, Savill et al used the systemic addition of apoptotic neutrophils (made 
apoptotic ex vivo) as an anti-inflammatory therapy.  In an LPS-driven mouse model of 
sepsis, enhanced survival of animals receiving apoptotic cells was observed, 
theoretically because apoptotic cells bound LPS and were subsequently cleared by 
macrophages (Ren et al. 2008). In this context, the benefit of apoptotic neutrophils was 
no doubt enhanced by their ability to confer a pro-resolution phenotype on macrophages 
thus curtailing any further inflammatory response.   
 
1.2 Granulocytes, inflammation and inflammatory disease 
 
Granulocytes, the collective name given to neutrophil, eosinophil and basophil 
leucocytes, play a prominent role in immune defence. Neutrophils, being the most 
abundant circulating granulocyte in human blood, play a key role in defence against 
bacterial, fungal and viral infections. Eosinophils account for less than 5% of the 
circulating granulocytes and confer resistance to parasitic invasion as well as being 
involved, with basophils (the third type of granulocyte and numerically scarce), in the 
allergic response. Granulocytes are the foot-soldiers of the inflammatory response and 
are dispatched in large numbers to overcome many challenges to the host organism. 
They are attracted by and follow a concentration gradient of chemotactic stimuli released 
by invading pathogens or tissues under challenge. They migrate from the circulation 
across post-capillary venule endothelial cells (or capillary endothelial cells in pulmonary 
inflammation (Downey et al. 1993)) and employ a formidable armamentarium to 
overcome their adversaries. Granulocytes are named for the numerous granules within 
their cytoplasm. Each of these granules contains a range of toxic products such as 
proteases, lysozyme and lactoferrin. Eosinophils have an armament more specific to the 
killing and digestion of parasites (including major basic protein, eosinophil cationic 
protein and eosinophil peroxidase) but, in asthma, respond to allergens or airway irritants 
in a concerted reaction which involves IgE, mast cells, lymphocytes, basophils and 
smooth muscle.  
 
                                                                                                                                           13
1.2.1 Granulocyte structure and function 
  
The mature granulocytes, neutrophil, eosinophil and basophil are distinguished by 
differences in nuclear morphology, size, granule content and function. They will be 
discussed individually in the following passages. 
 
Neutrophils 
Neutrophils are 12-15m in diameter and account for 70% of the circulating leucocyte 
population which corresponds to approximately 2-7.5x109 neutrophils. They survive in 
the circulation for approximately 7-10 hours but if compelled by inflammatory 
mediators or pharmacological agents can extend their lifespan up to 48h and it has 
recently been suggested that they may survive as long as 5 days in vivo. This population 
turnover requires efficient production by the bone marrow and prompt clearance by that 
same organ with help from the spleen and liver. Neutrophils are possessed of at least 
four different types of granule termed: primary (azurophilic), secondary (specific), 
gelatinase and secretory; each carries a specific arsenal of toxic chemicals that the 
neutrophil uses against non-host elements. The neutrophil is a key effector cell at the 
front-line of immune defence and is efficacious (and life-saving) in the majority of 
instances because of its versatility. Neutrophils prove effective phagocytes because on 
accomplishment of this task they are programmed to die a prompt, quiet and 
importantly, contained, apoptotic death. This limits the time available to internalized 
micro-organisms and prevents hijacking of cellular controls to enable subversion (as is 
thought to occur when Mycobacterium tuberculosis is internalized by macrophages 
(Sundaramurthy et al. 2007)). This timely death also signals larger-scale phagocytes 
such as macrophages, dendritic cells and epithelial cells to initiate a phagocytic 
response. If a neutrophil is unable to phagocytose an invader then it will disgorge 
granule contents into the surrounding environment causing tissue damage and 
amplifying the inflammatory response. This should not be construed as a purely 
detrimental response as it serves to block potential routes of entry for invading 
organisms as tissue damage causes capillary shut-down and collapses lymphatics, sends 
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a strong signal of imperilled defence and allows time for an alternative immune strategy 
to be adopted (Nathan 2006).  
 
Neutrophils may also employ NETs to ensnare and kill resistant organisms. NET 
formation involves the extrusion of fine chromatin and granule coated tendrils that are 
microbicidal and fungicidal. This effort proves fatal to the neutrophil (Brinkmann et al. 
2007). Finally, neutrophils are not just blunt effectors but also smooth operators 
responsible for negotiating the recruitment and education of other arms of the immune 
system. It is becoming appreciated that there is a false division between the innate and 
adaptive immune response systems and that a more realistic model involves a continual 
interplay between constituents of these systems. Neutrophils not only alert APCs and 
lymphocytes to danger but regulate their response to it and in return receive counter-
regulation. Appropriate resolution of an inflammatory immune response is finely 
balanced (Nathan 2006;Serhan et al. 2007).  
It is not surprising given the constant exposure of the vast respiratory mucosa to threat, 
the fine balance of the immune response and the pivotal inflammatory role played by 
neutrophils that neutrophil-dominant inflammation has been implicated in the 
pathophysiology of numerous inflammatory respiratory diseases including: pneumonia, 
COPD, IPF, cystic fibrosis (CF) and adult respiratory distress syndrome (ARDS)/acute 
lung injury (ALI).  
 
Eosinophils 
Eosinophils are approximately 12-17m in size and under normal circumstances account 
for less than 5% of the circulating leucocyte population. They may survive for up to 12 
hours in the circulation but have the ability to extend their longevity to over a week if 
required. Not only are they bigger than neutrophils but they also wear more flamboyant 
colours when stained by the Romanowsky method (methylene blue and eosin) which 
accounts for their name. Eosinophils may also be distinguished by their production of 
Charcot-Leyden crystals (manufactured from lysophospholipase an eosinophil-derived 
enzyme) which are often visible in their cytoplasm. Eosinophils, like neutrophils, are 
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supplied with numerous granules though their constituents differ including: major basic 
protein (MBP), eosinophil cationic protein (ECP), eosinophil peroxidase (EPO) and 
eosinophil-derived neurotoxin (EDN). This array is certainly capable of tissue damage 
and probably evolved in order to combat helminthic infection. Increasingly, new roles 
for eosinophils are being identified and it seems likely that they have a role in combating 
viral infection as ECP and EDN have been shown to degrade single-stranded RNA 
viruses. They are said to play an early role in innate immunity by production of 
important cytokines such as IL-4 though this is probably only physiologically important 
in the gastrointestinal tract. They can also modulate adaptive immunity by specific 
activation of T-cells (Rothenberg et al. 2006).  
 
Eosinophils are implicated in a different spectrum of disease from neutrophils, of which 
the most common variety is allergic/atopic disease which includes asthma, allergic 
rhinitis and eczema. In other countries parasitic infection is still common including 
schistosomiasis, dranunculoriasis, ascariasis, filariasis and hookworm. Eosinophil 
numbers may be increased in various cancers as well as in rare conditions such as 
Churg-Strauss, aspergillosis and eosinophilic pneumonia. In eosinophil-dominant 
disease it has been consistently demonstrated that eosinophil excess due to excessive 




Basophils are most often encountered in the literature as histamine-producing cells that 
appear to play second fiddle to mast cells in the IgE-driven response that is characteristic 
of allergic asthma. However they are a significant source of other cytokines including 
IL-4 and IL-13 and also contribute to the modulation of T-helper 2 (TH2)-type 
inflammation by influencing the interactions of T-cells with dendritic cells (Lambrecht 
et al. 2009). The extent of their contribution to innate immune defence and their function 
and interplay in a wider immune context remain to be elucidated 
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1.2.2 Granulocyte genesis and differentiation 
 
The life-cycle of the granulocyte and its differentiation in particular are under increasing 
scrutiny. Granulocytes, under the influence of well-characterised growth factors (IL-1, 
IL-6, granulocyte macrophage (GM)-colony stimulating factor (CSF) and IL-3) are 
differentiated from multi-potent stem cells in the bone marrow. They transition from 
stem cell through primitive progenitor cells called colony-forming unit (CFU) 
granulocyte-erythroid-monocyte-megakaryocyte (GEMM) and subsequently CFU- 
granulocyte macrophage progenitor cells (GM) into specific precursor lineages 
(Edwards 1994;Opferman 2007) (Figure 2). It is evident that a distinctive 
eosinophil/basophil progenitor cell exists termed CFU-Eo/Baso. The development of 
multipotential cells into CFU-Eo/Baso cells is controlled by SCF, IL-3, IL-4, GM-CSF, 
and eotaxin. The terminal differentiation into a mature eosinophil is driven by IL-5 and 
eotaxin (Gauvreau et al. 2009;Giembycz et al. 1999b). By contrast, neutrophil 
differentiation appears to be regulated by granulocyte (G)-CSF, IL-3, GM-CSF and 
lymphoid enhancer-binding factor 1 (LEF-1) (target genes survivin, cyclin D1, CCAAT-
enhancer-binding protein (CEBP)- and v-myc myelocytomatosis viral oncogene 
homolog (avian)(c-myc)) (Skokowa et al. 2006;Skokowa et al. 2007). This may vary 
under inflammatory conditions where there is knockout animal evidence that IL-1 and 
TNF- can promote a reactive neutrophilia by indirect effects on myeloid progenitors in 
the absence of other differentiation factors (Ueda et al. 2009).  
 


















Figure 2: Granulocyte life-cycle. Under the influence of well-characterized growth factors, granulocytes 
are differentiated from multi-potent stem cells in the bone marrow. At the termination of normal resolving 
inflammation, granulocytes undergo apoptosis as a prerequisite for non-inflammatory removal by 
phagocytes such as macrophages. Up-regulation of the receptor CXCR4 serves as a homing beacon 
drawing senescent cells towards the organs responsible for their clearance, i.e. the bone marrow, liver, 
and spleen. 
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Convincing evidence from mouse knockout models has recently advanced our 
understanding of the key transcriptional regulatory elements involved in granulocyte 
differentiation and these include: NF-B (p50 stimulates C/EBP when inflammatory 
stimuli present) (Wang et al. 2009), C/EBP, C/EBP, Transcription factor PU.1(PU.1) 
and Retinoic acid receptor (RAR) for neutrophils while eosinophil differentiation is 
directed by NF-B, nuclear factor of activated t-cells (NFAT) and GATA binding 
protein 3 (GATA-3) (Friedman 2007). As differentiation and maturation progress cells 
increasingly lose the ability to proliferate until in the terminally differentiated (fully 
mature) state they can progress only unto death. In the terminally differentiated state it 
seems logical to assume that cell-cycle machinery is either physically lost or 
functionally redundant.  Researchers in the field of granulocyte biology have previously 
been significantly limited in their experimental options by the requirement either to use 
primary and therefore short-lived, non renewable cells or ‘representative’ cell-lines that 
are usually a pale imitation of the unique biology of the cells they substitute for. 
Recently, a number of molecular biology techniques in routine use in other cell types 
have been attempted using neutrophils. Antisense/siRNA techniques have never become 
established in neutrophil work despite some early descriptions presumably because of 
the sensitivity of these cells to the reagents involved and the time required to achieve an 
adequate transfection (Leuenroth et al. 2000b;Sivertson et al. 2007). Sabroe et al have 
now shown that they can influence neutrophil longevity by targeting the TLR4/NF-B 
pathway with lentiviral technology (Dick et al. 2009). HIV-tat transduction has also 
been used with some success in granulocytes (Rossi et al. 2004) and our group has 
previously used this technique to target the NF-B pathway in eosinophils (Fujihara et 
al. 2002).  Additionally, Zemans et al., used retroviral transduction to introduce bcl-2 
into murine bone marrow-derived cells which were subsequently differentiated into 
neutrophils and demonstrated extended longevity (Zemans et al. 2009). Viral genetic 
manipulation of neutrophil precursors (indeed of any immune cell) has significant 
limitations so the directed development of neutrophils from pluripotent stem cells has, 
therefore, been an exciting and important advance. Previously, expansion and 
differentiation of CD34+ cells towards a myeloid lineage had been attempted but these 
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cells were unsatisfactory in that they had limited bactericidal capacity (Dick et al. 2008).  
In 2009, Yokoyama et al published a description of functionally characterised 
neutrophils derived from human embryonic stem cells (Yokoyama et al. 2009). They 
used bone morphogenic protein-4 (BMP-4), stem cell factor (SCF), Flt-3 ligand (FL), 
IL-6/IL-6 receptor fusion protein (FP6), and thrombopoietin (TPO) to form embryoid 
bodies which were co-cultured with OP9 cells and a combination of SCF, FL, FP6, IL-3, 
TPO, and G-CSF. This 2 week process produced neutrophils capable of superoxide 
anion production, phagocytosis, bactericidal activity, and chemotaxis but with different 
surface antigen expression patterns (differences in CD16, CD64 and CD14 expression). 
This process will no doubt undergo refinement and improvement in future to allow a 
production-line of faithfully replicated and conserved neutrophils for in vitro 
experimentation. 
The discovery that neutrophils could be driven to undergo apoptosis by pharmacological 
inhibitors of elements of the cell-cycle machinery termed CDKs has established a major 
research track for our group (Duffin et al. 2009;Leitch et al. 2009;Leitch et al. 
2010a;Rossi et al. 2006). This finding was unexpected given the cell-cycle status of 
neutrophils as the only other terminally differentiated cell type (neurons) studied with 
these pharmacological agents, prior to our work, demonstrated enhanced longevity 
(Dhavan et al. 2001). Additionally it had been shown that some CDKs were 
progressively down-regulated as myeloid lineage cells matured (Klausen et al. 2004). 
Myeloid lineage cells differentiate in the following order: myeloblast, promyelocyte, 
myelocyte, metamyelocyte, band cell, segmented cell, neutrophil. Klausen et al., using 
primary human bone-marrow cells from healthy volunteers described progressive loss of 
CDK2, 4 and 6 which began at the myelocyte/metamyelocyte stage and was almost 
complete by full maturation (Klausen et al. 2004). This occurrence coincided with 
upregulation of the endogenous CDK inhibitor p27kip1 and both results were shown at 
the mRNA and protein level. No consistent finding with regard to the up or down-
regulation of the CDK binding partners, termed cyclins, was obtainable illustrating the 
complexity of regulation involved in this system. This finding was important as other 
works on granulopoiesis had utilised a variety of cell-lines and discovered, perhaps 
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unsurprisingly, a variety of CDK/CDK binding partner expression patterns. It also 
suggested that p27kip1 might be more important than the commonly implicated 
endogenous CDK inhibitor, p21. Interestingly, p21 has come to the fore recently as a 
novel modulator of the response to LPS made by inflammatory macrophages (Lloberas 
et al. 2009;Scatizzi et al. 2006;Scatizzi et al. 2009).  
 
1.2.3  Mature granulocytes 
 
The largest granulocyte reserve is in the bone marrow though there are pools of 
neutrophils at the vascular margins and in the pulmonary capillary ‘sink’. Mobilisation 
of the bone marrow reserve occurs in response to infection/ allergen and results in 
significant increases in the circulating population (orders of magnitude in some cases). 
Granulocytes exit the bone marrow trans-cellularly across the sinusoidal endothelium. 
Neutrophils are retained in the bone marrow by high concentrations of SDF-1a which 
signals through the chemokine (C-X-C motif) receptor (CXCR)-4 (Figure 2) (Eash et al. 
2009). They are stimulated to begin egress by the presence of chemotactic factors such 
as leukotriene (LT)-B4, C5a and IL-8 (as well as CXC chemokines KC (chemokine (C-
X-C motif) ligand (CXCL)-1) and macrophage inflammatory protein (MIP-2, CXCL2) 
in murine models) (Wengner et al. 2008). Additionally, G-CSF has been shown to 
enhance mobilization as well as bone marrow production of neutrophils at resting state 
and may solely function by mobilization under inflammatory conditions (Panopoulos et 
al. 2008). The same effect in eosinophils is mediated by eotaxin and IL-5. Granulocyte 
exit from the bone marrow occurs via integrin-dependent processes. Once in the 
circulation both of the major granulocytes have half-lives from 6-12h though this may be 
greatly extended, in the case of eosinophils, by the presence of a pathological 
eosinophilia. In tissue eosinophils can survive much longer than neutrophils (up to 2 
weeks) (Cara et al. 2000;Giembycz et al. 1999a).   
 
Neutrophils are drawn to sites of inflammation by a variety of signals including formyl-
methionyl-leucyl-phenylalanine (fMLP), LTB4, IL-8, C5a, CXCL1, and CXCL5. 
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Eosinophils also follow chemotactic gradients of diverse stimuli including: platelet 
activating factor (PAF), LTB4, C5a, eotaxin and the cytokines IL-5, TNF- and IL-2 
(Baggiolini 1998;Baggiolini et al. 2000;Petri et al. 2008;Sallusto et al. 2008). These 
chemotactic mediators are sensed by specialised receptors on the granulocyte plasma 
membrane (the majority of which are g-protein coupled receptors (GPCRs)).  The 
detection of chemotactic stimuli allows the neutrophil to follow a gradient towards the 
epi-centre of inflammation. At sites of maximal stimulation the signal changes to bias 
neutrophils towards adhesion, transmigration and initiation of inflammatory function. A 
growing cohort of intracellular signalling effectors engaged by g-protein activation 
includes Ras- and Rho-family GTPases, PI3K, phospholipase (PL)- C and PLA2 but 
currently much attention has been focused on the PI3K family. Under certain conditions 
it has been shown that the chemotactic process can occur by polarisation of PI3K 
signalling, in alignment with the chemoattractant gradient, leading to cytoskeletal 
rearrangement (Ferguson et al. 2007;Stephens et al. 2008). Such is the diversity of 
signals that the neutrophil must respond to in order to maintain a comprehensive 
defensive response that it is perhaps not surprising that a variety of intracellular 
signalling responses have been identified. It appears likely that whichever intracellular 
signal is activated cell movement occurs in the direction of the leading edge of 
membrane with the strongest activation of signalling. 
 
Granulocytes traverse the vascular endothelium into tissue by the well-described 
processes of rolling (CD62L dependent), adhesion (margination) and translocation 
(diapedesis) across the post-capillary venule wall or in the lung at capillary level 
(CD11b/CD18-(integrin) dependent). The process of transmigration is not well 
understood but is believed to occur through two routes.  The first, more generally 
believed, is the paracellular route which occurs through small gaps at intracellular 
endothelial cell junctions. The second route is the transmigration pathway, where 
increasing morphological studies have demonstrated granulocyte migration through the 
endothelial cells themselves (Engelhardt et al. 2004;Fernandez-Borja et al. 2010). Which 
ever the mode of migration, it would seem that granulocyte crossing of the endothelium 
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is not a one-way system. Recent in vitro work by Buckley et al, has described a 
population of long-lived neutrophils which can migrate in a retrograde direction through 
an endothelial monolayer i.e. reverse transmigration neutrophils (RT neutrophils) which 
have a distinct phenotype (CD54high, CXCR1low) and function and are thought to be 
present in the peripheral circulation in humans (Buckley et al. 2006). The response 
involves millions of granulocytes and it is important that cells are effectively cleared so 
that there is no potential for undirected, self-destructive activity. This is delivered by   
apoptosis and macrophage driven phagocytic clearance (Savill et al. 1989), by epithelial 
cell phagocytosis of apoptotic cells or by mucociliary escalator clearance of cells and 
debris from the airway lumen. Where clearance is insufficient (i.e. under normal 
physiological conditions where there is still a vast daily turnover of approx 1011 
neutrophils/24h) it has been shown that upregulation of the receptor CXCR4 serves as a 
homing beacon drawing senescent (pre-apoptotic) cells towards the organs responsible 
for their clearance (Martin et al. 2003). The liver, bone marrow and spleen split this task 
in a roughly equal three-way fashion (Furze et al. 2008a;Furze et al. 2008b).  
 
1.2.4 Granulocyte apoptosis 
 
Neutrophils and to a lesser extent eosinophils are short-lived cells, a feature that may 
help to limit their potential for causing damage by ensuring that they can’t be subverted 
by pathogens. They are explosively, reactive cells and it is therefore surprising that their 
death is a model of contained self-restraint. Apoptosis is a physiological marvel that 
allows cells with an incendiary cargo (granules) to package it efficiently and safely (in 
plasma-membrane) so that the cellular environ is protected. In addition the cell nucleus 
condenses and chromatin is cleaved internucleosomally and re-organised into apoptotic 
bodies. Throughout this process the cell-membrane is retained intact though 
glycoprotein and phospholipid signals are displayed in order to attract macrophages and 
facilitate interaction and uptake (efferocytosis). Annexin-V is often used to label 
phosphatidylserine (PS) residues which are characteristically flipped to the outer-
membrane of apoptotic cells thereby enabling flow cytometric identification of 
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apoptosis. Another member of this family, Annexin-1, has been shown to induce 
granulocyte apoptosis but is also released by both neutrophils and macrophages in order 
to enhance phagocytosis of apoptotic cells (Perretti et al. 2004;Scannell et al. 2007b). 
The whole process is amplified by many orders of magnitude during inflammation 
whether it be neutrophil- or eosinophil-dominant. Apoptosis is not a persistent state and 
apoptotic cells not cleared by phagocytes may then undergo secondary necrosis with 
deleterious consequences for surrounding tissues. Large-scale granulocyte recruitment 
must necessarily be followed by large scale granulocyte apoptosis and clearance by 
macrophages. It is extremely important that this is taken into account when attempting to 
drive granulocyte apoptosis in order to promote resolution of inflammation (Bianchi et 
al. 2006;Rossi et al. 2007).  
 
Neutrophil and eosinophil apoptosis are similar but not identical processes. It is 
generally believed, though not universally (Maianski et al. 2003) that there are two 
pathways by which apoptosis proceeds both of which are ultimately dependent on the 
caspase family (Figure 3). The intrinsic pathway occurs when the cell is subjected to 
withdrawal of growth/survival factors, genotoxic stress or ultraviolet (UV)-irradiation. 
This pathway relies on pro-apoptotic members of the B-cell lymphoma (Bcl)-2 family 
which escape regulation by their anti-apoptotic counterparts and translocate to the 
mitochondria facilitating liberation of cytochrome-c. The various components of the 
apoptosome (Apaf-1, cytochrome-c etc.) then assemble to cleave the inactive zymogen, 
procaspase-9, to the active initiator caspase-9 which commits the cell to executioner 
caspase-3 mediated apoptosis. The extrinsic pathway proceeds via external cell-
membrane death-receptors such as the TNF receptor (TNFR), the Fas receptor (FasR) 
and TNF-related apoptosis-inducing ligand receptor (TRAILR). Ligand activation of 
receptors promotes clustering and enhances association with the internal adaptor 
proteins (Tumour necrosis factor receptor type 1-associated death domain (TRADD) and 
fas receptor associated death domain (FADD)) within the lipid-raft. Multiple 
procaspase-8 molecules assemble at the adaptor proteins (formation of the death 
inducing signal (DISC) complex) and their physical approximation generates an 
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autocatalytic reaction initiating the caspase-cascade. The death-receptor CD137 has also 
been implicated in neutrophil and eosinophil apoptosis but it is currently unclear what its 
physiological role is (Simon 2003).  
 
To further complicate the story it is apparent that there is a degree of cross-talk between 
the intrinsic and extrinsic pathways. Caspase-8 may alternatively cleave BH3 interacting 
domain death agonist (Bid) which can translocate to the mitochondrial-membrane and 
permeabilise it allowing apoptosis to proceed via intrinsic pathway apoptotic machinery 
(Bianchi et al. 2006;Simon 2003).  
 
Eosinophil apoptosis most likely occurs along approximately the same lines, however 
controversy still reigns with regard to the caspase family. It has previously been stated 
that caspases-3, -8 and -9 have no demonstrable role in eosinophil apoptosis (Daigle et 
al. 2001b). Subsequently, it has been suggested that perhaps caspase-9 plays a role and 
that therefore the mitochondrial pathway is of importance (Peachman et al. 2001;Simon 
2001). This work was confirmed by observations with regard to the effects of known 
eosinophil apoptosis-inducing agents such as glucocorticoids which appear to mediate 
their effects via mitochondrial permeabilisation with caspase activation merely a 
downstream effect. By contrast, Fas ligation has been shown to promote eosinophil 
apoptosis in a caspase-3 and -8 dependent manner and although mitochondrial integrity 
was disrupted it proved non-essential for apoptotic progression (Daigle et al. 
2001a;Simon et al. 1999;Simon 2001;Simon 2006).  
 
Support for the predominance of mitochondria-driven granulocyte apoptosis is provided 
by the increasing evidence that survival proteins are key determinants of neutrophil 
longevity. The anti-apoptotic Bcl-2 family member, Mcl-1, is present in both neutrophils 
and eosinophils but other family members show contrasting expression. Neutrophils 
express A1 (Bfl-1) while eosinophils favour Bcl-extra long (xl) and Bcl-2 itself appears 
not to be constitutively present at demonstrable levels. Interestingly however, in 
eosinophils Bcl-2 expression can be stimulated by IL-5 (Ochiai et al. 1997). These  
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survival proteins mediate their effects by marshalling pro-apoptotic Bcl-2 family 
counterparts away from the mitochondrial-membrane. Pro-apoptotic Bcl-2 family 
members are capable of causing permeabilisation of the outer mitochondrial-membrane 
(MOMP) when numbers predominate over those of their chaperones. Bcl-2-(associated 
X) protein (Bax) is perhaps the best characterised member of this family and appears to 
play a pivotal role in neutrophil apoptosis. In eosinophils however Bax fails to be down-
regulated by anti-apoptotic survival factors weakening its position as a key player in 
apoptosis (Weinmann et al. 1999). The role of Mcl-1 in neutrophil apoptosis has 
received a great deal of attention and it appears that this protein is an essential 
component of neutrophil viability. A contention that is supported by the neutropenic 
phenotype of the Mcl-1 knockout mouse in comparison with the increased apoptotic 
phenotype of the A1 knockout mouse (Dzhagalov et al. 2007b;Hamasaki et al. 1998). 
Additionally the pro-apoptotic protein BCL2-like 11 (apoptosis facilitator) (Bim) has 
recently been described as having a prominent role in neutrophil death following 
cytokine stimulation and is additionally implicated as a known binding partner of Mcl-1 
(Andina et al. 2009;Cowburn et al. 2010;Herrant et al. 2004;Villunger et al. 2003).  
 
1.2.5 Modulation of granulocyte apoptosis 
 
Granulocyte longevity is necessarily highly regulated and consequently highly variable 
from a matter of hours up to 2 days for neutrophils and extending to 2 weeks for 
eosinophils.  Persistent markers of bacterial infection such as LPS, pathogen derived 
molecules that act as ligands for TLR 2, 4 and 9 and inflammatory cytokines such as IL-
6, IL-8, GM-CSF and TNF- can delay neutrophil apoptosis whilst resolving infection 
indicated by successful neutrophil phagocytosis of bacteria, removal of bacterial 
products and down-regulation of inflammatory cytokines will promote apoptosis (Sabroe 
et al. 2005;Sabroe et al. 2007b).  
 
Granulocyte longevity is also extremely dependent on intracellular signalling pathways. 
Perhaps the most important of which is that controlled by the pivotal transcription factor 
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of inflammatory cytokines NF-B. NF-B can be activated by LPS and is known to 
control the survival proteins X-linked inhibitor of apoptosis protein (XIAP) (an inhibitor 
of caspase-3, -8 and -9) and Bcl-xl thus enhancing neutrophil and eosinophil longevity 
by tangible means. Pharmacological inhibitors of NF-B such as gliotoxin promote 
neutrophil apoptosis and in combination with TNF- cause dramatically enhanced 
apoptosis. This feature may partially explain why TNF- has opposing effects on 
neutrophils at early and late time-points (Lawrence et al. 2001;Ward et al. 1999). Other 
important signalling pathways include the phosphoinositide 3-kinase (PI3K) pathway 
which can be stimulated by GM-CSF to promote longevity by upregulation of Mcl-1 in 
neutrophils and which has an emerging role in the maintenance of eosinophilic 
inflammation (Pinho et al. 2005;Pinho et al. 2007). Similarly the extracellular signal 
regulated kinase (ERK) pathway is likely to be important for survival factor mediated 
anti-apoptotic effects at sites of inflammation. However, direct inhibition of either of 
these pathways will not promote granulocyte apoptosis per se (Rossi et al. 2007;Savill et 
al. 1995).  
 
Perhaps the most interesting and clinically relevant modulation of granulocyte apoptosis 
is that achieved with the use of glucocorticosteroids. These drugs extend neutrophil life-
span but promote eosinophil apoptosis. This effect seems to correlate with their ability to 
up-regulate Mcl-1 in neutrophils but down-regulate the same protein in eosinophils 
(Sivertson et al. 2007). Dexamethasone (a stereotypical glucocorticosteroid) has also 
been shown to promote macrophage phagocytosis of apoptotic neutrophils (Heasman et 
al. 2003). The impact of putative inflammation resolving agents on clearance of 
apoptotic neutrophils is of paramount importance as prompt removal is essential to avoid 
secondary necrosis and loss of toxic contents. This is perhaps why the discovery of a 
new class of endogenous lipid derived pro-resolution agents has been so exciting. The 
lipoxin family produced by neutrophils and macrophages limit the recruitment of 
neutrophils to inflammatory sites and enhance macrophage phagocytosis of apoptotic 
neutrophils. This occurs as part of a natural brake on progression of inflammation and 
there is hope that enhancement of this pathway may provide a novel therapeutic strategy 
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to counter inflammatory disease, a hypothesis that has already shown promise in several 
animal models (Serhan 2007). Another exciting prospect for therapeutic modulation of 
granulocyte apoptosis has emerged with the discovery of active cell-cycle machinery in 
neutrophils which can be inhibited to promote apoptosis. CDK inhibitor drugs promote 
neutrophil apoptosis and drive resolution of inflammation in animal models. Given that 
these drugs are already in use for the treatment of cancer it is possible that they could 
make the transition from bench to bedside for the management of inflammatory disease 
in the near future (Hallett et al. 2008a;Rossi et al. 2006).  
 
1.2.6  Alveolar macrophages and phagocytic clearance of apoptotic 
granulocytes 
 
In normal healthy lungs the predominant alveolar leucocyte is the macrophage, a cell 
that becomes resident following differentiation from a bone-marrow produced 
circulating pre-cursor monocyte. Alveolar macrophages occupy a unique position at the 
interface between inhaled air (and hence the external environment) and the circulation 
(in the form of the alveolar capillary network which is closely juxtaposed to the alveolus 
to promote efficient gaseous exchange) and because key macrophage functions include 
chemotaxis, phagocytosis and cytotoxicity they are lynch-pins of immune defence. 
Importantly, during pulmonary infective or inflammatory disease a key role in resolution 
of inflammation falls to both alveolar and recruited circulating macrophages. These cells 
are responsible for the removal of apoptotic neutrophils and to some extent eosinophils 
(though epithelial cells may be equally important for eosinophil removal) by 
efferocytosis (see figure 4 for an example of experimental quantification of this process). 
In order for an apoptotic cell to be recognized by a macrophage it must display specific 
signals. The most obvious change in the apoptotic granulocyte’s plasma membrane is the 
externalization of PS residues but this in itself is not sufficient to expedite phagocytosis. 
The search for a macrophage docking receptor on granulocytes has been exhaustive but 
inconclusive and currently a combination of various glycoproteins and phospholipids are 
of postulated importance. These putative receptors include the recently identified Tim4 
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(Kobayashi et al. 2007), stabilin-2 (Park et al. 2008), and BAI1 (Park et al. 2007). The 
process of efferocytosis, literally meaning ‘burying the dead’, is a pro-resolution strategy 
in itself. Macrophages that consume apoptotic neutrophils switch to a resolution 
phenotype that allows them to secrete transforming growth factor (TGF)- and IL-10 
(Fadok et al. 1998) as opposed to pro-inflammatory cytokines such as IL-6, IL-8 and 
TNF-. This is in contrast to macrophages that have consumed necrotic neutrophils 
where the opposite is true and inflammation is actively propagated. Additionally, the 
pro-resolution phenotype includes the production and enhanced responsiveness to 
lipoxins, protectins and resolvins. These mediators enhance macrophage phagocytosis 
and promote pro-resolution cytokine production (Serhan 2007).  
 






Figure 4: In vitro phagocytosis experiment with human monocyte derived 
macrophages and CellTrackerTM green labelled apoptotic neutrophils. Fluorescence 
microscopy- phase image on left and UV on right. Solid arrow shows macrophage that 
has ingested a neutrophil. Empty arrow shows apoptotic neutrophil. Bottom right 
macrophage may have already digested a labelled neutrophil 
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1.2.7  Granulocytes and disease  
 
There has been a tendency, certainly in clinical circles to question the validity of 
inflammation-based hypotheses for various diseases based on the efficacy or lack of 
efficacy of glucocorticosteroid medications. Given the complexity of the inflammatory 
response and the relative bluntness of this therapeutic tool it is overly simplistic to make 
such assumptions. Steroid medications have certainly been a paradigmatic therapy in the 
treatment of inflammatory disease but they do not and will not drive resolution of 
inflammation in all settings. With increased understanding of the mechanisms of the 
inflammatory response and a new focus on its resolution it is hoped that novel incisive 
or pleiotropic therapy combinations may be developed to address the inflammatory lung 
diseases discussed below. 
 
COPD 
In most cases of COPD (-1-antitrypsin deficient patients are a notable exception) the 
respiratory mucosa is damaged by repeated exposure to inhaled toxic chemicals leading 
to chronic inflammation, reduced immunity and susceptibility to respiratory infections. 
COPD is a prevalent, largely smoking-related (though there is an increasingly 
recognised occupational contribution) disease in this country (in others it is related to the 
burning of bio-fuels) which presents with increasing breathlessness and a productive 
cough. It is an obstructive airways disease but unlike asthma this obstruction is usually 
irreversible with inhaled therapies. The mainstay of current treatment is with inhaled or 
oral corticosteroids and antibiotics when exacerbations are judged infective (BTS 
1997;MacNee et al. 2003).  
Neutrophils are likely to play an important role in this condition and they are found in 
increased numbers throughout the respiratory tract. The highest concentrations of 
neutrophils are found in sputum and bronchoalveolar lavage fluid (BAL) (which is 
perhaps representative of rapid airway directed migration) but numbers of neutrophils 
are also increased in lung parenchyma and airway smooth muscle. Neutrophilic 
inflammation is characteristic of COPD exacerbations and there is a correlation between 
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the resting burden of lung based neutrophils and severity of disease phenotype. 
Neutrophilic inflammation appears to be driven by the irritant force as smoking drives 
alveolar macrophages and epithelial cells to express increased levels of IL-8, a potent 
neutrophil chemoattractant. IL-8 also stimulates neutrophils to release MPO while TNF-
 and LTB4 (produced by epithelial cells, mast cells and T-lymphocytes) cause 
neutrophil activation (degranulation, ROS production and exocytosis of lysosomal 
enzymes) (MacNee 2007;O'Donnell et al. 2006a;O'Donnell et al. 2006b). Meanwhile 
macrophage phagocytic function is impaired by cigarette smoking and cannot keep pace 
with the increased neutrophil burden (Kirkham et al. 2004).  Enhanced neutrophil 
recruitment and activity combined with decreased macrophage phagocytosis weigh the 
scales heavily towards neutrophil mediated tissue damage. COPD lungs are subjected to 
high levels of toxic neutrophil products including: ROS, elastase and proteinases. These 
toxic substances overload the capacity of native antiproteinases and antioxidants to 
neutralize them which leads to damaged epithelial cilia and decreased mucociliary 
clearance. Damage to the respiratory mucosa means that alveolar cells are replaced by 
goblet cells which increase mucous production (see figure 1). Furthermore, airways are 
progressively remodelled by the reparative process so that they become thicker, less 
efficient conductors of air.  There is some controversy with regard to the longevity of 
neutrophils isolated from the airways of COPD patients. Studies have shown both 
enhanced longevity and no enhancement of longevity while peripheral blood neutrophils 
appear to have an increased lifespan in keeping with systemic inflammation (Barnes 
2007;Churg et al. 2008;Quint et al. 2007a).  
 
COPD is notoriously resistant to glucocorticoid therapy perhaps because these drugs 
promote neutrophil longevity by upregulating the survival protein Mcl-1 (Sivertson et al. 
2007). It is also known that smoking promotes dysfunction of histone deacetylase 
(HDAC) 2 an enzyme which is usually recruited by glucocorticoid receptors to switch 
off the transcription of pro-inflammatory genes (Ito et al. 2006;Kagoshima et al. 2003). 
The small benefits attributable to steroid therapy in COPD may stem from enhancement 
of macrophage phagocytosis of apoptotic cells. Of other therapies currently in use 
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theophylline (a non-specific adenosine antagonist and phosphodiesterase inhibitor) is 
known to restore HDAC2 function, reversing corticosteroid resistance and reducing IL-8 
concentrations and sputum neutrophilia (Barnes et al. 2004). Long acting 2 agonists 
(originally employed to relax smooth muscle in peripheral airways) have now been 
shown to inhibit neutrophilic inflammation as measured by sputum or BAL analysis and 
they are reported to drive neutrophil apoptosis though the circumstances of this are 
difficult to ascertain. It is clear that potential therapies must consider targeting neutrophil 
recruitment as well as striving to drive neutrophil apoptosis and removal (Barnes 
2004;Barnes et al. 2004;Barnes 2007;Quint et al. 2007b).  
 
Idiopathic Pulmonary Fibrosis 
IPF is a condition characterized by the devastation of the respiratory mucosa though its 
pathophysiology is complex. There is a great deal of debate about the relative 
importance of inflammation versus aberrant wound repair in the pathogenesis of IPF but 
there is sufficient evidence to justify an argument in support of a significant neutrophil-
derived component to the disease model (Collard et al. 2007b;du Bois et al. 
2007b;Hunninghake et al. 2007;Seaton 2000;Strieter 2008;Wallace et al. 2007) ). 
 
The argument is that the initial and subsequent ‘exacerbatory’ insults are acute and 
inflammatory even if the characteristic phenotype is conveyed by a disordered ‘healing’ 
process. Healing by fibrosis results in significant loss of lung architecture and vital 
respiratory mucosa to scarring (Wallace et al. 2007). Neutrophils are known to be 
present in BAL from IPF patients and are also significantly increased within lung tissue 
(Kinder et al. 2008). Additionally there is evidence of the toxic chemicals produced by 
neutrophils including MPO, elastase, collagenases and proteases (Haslett 
1999;Hunninghake et al. 2007). The importance of this chemical insult is supported by 
the elastase knockout mouse which is significantly protected against lung injury and also 
fails to up-regulate TGF-(Chua et al. 2007). A recent clinical paper has shown that 
significant neutrophilia within the BAL fluid of IPF patients correlates with increased 
mortality (Kinder et al. 2008). It has been argued that the terminal scarring process of 
                                                                                                                                           33
IPF occurs because of a significant loss of lung architecture and that where lung 
architecture is preserved there is potential for reversal of the remodeling process and 
resolution (Wallace et al. 2007). It has also been suggested that the fibrotic response 
may in a sense be driven by a persistent but ineffective pro-resolution of inflammation 
phenotype. This hypothesis is drawn from the observation that TGF- is a key pro-
resolution molecule but is also intimately involved in fibrogenesis. In a disease model 
where non-resolving low level inflammation results in sustained TGF- production it is 
possible to conceive that a fibrotic healing phenotype might evolve. Therapeutic 
strategies that drive neutrophils towards apoptosis will certainly have something to add 
to treatment of this disease if they can prevent or ameliorate the inflammatory insult 
(whether it be acute, chronic or relapsing) that must be responsible for such extreme 
distortion of lung architecture (Collard et al. 2007a;du et al. 2007a).  
 
ARDS/ALI 
ARDS/ALI is the pulmonary component of the multi-organ dysfunction syndrome 
(MODS) and represents a global failing of lung function in response to a specific, non-
specific or unidentifiable stimulus. Effectively these conditions are the result of an 
aggressive mucosal inflammatory immune response (Abraham 2003;Bellingan 
2002;Leaver et al. 2007;Martin 2008;Matthay et al. 2005;Seaton 2000). 
Characterised by the pathological reaction termed diffuse alveolar damage (DAD), 
ARDS/ALI seems to be a neutrophil-dominant disease (interestingly DAD is also seen 
in the terminal stages of IPF (Tiitto et al. 2006)). Analysis of BAL fluid from patients 
with early-stage ARDS demonstrates increased numbers of activated neutrophils and 
their numbers correlate with severity of lung injury. Indeed persistence of BAL 
neutrophilia at day 7 is associated with increased mortality (Steinberg et al. 1994). The 
pulmonary circulation contains a large sequestered neutrophil population termed the 
‘marginated’ pool that does not normally circulate but is loosely adhered to the vessel 
walls (Summers et al. 2010). This population can be mobilized into the circulation by for 
example steroid therapy or exercise. Neutrophils are subject to slow transit through the 
pulmonary microvasculature where blood vessel diameters are smaller than their own. 
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The ability of neutrophils to progress depends on their considerable properties of 
distensibility. In ARDS/ALI neutrophils are recruited early in large numbers and an 
alteration in their rheological properties (they become less deformable) means they 
struggle to manoeuvre through vessels while cytokine excess encourages their adhesion 
to vessel walls and subsequent translocation into the lung parenchyma and airways. The 
influx of huge numbers of neutrophils and proteinaceous inflammatory oedema fluid 
from permeabilised vessels impairs gas exchange and makes adequate ventilation 
extremely difficult (Martin 2008;Matthay et al. 2005;Summers et al. 2010). 
 
Neutrophil influx is driven by alveolar macrophage production of IL-8 and excessive 
levels of this cytokine have been found to be predictive of progression to ARDS in 
susceptible patients (Donnelly et al. 1993). There is no effective, specific therapy for this 
condition and yet some patients survive with supportive therapy alone, implying that 
successful resolution is possible and can be mediated by physiological mechanisms. 
Neutrophils isolated from the BAL of ARDS patients have enhanced longevity, are 
activated and may cause insurmountable damage to the respiratory mucosa leading to 
healing by fibrosis and permanent scarring with loss of lung architecture and function. In 
experimental models where neutrophils are depleted ALI caused by endotoxin is 
attenuated. In other studies enhancement of neutrophil apoptosis also reduced 
inflammatory parameters and tissue damage. The picture is complicated by apparent 
ARDS/ALI in neutropenic human patients. It is also clear that given the extravagant 
neutrophil influx associated with this condition it would likely require a dual strategy of 
enhancing both neutrophil apoptosis and neutrophil clearance to ensure that secondary 
necrosis (and tissue damage) is prevented by prompt removal (Abraham 2003;Oeckler et 
al. 2007) .  
 
Pneumonia 
Pneumonia is the term given to an infection within the lower respiratory tract that is 
sufficiently significant to result in visible changes on a chest radiograph ( BTS 2001). 
There are many potential causative organisms including viruses and bacteria. Invading 
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pathogens that overcome immediate host defences are nonetheless recognized as foreign 
by their non-host constituents such as LPS or formylated peptides in their outer 
membranes. TLRs, CD14 and GPCRs (e.g. FMCPR) found on macrophages and other 
respiratory mucosal cells are responsible for this detection and subsequently stimulate an 
acute inflammatory reaction by the production of cytokines such as TNF-, IL-1, IL-6 
and IL-8. This pro-inflammatory milieu prolongs neutrophil lifespan and promotes 
neutrophil activation in order to allow effective microbial phagocytosis and killing 
(Droemann et al. 2000;Sabroe et al. 2005;Sabroe et al. 2007b). If the inflammatory 
reaction is successful in containing the pathogens and they are cleared by phagocytosis 
or killed then the inflammatory reaction remains localized to a single lobe or segment of 
the lung. The upregulation of anti-inflammatory, pro-resolution molecules should ensure 
containment of inflammation. Neutrophil phagocytosis of bacteria and the induction of 
pro-resolution cytokines such as IL-10 and transforming growth factor (TGF)- promote 
neutrophil apoptosis and removal by macrophages (Watson et al. 1996). The alternative 
is non-resolution with enhanced neutrophil longevity and local tissue damage (resulting 
in abscess, empyema or bronchiectasis) and/or loss of containment resulting in global 
lung inflammation characterized by ARDS or spread via the circulation to other organs 
(sepsis) with the potential for multi-organ dysfunction syndrome (MODS). Streptococcal 
pneumonia (the pathogen responsible is S.pneumoniae) is often cited as a paradigm of 
resolving inflammation as despite an acute inflammatory response characterized by a 
massive neutrophil influx (giving the pathological appearance referred to as ‘red 
hepatisation’) it is possible for the lung to achieve complete recovery (Haslett 1999). 
There is however a sub-population of severe pneumonia that behaves aggressively or is 
not contained by the patient’s immune system and antibiotic therapy resulting in 
admission to intensive care and potentially MODS, sepsis, terminal decline and death.  
 
Antibiotics are central to the treatment of pneumonia but they are not always sufficient 
and it is possible that addressing acute inflammation associated with pneumonia may 
prove a successful adjuvant therapy.  In this setting it is unclear whether the ideal 
strategy is to dampen down the inflammatory response or to augment it in the hope that 
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a supra-physiological immune reaction will prove successful in eradicating the organism 
responsible. Glucocorticoid therapy has been used as an adjuvant to antibiotics in this 
kind of patient with varying success rates in different trials (Cazzola et al. 2005). The 
theory is that steroids should dampen inflammation through down-regulation of NF-B 
activation and consequently the inflammatory cytokines under its direct transcriptional 
control. A recent study that utilized a physiological steroid dose (Supra-physiological 
doses had been employed in previous studies) has shown a significant reduction in 
length of hospital stay and mortality in ICU patients with severe community acquired 
pneumonia (Confalonieri et al. 2005). It is possible therefore that in a sub-group of 
patients with pneumonia strategies to aid resolution of inflammation (in combination 
with antibiotic therapy) may be warranted. 
 
Cystic Fibrosis 
CF is the commonest inherited disease in Caucasian populations affecting 1 in 2500 
births. The defect in salt transport (the genetic abnormality affects the cystic fibrosis 
transmembrane regulator gene (CFTR) which encodes a chloride channel) should be 
responsible for such widespread organ pathology including pancreatic insufficiency, 
bronchiectasis, liver dysfunction, infertility and gut defects (Doring et al. 2009). 
Mortality (on average at age 34 in Western society) is most frequently from respiratory 
failure caused by aggressive bronchiectasis (Seaton 2000).  
 
There are competing hypotheses as to the root cause of the repeated infective 
exacerbations that lead to bronchiectasis in CF. It is postulated that a relative 
dehydration of the respiratory mucosa means that the mucociliary escalator is 
compromised by viscid mucus and that altered mucosal pH results in malfunction of host 
antimicrobial peptides. There may also be a failure of normal bacterial internalisation 
processes and it has been suggested that an intrinsic pro-inflammatory phenotype is 
conferred by CFTR malfunction. The pro-inflammatory phenotype theory postulates that 
an over-burdened endosomal system encumbered by the processing of faulty CFTR 
signals distress which leads to activation of NF-B (Pahl et al. 1995;Venkatakrishnan et 
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al. 2000). Production of IL-8 is stimulated resulting in enhanced neutrophil recruitment.  
Regardless, the net result is a failure of mucosal immunity and a succession of bacterial 
infections occur (initially, Staphylococcus aureus and/or Haemophilus influenzae but 
subsequently and devastatingly Pseudomonas aeruginosa, Burkholderia cepacia and 
Stenotrophomonas maltophilia). With bacterial colonization innate defence is roused 
and a significant neutrophil influx occurs. This is usually thwarted, initially by microbial 
resistance and subsequently by distorted lung architecture. This results in an 
insurmountable accumulation of inflammatory cells and toxic damage from chemicals 
eluted by their necrotic carcasses. Elastase, ROS and myeloperoxidase cause further 
lung damage and the clearance of inflammatory cells is so poor that the lungs literally 
become clogged with inflammatory cell DNA. Eventually there is a terminal paucity of 
functional gas-exchange equipment and respiratory failure and death supervene if lung 
transplant is not possible (Elizur et al. 2008b) (Banner et al. 2009;Downey et al. 2009).  
 
Recent work on P. aeruginosa has provided an interesting insight into the mechanisms 
by which this organism thwarts immune defence. It was known that P. aeruginosa could 
effectively hide from the immune system in a protective and impenetrable bio-film. A 
more subtle effect mediated by pseudomonas produced pyocyanin has now been 
recognized. This chemical promotes neutrophil death but inhibits macrophage clearance 
resulting in neutrophil death by necrosis. This leads to the spillage of cathepsin G and 
elastase which can cleave the important chemokine receptor CXCR1 on other 
neutrophils. This receptor would usually allow IL-8 mediated enhancement of neutrophil 
killing prowess which enables neutrophils to kill pseudomonas. In CF patients 
neutrophils have little CXCR1 for the above reason and are consequently effectively 
crippled as well as out-manoeuvred. Even more detrimental, fragments of this receptor 
stimulate the TLR system resulting in enhanced neutrophil recruitment and prolongation 
of the inflammatory response (Sabroe et al. 2007a).  
 
Anti-inflammatory therapy in the form of non-steroidal anti-inflammatory drugs 
(NSAIDs) has been used to mild benefit in CF but it is appears that the early 
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introduction of a potent anti-inflammatory pro-resolution therapeutic strategy might be 
of enhanced benefit. Neutrophils in CF patients are dysfunctional and ineffective at 
restraining or removing typical CF pathogens so driving their apoptosis and removal 
might be of more benefit than allowing them to remain in the hope that they are 
contributing to defence against these microbes (Elizur et al. 2008a).  
 
1.3 Mcl-1, a key neutrophil survival protein 
 
In order to drive neutrophil apoptosis it is important to understand the mechanisms 
responsible for neutrophil survival. Potentially the most important neutrophil survival 
protein is Mcl-1 (Edwards et al. 2004a) as evidenced by studies utilising anti-sense Mcl-
1 RNA to knockout Mcl-1 in neutrophils and most recently by the Mcl-1 myeloid-
specific knockout mouse which was effectively neutropenic (Dzhagalov et al. 
2007a;Leuenroth et al. 2000b). 
 
1.3.1 Mcl-1 structure and function 
 
The Mcl-1 gene is located on chromosome 1q21 and encodes a 40kDa protein. Mcl-1 is 
a member of the bcl-2 homologue family. Mcl-1 has BH domains 1-3 but in common 
with the A1 protein is missing the putative protein interaction domain BH4. Bcl-2 the 
prototype for the family is a much smaller protein at 26kDa. This is because Mcl-1 
contains multiple domains rich in proline (P), glutamic acid (E), serine (S), and 
threonine (T) (PEST) in its C-terminal tail that target it for degradation by the 
proteasome. It also possesses 2 key asparagine sites that may function as substrate for 
caspase cleavage (Akgul et al. 2000;Mandelin et al. 2007). Thus Mcl-1 has an extremely 
short half-life between 0.5 and 3h though obviously this can vary considerably 
dependent on cell-type and conditions.  Mcl-1 was originally identified in the myeloid 
leukaemia myeloblastic cell line (ML-1) and was discovered to confer survival on 
various cell types. It has been noted that though Mcl-1 is expressed across a wide range 
of tissues it is most likely to be of functional importance where Bcl-2 is not expressed or 
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only minimally expressed (Akgul et al. 2000;Mandelin et al. 2007). Indeed in cells with 
little bcl-2 (e.g., the neutrophil) Mcl-1 tends to be expressed to a greater extent. Mcl-1 is 
known to be of particular importance in the early differentiation of myeloid cells. As is 
the case for many short-lived survival proteins Mcl-1 has been found to be significantly 
upregulated in various cancers (Ding et al. 2007;MacCallum et al. 2005;Moulding et al. 
2000;Raje et al. 2005;Yoon et al. 2002). The pro-survival effect conferred by Mcl-1 is 
mediated by interactions with the pro-apoptotic Bcl-2 homologues Bim, Bid, Bax and 
Bcl2-antagonist/killer-1 (Bak). Mcl-1 has been shown to directly interact with Bid, Bak 
and Bim and to sequester them in an inactive form which prevents association with the 
outer mitochondrial membrane, pore-formation and progression down the intrinsic 
apoptotic death pathway (Chen et al. 2005;Han et al. 2004;Hutcheson et al. 2005;Zhu et 
al. 2004).  Bim is likely responsible for the activation of Bax and to some extent Bak 
suggesting that Mcl-1 perhaps has indirect effects on these proteins. It has certainly been 
shown that double knockouts of Bim and Bax/Bak have enhanced longevity compared to 
single knockouts of any one of these pro-apoptotic bcl-2 homologues (Hutcheson et al. 
2005). There is increasing evidence for the importance of Bim in the regulation of 
neutrophil apoptosis and it seems increasingly likely that neutrophil survival is most 
dependent on the balance between Mcl-1 and Bim (Andina et al. 2009;Cowburn et al. 
2010;Villunger et al. 2003). This is likely to be especially true at sites of inflammation 
as Bim has been shown to be induced by cytokines (hypothetically as a brake on 
cytokine-induced longevity (Andina et al. 2009)) while Mcl-1 has been shown to be 
upregulated in neutrophils from the inflamed joints of rheumatoid arthritis sufferers. 
 
1.3.2 Mcl-1 transcription and post-transcriptional regulation  
 
There is evidence to suggest that Mcl-1 may be upregulated by a number of cytokines 
relevant to the inflammatory milieu including: TNF-, IL-1b, IL-6 and GM-CSF (Liu et 
al. 2005). A requirement for integration of these varied signalling pathways suggests the 
involvement of transcription factors and potential binding sites for NF-B, signal 
transducer and activator of transcription (STAT), steroid regulatory element (SRE), 
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cAMP responsive element binding protein (CREB) binding protein (BP) and v-ets 
erythroblastosis virus E26 oncogene homolog 1 (avian) (Ets) have been identified at the 
5’ flanking region of the gene transcription start site (Akgul et al. 2000). The functional 
significance of these sites, especially the NF-B site is debated but regardless rapid up 
or down-regulation of transcription in the presence of various agents and cytokines has 
been documented. Mcl-1 is subject to alternative splicing and it has been suggested that 
the exon-1 variant may have pro-apoptotic effects (Bingle et al. 2000). Post-transcription 
Mcl-1 is subject to phosphorylation at various sites including ERK-mediated 
phosphorylation of Threonine 163 (Derouet et al. 2004) which serves to stabilise the 
protein and glycogen synthase kinase (GSK)-3 (itself inhibitied by v-akt murine 
thymoma viral oncogene homolog 1 (Akt-1) phosphorylation) phosphorylation at Serine 
159 (Maurer et al. 2006) which enhances its proteasomal degradation. In addition the 
ubiquitin ligase, HECT, UBA and WWE domain containing-1(MULE) may be 
responsible for polyubiquitination of Mcl-1 which targets it to the proteasome (Zhong et 
al. 2005). Another pro-apoptotic variant of Mcl-1 may be created by caspase 3 or 8 
mediated cleavage at conserved Asp residues with studies suggesting that the resultant 
fragments actively drive apoptosis as opposed to merely being a silent part of the 
process (Derouet et al. 2006;Herrant et al. 2004). Granzyme B (Han et al. 2004), TRAIL 
(Han et al. 2006), TNF-(Cross et al. 2008)sodium salicylate (Derouet et al. 2006), 
okadaic acid (Derouet et al. 2006) and CDK inhibition (Leitch et al. 2010b;Rossi et al. 
2006) have all been shown to downregulate Mcl-1 whilst dexamethasone (Sivertson et 
al. 2007), GM-CSF (Derouet et al. 2004) and proteasome inhibitors (Edwards et al. 
2004b) are known to stabilise it.  
 
1.3.3 Mcl-1 and signalling pathways 
 
In the preceding section the regulation of Mcl-1 by GSK-3 and ERK was mentioned but 
other signalling pathways have also been implicated. Given that the best characterised 
neutrophil survival pathway is the NF-B signalling system it would seem logical that 
there should be a link between it and Mcl-1. Although there is a transcription factor 
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binding site for NF-B at the Mcl-1 promoter it has been contended that is not functional 
(Akgul et al. 2000). Indeed it has been suggested that the effects of traditional stimulants 
of the NF-B pathway on Mcl-1 may in fact be mediated by PI3K mediated 
phosphorylation of Akt (Epling-Burnette et al. 2001;Liu et al. 2001).  This not only 
prevents GSK-3 destabilisation of Mcl-1 but may promote Mcl-1 transcription by an 
interaction with the transcription factor CREB. Additionally, the Janus kinase 
(JAK)/STAT pathway has been shown to be important for the expression of Mcl-1 
induced in neutrophils by GM-CSF (Derouet et al. 2004) while STAT-3 has a key role in 
Mcl-1 expression in macrophages (Liu et al. 2003).  Epidermal growth factor (EGF)/ v-
raf-1 murine leukemia viral oncogene homolog-1(Raf 1) and p38 mitogen associated 
protein kinase (MAPK) have also been shown to regulate Mcl-1 under specified 
conditions (Saffar et al. 2008;Yoon et al. 2002). 
 
Mcl-1 is subject to rapid up or down-regulation of transcription in response to 
inflammatory cytokines, a short half-life and extensive post-trancriptional regulation. 
This makes Mcl-1 an ideal ‘survival switch’ for the neutrophil population it allows 
enhanced longevity at times of need but ensures prompt turnover of unrequired cells.   
 
1.4    Cyclin-dependent kinases, CDK inhibitor drugs and resolution of 
inflammation 
 
1.4.1 Cyclin-dependent kinases: structure and function 
 
CDKs are serine/threonine kinases and part of the diverse protein kinase family. They 
are essential facilitators of life at the molecular level via their ubiquitous 
phosphorylation reactions. The majority of CDKs identified rely on binding partners 
called cyclins for their activation. In all there are 13 CDKs and 25 identified cyclins so 
far and though there is a high level of sequence and structural homology between them, 
knowledge of their function varies. A typical protein kinase consists of a small N-
terminal domain formed of -sheets and a large C-terminal domain (CTD) formed of -
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helices; between the terminals there is an ATP binding pocket and this pattern is also 
observed in CDKs. CDKs switch to an active conformation on binding to cyclin proteins 
which reveals enzymatic elements crucial to the catalytic function of their ATP-binding 
clefts. CDKs were named for this interaction with cyclin proteins which facilitates 
passage of cells through the G1, S, G2 and M phases of the cell division cycle (Meijer et 
al. 2003).  Progression of the cell cycle depends more on the concentrations of 
endogenous CDK inhibitors (e.g. the WAF/CIP/KIP family) and cyclins than on the 
relatively stable CDK population. We commented earlier that CDK inhibitor drug action 
on neutrophils appears counter-intuitive but given the diversity of function that CDKs 
have been demonstrated to possess it is perhaps not surprising that another role for them 
has been found. Though initially identified as key components of the cell-cycle 
machinery they have subsequently been shown to play roles in cell differentiation, cell 
death (especially apoptosis), transcription and neuronal function. These alternative roles 
are mediated by different CDKs, an important factor in the drive to develop increasingly 
specific pharmacological CDK inhibitors (Knockaert et al. 2002).  
 
Cyclin-dependent kinases 1 and  2 
CDKs 1 and 2 have integral roles in the cell cycle, putative roles in transcriptional 
regulation and a controversial role in apoptosis (Golsteyn 2005). Traditionally, it has 
been believed that the CDK2 interaction with cyclin E facilitates G1/S transition though 
this role has recently been called into question by knockout mouse studies suggesting 
that the complex is dispensable for transition though it does have a role in centrosome 
duplication (Roberts et al. 2003). A second CDK2 complex, CDK2 –cyclin A, 
phosphorylates multiple substrates to inactivate G1 transcription factors and allow DNA 
replication. CDK 1 binds cyclin A at S/G2 transition but moves onto cyclin B to trigger 
G2/M transition and subsequently completes mitosis with the transition to anaphase 
(Golsteyn 2005). CDKs 1 and 2 have been implicated in induction and facilitation of the 
apoptotic process in some experimental scenarios whilst in others it is clear that their 
inhibition promotes apoptosis. CDK2 knockout in HeLa cells and CDK1 knockout in an 
FT210 cell-line resulted in a reduction in apoptosis whilst levels of CDK1-cyclin 
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complexes were noted to be elevated during apoptosis in HL-60 cells, YAC lymphoma 
cells and Jurkat cells. This observation had led some investigators to speculate that 
apoptosis might represent a form of ‘failed mitosis’ (Golsteyn 2005). Additionally, CDK 
inhibition with R-roscovitine appeared to prevent apoptosis in human hepatoma cell-
lines and rat cerebellar neurons. In the latter model it was suggested that CDK1 
phosphorylates BAD (a pro-apoptotic bcl-2 homologue) which facilitates its liberation 
from sequestration by 14-3-3 proteins. This allows BAD to translocate to the 
mitochondrial membrane where it mediates apoptosis (Konishi et al. 2002). This work is 
in complete contrast to experimental experience with CDKi in various cancer cell-lines 
where induction of apoptosis has been demonstrated (MacCallum et al. 2005). Several 
CDKs have roles in transcriptional regulation which is perhaps not surprising given the 
extensive degree of regulation that the transcription process receives from protein 
kinases. CDK2 has been implicated in cisplatin-related acute kidney injury through 
involvement in the release of E2F1 transcriptional machinery by phosphorylation of 
Retinoblastoma (Rb) protein which promotes transcription of pro-apoptotic genes 
(Obligado et al. 2007). Additionally, CDK2 inhibition has been implicated in the 
induction of apoptosis in diffuse large B-cell lymphoma where CDK2 was linked to 
transcription of Mcl-1 (an important survival protein). Apoptosis induced by CDK2 
inhibition was associated with down-regulation of Mcl-1 and reduced phosphorylation 
of the enzyme responsible for Mcl-1 gene transcription, RNA polymerase II (RNA Pol 
II) (Faber et al. 2007). CDK1 mediated phosphorylation of the CTD of RNA Pol II has 
also been reported in vitro (Bregman et al. 2000). Despite a degree of controversy, the 
involvement of CDKs 1 and 2 in apoptosis and transcription (particularly of an 
important neutrophil survival protein) remains interesting when trying to understand the 
mechanism of action of CDK inhibitor drugs in the resolution of inflammation. 
 
Cyclin-dependent kinase 5 
CDK5 is perhaps most renowned as an important player in regulation of neuronal cyto-
architecture and migration though evidence for its extra-neuronal abilities is increasing. 
So far, there is literature describing involvement in apoptosis, transcription, 
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differentiation and endocytosis. Interestingly, there is no evidence that it has any role to 
play in the cell-cycle and as it can function independently of cyclin proteins it is 
essentially mis-named. CDK5 has been implicated in the progression of apoptosis in 
mouse models of ovarian follicle degeneration, embryonic limb interdigital web 
apoptosis and digoxin-mediated prostate apoptosis (Rosales et al. 2006). CDK5 has also 
been shown to phosphorylate the important transcription factor STAT3 whose gene 
products include c-fos and jun-b as well as monocyte non-specific esterase. Of particular 
relevance to inflammation and apoptosis CDK5 complexed to p35 was expressed in 
Human promyelocytic leukemia cell-line (HL-60) induced to differentiate towards a 
monocytic phenotype. Specifically, this complex was shown to confer monocyte 
morphology-defining features such as CD14 and non-specific esterase suggesting a role 
for CDK5 in myeloid differentiation. Additionally, a key neutrophil function, GTP 
dependent secretion, was shown to depend on CDK5-p35 (Rosales et al. 2004). 
Numerous CDK5-p35 substrates were found within neutrophil granules whilst 
neutrophils treated with a CDK inhibitor drug lost GTP-dependent secretory function as 
well as CD63 and CD66b expression. Evidence of CDK5 involvement in transcriptional 
regulation, apoptosis and specific effects on inflammatory cells appears to be convincing 
(Dhavan et al. 2001). 
 
Cyclin dependent kinases 4 and 6 
CDKs 4 and 6 are required for progression through G1 phase and are activated by cyclin 
D in the presence of appropriate growth factors. As we have previously noted 
neutrophils are terminally-differentiated granulocytes. This irreversible cell-cycle arrest 
is mediated by withdrawal of CDK4 and 6 and up-regulation of p27kip1 (an endogenous 
CDK inhibitor). CDK4 and 6, like CDK2, phosphorylate retinoblastoma protein (Rb) to 
relieve elongation factor (EF)-2 transcription factors that initiate the switch to S-phase 
transcription (Klausen et al. 2004). CDK4 and 6 have been implicated in inflammatory 
events within the rheumatoid joint where they are said to modulate rheumatoid synovial 
fibroblast production of MMP-3 and monocyte chemotactic protein-1 (MCP-1) via Rb-
dependent and -independent mechanisms (Nonomura et al. 2006). Importantly, cyclin 
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D/CDK4 complexes have been shown to activate the STAT transcription pathway 
independently of JAK in Drosophila and CDK4 and 6 have been shown to be important 
in leucocyte adhesion and migration (Liu et al. 2008;Silver et al. 2003). CDK4 and 
appear to have roles in inflammatory cell differentiation, adhesion and recruitment as 
well as inflammatory cytokine production and possibly inflammatory signalling. 
Targeting these CDKs would be facilitated by the current availability of specific 
pharmacological inhibitors of CDK4 and 6. 
 
Cyclin dependent kinases 7 and 9 
CDK7 is a CDK activating kinase responsible for enhancing the kinase activity of CDK1 
and 2 by phosphorylation of the activation segment or T-loop. CDK7 associated with 
Cyclin H and menage a trois-1 (MAT1) is responsible for initiation of transcription by 
the holoenzyme RNA Pol II and mediates this effect by phosphorylation of the CTD. 
This is a function it shares with CDK9 which, when associated with cyclin T, is 
responsible for transcriptional elongation by RNA Pol II (Oelgeschlager 2002). CDK7 
and 9 have been implicated in transcription during early infection by CMV and are 
known to be important in activation of HIV1 transcription (Fisher 2005;Kapasi et al. 
2008). Perhaps most interestingly, CDKs 7 and 9 with their respective binding partners 
have been shown to play an integral role in the aberrant survival of multiple myeloma 
cells. This effect is thought to be mediated by RNAPol II transcription of the survival 
protein Mcl-1. R-roscovitine, a CDKi which has specificity for CDK 1,2,5,7 and 9, was 
able to promote apoptosis in these cells which was associated with down-regulation of 
Mcl-1 (MacCallum et al. 2005). Additionally CDK9 has also been shown to bind TNF 
receptor associated factor-2 (TRAF2) a protein that is of known importance in the 
activation of NF-B mediated by TNF- (MacLachlan et al. 1998;Wang et al. 2008). 
Regulation of transcription of Mcl-1 (a key neutrophil survival protein) and involvement 
in pivotal inflammatory signalling via NF-B are functions of CDKs 7 and 9 that might 
be applicable to the regulation of neutrophil apoptosis in inflammatory resolution.  
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1.4.2 Cyclin-dependent kinases in neutrophil granulocytes 
 
As neutrophils do not undergo cell division and can progress no further in the cell-cycle 
(they are thought to remain in Go phase) CDKs had not been thought relevant to their 
biology. There is, therefore, a paucity of information about CDKs, their interactions and 
potential roles in these cells. CDK1 and CDK2 proteins had been identified in 
neutrophils but there was little indication of their function. No change in CDK1 or 
CDK2 protein expression was found in a variety of neutrophil populations including 
fresh human neutrophils, aged human neutrophils, survival factor treated neutrophils at 
various time-points and CDK inhibitor drug treated neutrophils (Rossi et al. 2006). This 
is perhaps not a surprising finding as levels of CDKs 1 and 2 are relatively constant 
throughout the cell cycle and it is changes in expression of their binding partner cyclins 
and endogenous CDK inhibitors that modulate effects on cell-cycle progression 
(Knockaert et al. 2002). It cannot be assumed therefore, that these CDKs are not 
important in the induction of apoptosis even though they are not targets for degradation. 
As previously discussed CDK1 and CDK2 can bind to various cyclin subtypes, whereas 
CDK5 binds non-cyclin partners including p35 and p39 regulatory proteins. In addition, 
CDK5 is expressed in human neutrophils as evidenced by detection of CDK5 mRNA 
and protein (Rosales et al. 2004). Evidence of CDK1, CDK2 and CDK5 activity in 
neutrophils is scarce but available. Our group have demonstrated a prompt reduction in 
CDK1 activity during induction of apoptosis by the activating Fas antibody CH11. The 
CDK-binding partners and regulatory proteins in neutrophils remain to be identified 
(Rossi et al. 2006). It is known that despite the terminally differentiated status of 
neutrophils they are capable of phenotypic alteration. Indeed, it has been postulated 
following work with the ‘MacGreen’ mouse that mouse neutrophils sufficiently 
stimulated with CSF-1 in vitro can transdifferentiate into dendritic-type cells (Sasmono 
et al. 2007). This has implications for the role of neutrophils in the resolution of 
inflammation as it may significantly extend their capability to positively contribute. 
Another phenotypic switch from generation of pro-inflammatory mediators to anti-
inflammatory and/or pro-resolving mediators such as lipoxins and resolvins has also 
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been identified (Serhan 2007). This raises the possibility that a transcriptional effect 
might be mediated by up or down-regulation of protein kinases such as the CDKs. More 
information is required about CDKs, cyclins, endogenous CDK inhibitors and their 
function in inflammatory cells. 
 
1.4.3 Cyclin-dependent kinase inhibitor drugs in inflammation 
 
The research discussed above led our group to investigate a role for CDK inhibitor drugs 
in inflammation. Our research paradigm has been that inflammation should be driven 
down resolution pathways by the induction of apoptosis in granulocytes followed by 
their effective clearance by professional phagocytes such as macrophages (Leitch et al. 
2008). Rossi et al initially examined the in vitro effects of R-roscovitine, NG-75 and 
hymenialdisine on human neutrophils at different time-points and drug concentrations 
(Rossi et al. 2006). These CDK inhibitor drugs are structurally diverse but their uniform 
effect was to promote neutrophil apoptosis in a time and concentration dependent 
manner as evidenced by annexin-V binding and morphological assessment. Neutrophils 
treated with R-roscovitine and the caspase-inhibitor zVAD-fmk failed to enter apoptosis, 
suggesting that R-roscovitine was acting in a caspase-dependent manner. This was 
evident at 4 hours post-incubation when caspase-3 cleavage was already detectable. The 
most intriguing in vitro result was the ability of the CDK inhibitor drugs to overcome 
diverse survival factors including db-cAMP, GM-CSF and LPS. These survival factors 
utilise the major inflammatory signalling pathways: PI3K, NF-B, JAK/STAT and 
MAPK, to augment neutrophil survival. Given that the major hurdle to development of 
anti-inflammatory agents is the redundancy conferred by these same signalling pathways 
this result underlined the potential of CDK inhibitor drug therapy for treatment of 
inflammatory disease. Inflammation research demands in vivo experimentation as it is 
impossible to recreate the inflammatory milieu in vitro and hence to predict the 
efficacious translation of an agent that has been successful in vitro. R-roscovitine was 
investigated in three mouse models of neutrophil dominant inflammation including: 
carageenan-induced pleurisy, bleomycin lung injury and passively induced arthritis. In 
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the carageenan pleurisy model 100mg/kg of R-roscovitine administered intraperitoneally 
reduced an established inflammatory infiltrate to near basal levels consistent with those 
found in an untreated mouse pleural cavity. There was a reduction in populations of 
inflammatory cells (including neutrophils, monocytes and macrophages), oedema 
formation and pro-inflammatory cytokines. This effect was reversed in vivo by 
administration of the caspase inhibitor zVAD-fmk. In mice with established bleomycin-
lung injury there was a reduction in BAL neutrophil numbers assessed after three days, a 
reduction in histopathological lung inflammation after 7 days and an effect on 
bleomycin-induced lethality. Finally, in mice with established passively-induced arthritis 
there was an improvement in clinical scores of arthritis following R-roscovitine 
administration (Rossi et al. 2006). These in vivo findings suggest encouraging pleiotropic 
effects of CDK inhibitor drugs on granulocyte recruitment, survival and removal. 
Pleiotropic effects of CDK inhibitors are supported by work from Liu et al who have 
shown that CDK4 is important in leucocyte recruitment and adhesion. They studied 
CDK4 -/- knockout mice with bleomycin lung injury and utilised siRNA to CDK4 and 
CDK inhibitor drugs to show that CDK4 inhibition inhibited leucocyte recruitment in the 
mouse model and leucocyte adhesion in endothelial cell (EC) matrix models (Liu et al. 
2008). In addition Sekine et al have now demonstrated positive effects of flavopiridol 
and a specific CDK4, 6 inhibitor on animal models of rheumatoid arthritis (Sekine et al. 
2008). Their findings suggest lymphocyte independent effects of CDK inhibitors 
(including down-regulation of fibroblast proliferation and growth) are responsible for 
improvement in joint histology and clinical arthritis scores in various mouse models. 
Findings in inflammatory joint and lung disease models are mirrored in kidney disease 
models where the CDK inhibitor drug R-roscovitine has entered phase 1b clinical trials 
for inflammatory kidney disease. Glomerulonephritides are characterised by 
inflammation and progressive, scarring destruction of key functional kidney units 
leading to renal dysfunction and failure. Pre-clinically, CDK inhibitor drugs have been 
shown to protect renal tubular epithelium from enhanced apoptosis whilst inhibiting the 
abnormal proliferation of tubular epithelial and mesangial cells.  In vitro and in vivo 
work has demonstrated that R-roscovitine can restore normal kidney function in animal 
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models of IgA-mediated glomerulonephritis, crescentic glomerulonephritis, lupus 
nephritis and collapsing glomerulonephropathy (Gherardi et al. 2004;Milovanceva-
Popovska et al. 2005;Obligado et al. 2007;Zoja et al. 2007). The work with NZBxNZW 
mice affected by early or established proliferative lupus nephritis is particularly 
interesting as whilst leucocyte driven inflammation was shown to be reduced there was 
also evidence of a direct effect of CDK inhibitor drugs against autoimmune T- and B-
lymphocyte responses. It is perhaps less surprising that CDK inhibitors should work in 
this setting given the proliferative potential/state of differentiation of lymphocytes but 
nonetheless the possibility of pleiotropic action against autoimmune inflammation is an 
exciting one. 
 Further evidence for the utility of CDK inhibitors has been provided by research into the 
properties of endogenous CDK inhibitors. The physiological CDK inhibitor p21 (WAF1, 
SD1, Cip1), a specific inhibitor of CDK2, 4 and 6 has been shown to negatively regulate 
macrophage activation by reducing TNF- and IL-1production in response to LPS. 
Additionally, p21-/- mice have an increased susceptibility to LPS-induced shock which 
is associated with elevated levels of IL-1 (Lloberas et al. 2009;Scatizzi et al. 2009). In 
an inflammatory lung disease model, p21 was over-expressed in the lungs of mice 
subjected to bleomycin injury by an intra-tracheal adenoviral transfer method (Inoshima 
et al. 2004). p21 expression in lung epithelial cells led to a reduction in lung 
inflammation, preservation of epithelial cells and reduced fibrosis. In rheumatoid 
arthritis patients, p21 gene transfer was shown to down-regulate expression of 
inflammatory mediators and tissue-degrading proteinases such as: IL-6, -8, type I IL-1 
receptor, MCP-1, MIP-3, cathepsins B and K, and MMPs -1 and -3  (Nonomura et al. 
2003).  
In summary, CDK inhibitor drugs promote neutrophil apoptosis in vitro even in the 
presence of powerful survival factors and promotes resolution of inflammation, in vivo, 
in various animal models of neutrophil-dominant inflammation. Neutrophil apoptosis has 
been shown to be central to the resolution of inflammation by caspase inhibition which 
reversed the beneficial impact of CDK inhibitors. In addition the anti-proliferative and 
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anti-apoptotic effects of CDK inhibitors protect epithelia against inflammatory insult.  
CDK inhibitor drugs also prevent lymphocyte proliferation and pro-inflammatory 
signalling indicating potential effects against chronic and autoimmune, inflammatory 
disease. An understanding of the mechanism of action by which these powerful anti-
inflammatory effects are achieved may allow optimisation of CDK inhibitor drugs and 
suggest further targets for pharmacological intervention. 
 
1.4.4 Cyclin-dependent kinase inhibition  
 
Cyclin-dependent kinase inhibitor drugs such as R-roscovitine have emerged as 
potential, anti-inflammatory agents that augment neutrophil apoptosis and suppress 
lymphocyte proliferation and secretory function (Obligado et al. 2007;Rossi et al. 2006). 
This former finding seems counter-intuitive because the neutrophil is a terminally-
differentiated cell and its cell-cycle machinery ought to be effectively vestigial. Further 
research is required before we develop a functional understanding of the mechanism of 
action of CDK inhibitor drugs in inflammation but already some tantalising clues are 
emerging. This section will focus on the CDKs, their inhibitors, the role of CDK 
inhibitors in inflammation and areas for further research. It is anticipated that CDK 
inhibitor drugs will provide the basis for the development of novel therapeutic agents 
that drive resolution of inflammation and counter inflammatory disease. 
 
Pharmacological CDK inhibitors  
Pioneering work on the cell-cycle in starfish oocytes in the 1990s, driven by the 
realisation that anti-mitotic agents would make effective anti-cancer drugs, led to the 
discovery of CDK inhibitors (Meijer et al. 2003). The widely available, non-specific 
kinase inhibitors staurosporine, 6 D-MAP and isopentanyladine were found to potently 
inhibit CDK1/cyclin B but were too non-specific in action to yield useful information 
about the functional impact. A laborious screening process subsequently uncovered 
olomoucine, a purine analogue that showed enhanced specificity for CDKs but some 
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action against MAPKs. This compound was shown to mediate its inhibitory effect by 
competing with ATP for a binding site on CDK1. Further structural analysis of this 
ATP-binding site interaction identified the 2,6,9 trisubstituted purine family as likely 
candidates for effective CDK inhibition. This was the development that brought R-
roscovitine and Purvalanol B into the frame and led to the identification of a family of 
approximately 50 CDK inhibitors (Table 1) (Meijer et al. 2003). 
 
Table 1: IC50 values for selected CDK inhibitor drugs (Bettayeb et al. 
2007;Knockaert et al. 2002;Krystof et al. 2002;Obligado et al. 2007) 
 
 


























0.16 0.49 0.74, 
0.78 
130 34 14 
Olomoucine  7 7 >1000 3   100 30 50 
Olomoucine II 7.6 0.1 19.8  0.45 0.06 >100  32 
Purvalanol B 0.006 0.009 >10 0.006   >10 3.33  
Flavopiridol 0.06, 
0.4 
0.15 0.4 0.17 0.3 0.006 0.45   
Aminopurvalanol 0.033 0.028  0.02    12 2.4 
Hymenialdisine 0.022 0.04 0.6 0.028   0.01 0.47 2 
Fascaplysin >100 >50 0.35 20      
OL567 0.23         
H717 0.23 0.05        
NU2058 5 12        
NU6027 2.5 1.3        
Staurosporine 0.006 0.007 <10     0.02 0.02 
PD183812 >40 0.17 0.008       
Meriolin 1 0.78 0.09  0.51  0.026 0.63   
SU 9516 0.04  0.2       
DRB     20 3    
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CDK inhibitor drugs are universally (to date) flat, hydrophobic heterocycles of low 
molecular weight that mediate binding to the ATP pocket via hydrophobic interactions 
and hydrogen bonds. Surprisingly, despite this uniformity, it is possible to categorise the 
CDK inhibitors on the basis of their relative specificity for CDKs: 1. Non-specific 
(Flavopiridol), 2. CDK 1,2,5,7-specific (Olomoucine, R-roscovitine and Purvalanol B), 
3. CDK 4,6-specific (fascaplysin, PD0183812). It is clear that any discussion of CDK 
inhibitor specificity for individual CDKs can only be couched in relative terms. 
Additionally, there are some non CDK targets of these inhibitors identified on random 
screening which include ERK, GSK3 and pyridoxal kinase (Knockaert et al. 2002). 
Given the range of activities performed by CDKs on a variety of vital cell processes a 
lack of incisive specificity attributable to an inhibitor makes it extremely difficult to 
assign outcomes to specific actions on defined targets. The basis for this work is that 
CDK inhibitor drugs have proven efficacy in models of inflammation but the reality is 
that these effects may not relate to any action on CDKs themselves. An obvious point of 
interest then, is the inhibitory effect of certain CDK inhibitor drugs on the ERK 
signalling pathway. Recent work has shown that specific ERK-inhibitors can enhance 
the resolution of carageenan-induced pleurisy in rats, an accepted model of acute 
inflammation (Sawatzky et al. 2006). However, it seems likely that the inhibitory effect 
of CDK inhibitors on the ERK pathway would not account for the anti-inflammatory 
actions of R-roscovitine.  In addition, the biological effect of CDK inhibitors and ERK 
inhibitors on neutrophil apoptosis differ markedly. For example: the ERK inhbitor 
PD98059 does not induce neutrophil apoptosis per se whereas CDK inhibitor drugs do; 
R-roscovitine reverses LPS, GM-CSF and dibutyryl (db)-cAMP mediated prolongation 
of neutrophil survival whereas PD98059, only reverses LPS and GM-CSF survival; 
finally, PD98059 completely inhibits LPS induced phospho-ERK expression in 
neutrophils whereas R-roscovitine does not (Leitch et al. 2010b).  Regardless of the 
difficulties associated with non-specificity the ability of CDK inhibitor drugs to 
selectively induce apoptosis in actively proliferating cells has meant that research into 
their use as anti-cancer agents has progressed rapidly.   
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CDK inhibitor drugs including R-roscovitine, flavopiridol and SU9516 have anti-cancer 
actions and R-roscovitine alone is known to reduce the proliferation index of 19 distinct 
cancer cell-lines in vitro (McClue et al. 2002). The mechanism of action of CDK 
inhibitors in cancer cell-lines whilst not directly applicable to inflammatory cells is of 
great interest to those interested in targeting CDKs to resolve inflammation. CDK 
inhibitors were an exciting therapeutic prospect because CDKs interact with the Rb 
family widely regarded as the master-switch of the cell cycle. CDKs are overabundant in 
some cancers resulting in excessive phosphorylation and functional inactivation of Rb, 
allowing unregulated proliferation (Johnson et al. 1994). However, it was noted that R-
roscovitine was capable not only of inducing cell cycle arrest, but of active promotion of 
apoptosis. The induction of apoptosis by R-roscovitine in myeloma cell-lines has been 
reported to be promoted by CDK modulation of RNA Pol II mediated transcription of 
Mcl-1. Additionally, down-regulation of XIAP, another Bcl-2 homologous survival 
protein, was observed in chronic lymphatic leukaemia cells and apoptosis in both cell-
lines was found to be caspase-dependent (Hahntow et al. 2004;MacCallum et al. 2005). 
A recent paper has shown inhibition of the well known inflammatory transcription 
factor, NF-B by R-roscovitine in A549, 293, H1299 and ARN8 cancer cell lines (Dey 
et al. 2008). It is tempting to directly extrapolate from these findings to inflammation 
studies but given the sometimes, directly contrasting effects of pharmacological agents 
in different cell-types (for example the anti-apoptotic effects of CDK-inhibition in 
cerebellar neuronal cells) we must await further definitive studies. The availability of 
this mechanistic information and encouraging safety profiles in animal studies have 
allowed progression to clinical trials of CDK inhibitor drugs in conditions such as B-cell 
malignancy, non-small cell lung cancer and breast cancer. The side-effect profile has 
been promising but includes tolerable and limited gastrointestinal disturbance, skin rash, 
reversible transaminitis and hypokalaemia (Senderowicz 2003). This transition to human 
studies makes an elucidation of the mechanism of action of CDK inhibitor drugs in 
inflammation imperative, as trials of these drugs in inflammatory disease are likely to be 
on the near horizon. 
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1.5. Modelling inflammatory lung disease in vivo 
 
There are many methods available for the production of relevant animal models of 
inflammatory disease. These include: direct chemical/other injury, constitutive and 
inducible transgenics, viral-vector delivery of relevant genes, adoptive cell transfer and 
direct infection strategies. The advantage of the animal model is that it reproduces the 
complexity of the wider immune/inflammatory response on an organ or systems-wide 
basis as opposed to cell-line strategies which can only examine individual cellular 
responses. Clearly, reliable animal models are central to the development of efficacious 
and safe pharmaceutical agents that drive granulocyte apoptosis and clearance to 
enhance resolution of inflammation. The animal model examined in this thesis is the 
murine bleomycin acute lung injury model. 
 
1.5.1 Bleomycin lung injury 
 
Murine bleomycin lung injury is one of the most widely used and well characterised 
animal models of lung disease described. The drug bleomycin is an antibiotic that can be 
isolated from streptomyces verticillatus and has been used as an antineoplastic agent for 
a number of cancers including Hodgkin’s lymphoma and testicular cancer. It was in this 
setting that toxic lung fibrosis was first encountered as an unwanted side-effect. 
Bleomycin causes damage by inducing DNA strand brakes and causing oxidative 
damage. It induces dose-dependent lung injury and fibrosis in a range of animals and it 
can be administered intravenously (i.v.), intra-tracheally (i.t.), subcutaneously (s/c) or 
intraperitoneally (i.p.). There are advantages to each method of administration but the 
usual outcome is acute lung injury consisting of necrotic loss of alveolar epithelium, 
hyaline membrane formation, alveolar consolidation (neutrophil/lymphocyte influx) and 
protein leak followed by a fibrotic reparative phase of collagen deposition (Moeller et al. 
2008;Moore et al. 2008). 
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At 1-7 days following bleomycin administration the major histopathological events are 
epithelial cell damage and loss and an intense mixed infiltrate of neutrophils, activated 
macrophages and lymphocytes within the alveolar spaces and parenchyma. The 
inflammatory cytokines TNF-, IL-6, IL-8 and GM-CSF are said to predominate in the 
acute phase. During days 7-14 the inflammatory infiltrate begins to clear and fibroblast 
proliferation with extra-cellular matrix deposition predominate. At day 14 the first signs 
of fibrosis are evident and this persists and progresses to day 28. TGF- and other genes 
regulated by it are the major drivers of the fibrotic phase. Beyond this point lung fibrosis 
begins to resolve spontaneously, a feature that is the major weakness of the murine 
model in comparison to the relentlessly progressive human disease. The major strengths 
of this model are its reproducibility and similarity to human disease pathology especially 
in the production of predominantly bronchiolocentric fibrotic changes and acute alveolar 
and interstitial inflammation leading to epithelial cell death and basement membrane 
damage (Moeller et al. 2008;Moore et al. 2008).  
 
In this thesis the acute lung injury phase of the bleomycin model is investigated because 
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1.6 Summary of Introduction and Aims 
 
Inflammation is the main cause or a major contributor to the pathogenesis of a number 
of lung diseases. Many of the damaging sequelae of inflammation are attributable to 
neutrophil granulocytes that are either inappropriately activated, unnecessarily persistent 
or insufficiently regulated. A strategy for the resolution of inflammation may involve the 
promotion of neutrophil granulocyte apoptosis provided that professional phagocytes are 
able to clear the increased apoptotic cell burden. Neutrophils are critically dependent on 
the bcl-2 homologue survival protein Mcl-1 which is known to be rapidly turned over 
within the cell. CDKs are key proteins involved in the regulation of the cell cycle but 
also have important roles in transcription and apoptosis. CDK inhibitor drugs can drive 
neutrophil apoptosis and resolution of inflammation. This thesis will aim to investigate: 
 
1. The mechanism by which CDK inhibitor drugs induce neutrophil apoptosis  
2. The molecular events involved in apoptosis driven by CDK inhibitor drugs 
3. The relevance/importance of CDKs as targets of CDK inhibitor drugs in the 
induction of neutrophil apoptosis 
4. The possibility of producing molecular biology tools/agents to reliably and 
specifically knockdown key targets of CDK inhibitor drugs in neutrophil 
granulocyte cells 
5. The mechanisms by which inflammation is resolved by CDK inhibitor drugs in 
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1.7   Hypotheses 
 
1. CDK inhibitor drugs drive neutrophil apoptosis by the 
intrinsic (mitochondrial) pathway 
2. Mcl-1 is required for neutrophil survival 
3. Neutrophils have transcriptional machinery and  
functional CDKs  
4. CDK inhibitor drugs target CDKs 7 and 9 to down-regulate 
transcription of the key survival protein Mcl-1 
5. Neutrophils are dependent on their transcriptional 
capacity for survival 
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2. Materials and Methods 
2.1 Materials  
TRIzol® Reagent (Gibco) 
Diethyl Pyrocarbonate (DEPC) (Sigma)  
NDSB-201 (3-(1-Pyridino)-1-propane sulfonate) 
18S competimers (Applied Biosystems) 
2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine (R-Roscovitine; 
Calbiochem, UK) 
2-Val-Ala-DL-Asp (OMe) Flrylmethoketone (Z-Vad-fmk; Bachem, Switzerland) 
5,6-Dichlorobenzimidazole 1-β-D-ribofuranoside (DRB; Sigma) 
Annexin V Fluos (Roche) 
BioMax MS-1 light–sensitive film (Kodak) 
Bleomycin (Apollo Scientific) 
Calcium chloride (Sigma) 
CDK4 inhibitor (2-Bromo-12,13-dihydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-
5,7(6H)-dione, Calbiochem)  
Cell culture medium and Trypsin/EDTA (PAA Laboratories Ltd, UK) 
CellTrackerTM Green (Molecular Probes, Invitrogen, UK) 
DAPI (Invitrogen) 
Dexamethasone, LPS (E Coli) (Sigma) 
Dextran (Pharmacosmos) 
Diff-QuikTM (Gamidor Ltd., Abingdon, GB). 
ECL reagents (GE Healthcare) 
Fetal Calf Serum (Biosera, UK) 
FITC (Sigma) 
Gliotoxin (Calbiochem) 
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PCR Master-mix (Promega) 
PercollTM (GE Healthcare, UK) 
PI (Sigma) 
Precision Precast gels (Pierce) 
PVDF (Immobilon-P, Millipore) 
Recombinant human GM-CSF (R&D Systems) 
Recombinant human TNF-α (R & D Systems, Abingdon, Oxon, UK) 
Mcl-1 primers (eurofins): Mcl-1FOR 5'-GCGTAACAAACTGGGGCAG-3', Mcl-1REV 
5'-GCAAAAGCCAGCAGCACATT-3' 
XIAP primers (eurofins): XIAPforward 5’-GGAACCTTGTGATCGTGCCT-3’ 
XIAPreverse 5’-AATCAGTTAGCCCTCCTCCA-3’  
CDK7 primers (eurofins):  
CDK7DNFOR1 5’GAATTCGATGGCTCTGGACGTGAAGTC TCG-3'  HPLC+ 
CDK7DNREV1 5'-GCGGCCGCTTAAAAAATTAGTTTCTTGGGCAA-3'  HPLC+ 
CDK7DNFOR2 5'-GGCTTATTCTTATTTAATCCATGTG-3'  HPS 
CDK7DNREV2 5'-GACAAGGCTAATATTAGATTTATGT-3'  HPS          
CDK9 primers (eurofins):  
CDK9FOR1 5'-GAATTCTATGGCAAAGCAGTACGACTCGGTG-3'  HPLC+ 
CDK9REV1 5'-GCGGCCGCTCAGAAGACGCGCTCAAACTCCGT-3'  HPLC+ 
CDK9FOR2 5'-CCTGCCCAGCGCATCGACAGCGATG-3'  HPS 
CDK9REV2 5'-CTTCTTCAGAGCCACCTTCTGGCC-3'  HPS 




4x Sample Buffer: 2.4ml 1 M Tris pH 6.8, 0.8 g SDS stock, 4ml 100% glycerol, 0.01% 
bromophenol blue, 1ml ß-mercaptoethanol, 2.8ml water. 
 
Annexin-V binding buffer (HBSS (w/o cations) + 5mM CaCl2). 
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IMDM, HBSS, PBS, PBS 10x (Life Technologies, Paisley, United Kingdom). 
 
Whole cell lysis buffer (standard): 0.5ml aliquot of 1:50 dilution of Sigma Protease 
cocktail P8340 in 1xTBS plus 0.3ml 1xTBS, 1.5mM EDTA, 10mM KCl, 0.5mM 
dithiothreitol, 1mg/ml aprotinin, leupeptin, and pepstatin A, 1mM 4-(2-aminoethyl) 
benzenesulfonyl fluoride, 1mM sodium orthovanadate, 0.5mM benzamidine, and 2 mM 
levamisole. 
 
TBE: 0.45M Tris, 0.45M Boric acid, 10mM EDTA, pH 8.3. 
 
Running Buffer: 100mM Tris, 100mM HEPES, 3mM SDS, pH 8. 
 
Transfer Buffer: 25mM Tris, Glycine 192mM, 10% methanol. 
 
TBS: 50mM Tris, 150mM NaCl, pH 7.4. 
 
Blocking solution: TBS/Tween (0.1%)/Dried milk (Marvel) 5%. 
 
Cytoplasmic Lysis Buffer: AEBSF 0.5mM, HEPES 50mM, KCl 50mM, MgCl2 2mM, 
EDTA 0.1mM, Aprotinin 10g/ml, Levamisole 2mM, Leupeptin 10g/ml, Sodium 
orthovanadate 1mM, Benzamidine 0.5mM, -Glycerophosphate 10mM, Pepstatin A 
10g/ml, Phenanthroline 1mM, PMSF 1mM. 
 
Nuclear Lysis Buffer: AEBSF 0.5mM, HEPES 50mM, KCl 50mM, NaCl 300mM, 
Glycerol 10%, EDTA 0.1mM, Aprotinin 10g/ml, Levamisole 2mM, Leupeptin, 
10g/ml, Sodium orthovanadate 1mM, Benzamidine 0.5mM, -Glycerophosphate 
10mM, Pepstatin A 10g/ml, Phenanthroline 1mM, PMSF 1mM. 
 
Resuspension buffer: 25mm NaH2PO4. 
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Solubilisation buffer: 6M Guanidine HCl, 25mm NaH2PO4, 0.5M NaCl, 1mM -
mercaptoethanol. 
 
Refolding buffer 1: 25mM NaH2PO4, 0.5M NaCl, 1mM -mercaptoethanol. 
 
Refolding buffer 2: 50mM HEPES pH 7.5, 0.2M NaCl, 1mM DTT; 1mM reduced 
glutathione; 10% Glycerol; 0.5M Guanidine HCl; 1mM EDTA. (DTT and glutathione 
added fresh). 
 
Refolding buffer 3: 50mM HEPES pH 7.5, 0.2M NaCl, 1mM DTT, 1mM reduced 
glutathione 10% Glycerol, 0.5M NDSB-201, 1mM EDTA. (DTT and glutathione added 
fresh).  
 
Elution buffer 1: 25mM NaH2PO4, 0.5M NaCl, 1mM -mercaptoethanol, 250mM 
imidazole. 
 
Elution buffer 2: 6M Guanidine HCl, 25mm NaH2PO4, 0.5M NaCl, 1mM -
mercaptoethanol, 250mM imidazole. 
 
Elution buffer 3: 50mM HEPES pH 7.5, 0.2M NaCl, 1mM DTT, 1mM reduced 
glutathione, 10% Glycerol, 0.5M NDSB-201, 1mM EDTA. (DTT and glutathione added 






Anti-Bid (Santa Cruz) 
Anti-Bax (Santa Cruz) 
Anti-Bim (Cell Signalling) 
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Anti- IкBα (Abcam) 
Anti--actin (Sigma-Aldrich)  
Goat anti-mouse/-rabbit and rabbit anti-goat horseradish peroxidase (HRP)–conjugated 
(Dako)  
Anti-RNA polymerase II (PS 2, PS 5, Total) (Covance) 
Anti-CDK 2,5,7,9 (Santa Cruz) 
Anti-cyclin T1, H, MAT1 (HRP-conjugated, Santa Cruz) 
Alexa (Goat anti-Mouse) 647 Fab fragments (Invitrogen)  
Alexa (Goat anti-Rabbit) 647 Fab fragments (Invitrogen 
 
2.4 Methods  
 
2.4.1 Cell Isolation and Culture 
 
Polymorphonuclear leukocytes were isolated from peripheral venous blood of healthy 
human donors. Approximately 40-160ml of blood was isolated on any one occasion and 
collected in 50ml polypropylene tubes containing sterile sodium citrate (to final conc. 
0.38%). After centrifugation of citrated whole blood at 300g for 20min and removal of 
platelet-rich plasma, leukocytes were separated from erythrocytes by dextran 
sedimentation over 25-30min using pre-warmed 0.6% (wt/vol) dextran T500. The upper 
leukocyte-rich layer was carefully aspirated and the volume adjusted to 50ml using pre-
warmed 0.9% saline. Leukocytes were subsequently pelleted by centrifugation at 350g 
for 6min. Polymorphonuclear leukocytes were then separated from mononuclear 
leukocytes using discontinuous isotonic Percoll (a 9:1 ratio of percoll:10xPBS) gradients 
(81%, 70% 55% Percoll in 1xPBS without cations). Gradients were prepared by layering 
3ml of 70% isotonic percoll on 3ml of 81% isotonic percoll in a 15ml polypropylene 
tube before layering leucocytes re-suspended in 3ml 55% percoll on top. Gradients were 
centrifuged at 720g for 20min at which point mononuclear cells were found at the upper 
55:70% interface while polymorphonuclear leucocytes were at the 70:81% interface. 
Cell yield was estimated with a bright-line haemocytometer. Leukocytes underwent a 
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further two wash steps in pre-warmed 1xPBS without cations. Polymorphonuclear 
leukocytes were at least 98% neutrophils using morphologic criteria and cell viability 
was assessed by trypan blue exclusion. Cells were re-suspended at 5x106/ml in IMDM  
plus 50U/ml penicillin and 50U/ml streptomycin plus 10% autologous serum and treated 
in 2ml eppendorf tubes at 37oC  on a shaking heat block or cultured in flat-bottomed 
flexible well plates in a humidified, 5% CO2  atmosphere at 37 º C. 
 
2.4.2 Assessment of granulocyte apoptosis by microscopy and flow 
cytometry 
 
Neutrophil apoptosis was assessed morphologically by cyto-centrifuging 100µl of 5x106 
cells/ml at 300rpm for 3min. Cells were air-dried then fixed for 1min in methanol and 
stained with Diff-QuikTM. Morphology was assessed at 100x objective on an oil-
immersion microscope. Apoptotic cells were defined as those containing one or more 
darkly stained pyknotic nuclei (500 cells were counted over 5 fields of view). 
Additionally, flow cytometric assessment of annexin-V binding and propidium iodide 
(PI) staining were used to assess apoptosis and necrosis respectively. Annexin-V was 
diluted 1/500 in binding buffer (HBSS + Ca2+) and 280µl added to 20µl of cells 
(5x106cells/ml). Samples were then incubated on ice at 4C for 10min.  Immediately 
prior to processing on the Coulter FACSCaliber flow cytometer (Beckman Coulter, 
California, USA), 1µl of PI (1mg/ml) per sample was added. Data were captured with 
the use of cellquest software (Becton Dickinson) with FL1 designated as Annexin-V 
positivity while FL2 reflected PI positivity. Measurements were made as percentages of 
total gated neutrophils. 
 
2.4.3 Standard cell lysis protocol 
 
Cells were pelleted at 10000g for 30s then re-suspended in 180µl of whole cell lysis 
buffer they were then incubated on ice for 10min. Following this 10µl of 10% NP-40 
lysis buffer was added and samples quickly vortexed before incubating on ice for a 
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further 10min. The samples were then centrifuged at 10000g, 4oC for 20min after which 
supernatants were removed, 4x sample buffer added and samples boiled on a 95oC heat 
block for 5min and stored at -20oC/-80oC. 
 
2.4.4 Western Blotting 
 
Cells at a concentration of 5x106/ml per condition were incubated at 37oC on a shaking 
heat block. For times and reagent concentrations please refer to figure legends. Lysates, 
prepared as described above, and run on 4, 10, or 12% SDS gel (either precast gels or 
prepared to above recipe) and transferred onto PVDF. Membranes were blocked for 1h 
in 5% (wt/vol) dried milk/TBS/0.1% Tween-20 or 5% (wt/vol) BSA/TBS/0.1% Tween-
20 prior to overnight incubation at 4ºC (or 1.5h at room temperature for -actin and HRP 
conjugated primary antibodies) with primary antibodies diluted as indicated above. 
Following 3x 5 min washes in TBS/0.1% Tween-20 blots were incubated with the 
appropriate HRP-conjugated secondary antibody diluted 1:2500 for 1h at room 
temperature (if required) prior to incubation with ECL reagents, exposure to light–
sensitive film, and processing through an x-ray developer (X-Ograph Imaging Systems). 
 
2.4.5 RNA isolation and reverse transcriptase-polymerase chain reaction 
(PCR) (semi-quantitative) 
 
Total neutrophil RNA was isolated with the sole use of a Nucleospin RNA II kit 
(Macherey-Nagel) as per manufacturer’s instructions apart from for the illumina gene 
chip experiment where a dual method with a trizolTM extraction stage was performed. 
2g of RNA was made up to a final volume of 25l with DEPC-ddH2O. Reaction mix 
for each sample prepared as follows: 10l  5x M-MLV reaction buffer, 5l 100mM 
DTT, 5l 100g/ml oligo(dT) primer, 4l 10mM dNTPs, 0.5l  Rnasin, 0.5l M-MLV 
reverse transcriptase. 25l of this mix added to each 2g RNA sample prior to 
incubation for 90 min at 37oC to allow cDNA synthesis. Reaction stopped by incubating 
at 90oC for 10min. 2μL Primers and 5l cDNA added to 25l Master-mix and volume 
                                                                                                                                           65
made up to 50l with DPEC H2O. Tubes placed in thermal-cycler with following 
program: 94°C for 4min then: 94° C for 45s, 55° C for 45s, 72° C for 45s x 30 - 35 
cycles, 72° C for 10min. Products separated by agarose gel electrophoresis on 1-2% (in 
TBE) gels (using GelRed nucleic-acid detection dye/ethidium bromide) in TBE prior to 
visualisation and image capture with a UV-light camera. 
 
2.4.6 Immunohistochemistry and confocal microscopy 
 
Freshly isolated neutrophils at 2.5x106/ml or incubated with treatments in 2ml 
eppendorfs on 37oC shaking heat block for indicated time-points were pelleted by 
centrifugation at 300g for 4min prior to resuspension and transfer to coverslips. They 
were then fixed for 20min in 3% paraformaldehyde (PFA). After washing and quenching 
with 50mM glycine, cells were re-suspended in 50μl of 10% goat serum (as secondary 
antibodies were goat) and blocked for 1h. Supernatant was removed and coverslips were 
gently placed onto 100μl of indicated primary antibody diluted as indicated for 1h. 
Following washing, the cells were incubated with 50μl of appropriate fluorescent-
conjugated secondary antibody as well as nuclear stain (DAPI/PI, 2μl in 1ml) for 1h 
before further washing in PBS and finally ddH2O. Coverslips were transferred to slides 
and mounted with mowiol and nail varnish prior to visualization on confocal microscope 
(Zeiss LSM510meta/Leica SP5). All experiments were performed with controls in the 
form of unlabelled cells, cells labelled with primary antibody only and cells labelled 
with secondary antibody only. 
 
2.4.7 Neutrophil/cytoplasmic differential lysis  
 
Neutrophils incubated in 2ml Eppendorf tubes on shaking heat block (37oC) and pelleted 
by centrifugation at 3000g for 60s and re-suspended in 100l of cytoplasmic lysis 
buffer. Sample incubated on ice for 10min then 10l of NP-40 added, briefly vortexed 
and centrifuged for 10min at 4300g. Supernatant removed, added to appropriate volume 
of sample buffer and boiled for 2min at 95 oC. Remaining cell pellet re-suspended in 
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50l of nuclear lysis buffer and placed at 4 oC plus constant shaking for 20min to 
solubilise nuclear proteins. Samples then centrifuged at 23100g for 10min and 
supernatants added to appropriate volume sample buffer before boiling at 95 oC for 
2min. 
 
2.4.8 Assessment of apoptosis by MitocaptureTM assay 
 
MitoCaptureTM is a fluorescence-based tool for distinguishing between viable and 
apoptotic cells by detecting changes in the mitochondrial transmembrane potential. 
Neutrophils were isolated as above and incubated with appropriate reagent at a 
concentration of 5x104/ml in a flat-bottomed 96-well plate at 37oC, 5%CO2 for 2h.  
MitoCaptureTM kit used as per manufacturer’s instructions. Briefly, media removed and 
replaced with MitocaptureTM dye:MitocaptureTM buffer 1:1000 followed by incubation 
as previous for 30min. MitocaptureTM dye/ buffer then removed and replaced with 
MitocaptureTM buffer alone. Fluorescence microscopy was performed using a Zeiss 
Axiovert S100 microscope. Cells fluorescing green were adjudged to have lost 
mitochondrial membrane potential whilst those fluorescing orange/red were deemed to 
have intact mitochondria. Three separate experiments with three replicates of individual 
treatments were performed. Photographs were made and 500 cells were counted per 
replicate. 
 
2.4.9 Assessment of apoptosis by DNA laddering 
 
DNA was extracted from 10x106neutrophils per treatment. Treatments were performed 
as before in 2ml eppendorf tubes on a shaking heat block and purified with the use of the 
DNAeasy kit (Qiagen) according to manufacturer’s instructions for isolation of DNA 
from blood. Briefly: cells centrifuged (5min, 300g), pellet resuspended in 200μl 1xPBS 
(no cations), 200μl Buffer AL prior to vortexing, and incubation at 56°C for 10min on 
heat block. Ethanol (200μl, 96–100%) added before further vortexing to obtain a 
homogeneous solution. Sample loaded to DNeasy Mini spin column placed in a 2 ml 
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collection tube and centrifuged (6000g, 1min). Flow-through and collection tube 
discarded before sequential wash-steps with 500μl Buffer AW1 and 500μl Buffer AW2. 
DNeasy Mini spin column placed in a clean 2ml microcentrifuge tube and DNA eluted 
with 100μl Buffer AE (spin column centrifuged for 1min at 6000g). DNA concentration 
and purity was checked with the use of a Nanodrop 100. Approx. 0.5-1g DNA obtained 
per treatment. DNA was resuspended in 4x sample buffer and subjected to 1% agarose 
gel electophoresis as described previously.  
 
2.4.10 Assessment of apoptosis by ApoalertTM assay  
 
A fluorometric caspase activation detection kit (ApoAlertTM kit) was used to measure 
the kinetics of caspase activation in neutrophils. This kit utilizes caspase substrates 
attached to fluorescent linker molecules that emit following successful caspase cleavage 
of substrate. This was carried out in accordance with manufacturer’s (Clontech) 
instructions. Briefly: Neutrophils were incubated as described previously with/without 
R-roscovitine for times indicated in figure. Cells were pelleted and lysed in 1x cell lysis 
buffer (manufacturer’s own) for 10min on ice. Cells centrifuged at 21000g for 5 min at 
4oC and 50l of cell lysate supernatants was added to a 96-well plate preincubated 
(37oC, 5min) with 50l 2xreaction buffer/DTT mix. Plate was incubated for 2h at 37oC 
and analysed in a fluorescent plate reader (excitation: 380nm, emission: 460nm).  
 
2.4.11 Assessment of apoptosis related proteins by proteome profiler 
 
This was carried out in accordance with manufacturer’s instructions. Briefly: each array 
blocked with Array Buffer 1 in 4-Well Multi-dish (manufacturer’s own) for 1h on a 
rocking platform shaker. Cell lysates as prepared previously added to 1.25 mL of Array 
Buffer 1 and adjust to a final volume of 1.5ml with lysis Buffer 15. Diluted lysates 
incubated with array overnight at 4° C on a rocking platform shaker. Array washed with 
1X wash buffer and rinsed in distilled water. Followed by 3 further washes with 1X 
Wash Buffer (10min, rocking platform shaker). Array incubated with detection antibody 
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cocktail and incubated for 1h followed by further washing steps x3. Array incubated 
with Streptavidin-HRP for 30min and subsequently washed as previous. Each array 
exposed to ECL followed by X-ray film requisite time. Apoptosis array data on 
developed X-ray film quantitated by scanning the film on a transmission-mode scanner 
and analysis using photoshop image analysis software (Adobe). 
 
2.4.12 Cloning of tat-dn-CDK 7 and 9  
 
DNA was mini-Prepped as per DNAeasy kit (Qiagen) protocol (and see above). DNA 
was cut with the appropriate restriction enzyme and buffer. The reaction was incubated 
at the appropriate temperature for the enzyme (usually 37ºC) for a minimum of 4h. 
Double enzyme restriction digest for directional cloning was carried out in a similar 
manner, but using an enzyme buffer that gave optimal cutting for both enzymes. DNA 
could then be isolated by gel purification. Band released by cutting (NcoI/BamHI) was 
isolated and subjected to PCR reaction to add EcoRI/NotI restriction sites to CDK 7/9 
fragment (and ensure in frame)- High fidelity reaction: (94oC (15s), 55oC (30s), 68oC 
(1min) x30cycles. Reaction recipe: DNA 5l, Primers FOR and REV (see materials) 
2l, Taq enzymel, dNTPs. 
 
The PCR product was purified by agarose gel electrophoresis (crystal violet as per topo-
xl protocol) and sequencing of PCR product (5l DNA, 2l primer) was carried out to 
ensure fidelity. TOPO XL cloning of the PCR product was as per protocol (Invitrogen). 
The excised PCR band (CDK7/9 plus restriction enzyme sites) was used in a 
topoisomerase ligase reaction carried out with 3l of PCR product to 1l of tat vector  
 
Plasmid transformed into one-shot bugs, selected by kanamycin (KAN)/ampicillin 
(AMP) resistance. Colonies were picked and Mini-Prepped. Sequencing was carried out 
to ensure insertion of CDKdn into TOPO vector. TOPO vector was cut with EcoRI/NotI 
to release fragment (digestion reaction constituents see above) which was gel purified. 
The gel purified fragment was cloned into the tat plasmid: tat plasmid cut with 
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EcorI/NotI, SAP (Shrimp Alkaline Phosphatase) treated and ethanol precipitated. 
Fragment annealed by DNA ligase reaction (Buffer 1, 2 and 3 (23l reaction: 7l insert, 
1l vector, buffers, ddH2O). 5min on ice (Rapid DNA ligation kit Roche). 
 
‘One-shot’ E.coli transformed with 3l pTAT-CDK-DN-His and plated on KAN agar. 
Colonies picked and mini-prepped (Qiagen protocol). The plasmid was then sequenced 
bi-directionally with 4 different primers. Once the sequence was confirmed plasmids 
were maxi prepped and stored at 4oC. 
 
2.4.13 Transformation of E.coli BL21 
 
pTat-CDK7/9-DN was transformed into pLys BL21 E.coli cells: 3l of plasmid was 
added to one aliquot of DH5cells which spent 30min on ice prior to heat shock at 42oC 
(45-50s), a further 2min on ice before  200l SOCS medium was added. Cells were 
incubated on orbital shaker (37 oC) for 1h and cultured overnight on agar/ampicillin 
(100g/l) plates at 37oC. Resistant clones (6 on first occasion) were picked (using 
pipette tip) and grown in L-broth overnight at 37 oC (50ml tubes, 10ml L-broth). The 
cells were pelleted at low speed in a centrifuge (2000g) before being resuspended in 
100µl of L-broth and spread on to LB-agar plates with the appropriate antibiotic for 
positive selection. Plates were placed in a 37ºC incubator overnight. DNA was isolated 
from BL21s and sequenced. 
 
2.4.14 Protein production 
 
Chemically competent BL21 (pLysS DE3) cells were transformed with pTAT-CDK-
DN-HIS and selected on antibiotic plates. Colonies were picked and incubated till log 
phase growth OD600 = 0.6. IPTG induction (1mM). Optimal incubation time and 
temperature were assessed in small-scale experiments. After 4h incubation at 37oC cells 
were centrifuged at 50000g and sonicated in 1ml resuspension buffer (see buffers) 
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before disruption in a cell disruptor. Coomassie gels following centrifugation at 50000g 
demonstrated protein in pellet fraction. Pellet was washed in isolation buffer (see 
buffers) prior to resuspension in solubilisation buffer (see buffers). Solubilisation was 
performed in the presence of protease inhibitor cocktail at 4oC with a magnetic stirrer for 
2h. After a further centrifugation step at 50000g supernatant was filtered through a 
0.22M filter prior to batch or HPLC isolation. 
 
2.4.15 Protein isolation (batch method) 
 
As per Clontech Talon system instructions. Briefly, solubilised protein incubated with 
pre-equilibrated talon resin for 1h at RT or overnight at 4oC. Resin centrifuged at 300g 
and supernatant retained for analysis. Resin washed with solubilisation buffer x3 and 
wash supernatant retained for analysis before elution with elution buffer. Samples 
checked by coomassie staining and western blotting for protein of interest.  
 
2.4.16 Protein purification by immobilised metal affinity chromatography 
(IMAC) (Refolding on column method) 
 
Filtered protein eluate was loaded onto a 1ml/5ml nickel/cobalt IMAC FF column which 
had been pre-equilibrated in solubilisation buffer on an ÅKTA liquid chromatography 
unit. Flow rate was 0.5ml/min and column was washed with 10 column volumes (CV) of 
solubilisation buffer followed by a 50CV gradient of solubilisation to refolding buffer at 
1ml/min. Elution was with 5CV of elution buffer. Fractions (50 ml for run through and 
wash, 1ml for gradient and elution) were collected for the entire run (Solubilisation 
buffers 1-3 and respective elution buffers were trialled). 
 
2.4.17 Protein purification by gel filtration and ion exchange 
 
Method 1: Buffer exchange by size exclusion (solubilization buffer components are 
retarded and the protein will therefore be transferred to a denaturant-free buffer).  
                                                                                                                                           71
 
A HiPrep 16/60 S200 HR column was used on an ÅKTA liquid chromatography unit. 
Column was equilibrated in 180ml of refolding buffer and eluted batch sample 
(containing the solubilized inclusion bodies/proteins in solubilization buffer) was loaded 
into a 5ml loop (pre-washed with denaturing buffer) and run at 0.2 ml/min with 100% 
solubilisation buffer, loading 5ml of sample. Fractions (1ml) were collected for the 
entire run 
 
Method 2: Introducing into the column a decreasing gradient from solubilization buffer 
to the refolding buffer before sample application. The refolding buffer is then used to 
elute the protein. This approach should involve a more gradual transfer of the protein to 
a denaturant-free buffer (Gu et al. 2001).  
 
A HiPrep 16/60 S200 HR column was used on an ÅKTA liquid chromatography unit. 
Column was equilibrated in 180ml of refolding buffer. Then a gradient was manually 
run from 0 - 100% solubilisation buffer over 30ml onto the top of the column. Eluted 
batch sample was loaded into a 5 ml loop (pre washed with solubilisation buffer) and run 
at 0.2ml/min with 100% solubilisation buffer, loading 5ml of sample. Fractions (1ml) 
were collected for the entire run  
 
Method 3: Cation exchange 
Based on the theoretical isoelectric point of CDK9 we decided to attempt further 
purification of tat-cdk9dn by cation exchange. Eluted protein was initially desalted by 
running sample through a HiPrep 26/10 Desalt column prior to cation exchange in 
HEPES buffer with a 1M NaCl gradient on a MonoS 5/50 GL column. 
 
2.4.18 Coomassie staining of protein gels 
 
Samples were run on 10% gels which were subsequently stained with coomassie dye 
(see materials) for 30min and destained using destain (see materials) to allow  
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visualisation of bands. 
 
2.4.19 Glycerol stocks 
 
For long term storage, 8% glycerol stocks of bacterial clones were made by addition of 
20μl of a mini prep culture to 1 ml of 8% glycerol in L broth and stored in a minus 80ºC 
freezer. 
 
2.4.20 Labelling of protein with FITC 
 
A solution of 1mg/ml protein in 0.1M sodium carbonate buffer (pH9) was prepared. To 
protein solution 50ml of 1mg/ml FITC in DMSO was added in 5ml aliquots whilst 
continually stirring. Reaction was incubated in dark at 4oC overnight. NH4Cl was added 
to final concentration of 50mM and incubatded for 2h at 4oC. Xylene cylanol and 
glycerol were added to 0.1% and 5% respectively. Labelled protein was separated from 
free FITC by gel filtration through a PD-10 column. 
 
2.4.21 Illumina gene chip assessment of neutrophil transcriptome 
 
This was performed by ARC genomics at Roslin Bioquarter and subsequent 
bioinformatics data was generated by Dr Jon Manning, CIR Bioinformatics division and 
the following description of the bioinformatical calculations involved is by him, “Data 
output by the proprietary Illumina software were handled using modules of the R-based 
Bioconductor software suite (www.bioconductor.org). Version 1.14.0 of the 'lumi' 
package (Du et al. 2008) formed the core of the analysis, providing the routines 
employed to read, adjust background intensity, transform and normalise the data. The 
'variance stabilising transform' suggested by this module's authors was employed in 
place of the more conventional log-transform, prior to robust spline normalisation. 
Annotation data were derived initially from an Illumina-provided annotation file, with 
complementary information taken from the chip-specific 'illuminaHumanv3' and more 
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generic 'lumiHumanAll' Bioconductor annotation packages. The level and significance 
of differential expression for each probe was assessed by use of linear models and 
empirical Bayes from the 'Limma' package (Smyth 2004) and the resulting p values were 
adjusted for multiple testing by use of the Benjamini-Hochberg method (Hochberg et al. 
1990;Hochberg et al. 1995). Fold changes were derived with the aid the the 'gtools' 
package. Processed data were stored in a relational database with a dynamic front-end 
for further analysis”. 
 
2.4.22 Administration of bleomycin sulphate and CDK inhibitor drugs (i.t.) 
 
Female C57BL/6J mice weighing a minimum of 20g were used for all experiments.  The 
mice were briefly anesthetised using Isofluorane and bleomycin sulphate (Apollo 
Scientific) administered to the lungs via the trachea, in a volume of 50µl.  Following 
induction of anaesthesia, mice were suspended upright on a purpose-built rig, by resting 
their teeth on a rigid wire. Their tongues were protruded, and 50 µl of 0.033mg 
bleomycin sulphate (Apollo Scientific) placed on the oropharynx. The nares of the mice 
were briefly covered to induce involuntarily aspiration of solution, before mice were 
returned to the cage to recover from anaesthesia (typically 30s).  On day 2 and day 5 
post-bleomycin administration, mice (6 per group) were treated I.T. with either 50µl of 
0.05% DMSO vehicle control or 10 mg/kg of R-roscovitine or DRB.  
 
2.4.23 Bronchoalveolar lavage (BAL) and histology 
 
Mice were killed 7 days after bleomycin or saline administration with a single 200µl 
intraperitoneal injection of sodium pentobarbitone (200 mg/ml).The diaphragm was 
opened via the peritoneal cavity and the rib cage removed.  The lungs were cannulated 
via the trachea in situ using a fine cannula which was tied in place with a single suture 
and BAL was performed using three sequential washes consisting of 0.8 ml ice-cold 
sterile 0.9% saline. All samples were centrifuged at 180g for 5min at 4°C, the 
supernatants removed and the cell pellets resuspended in 0.5ml sterile 0.9% saline. Total 
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cell numbers were counted using a nucleocounter and cytocentrifuge smears prepared 
and stained with Diff Quik™ for differential cell-counts to be made. At least 300 cells 
per slide were counted and the results expressed as total number of neutrophils and 
macrophages in the lung lavage.  Histological analysis of the 7 day experiments was 
undertaken without BAL to maintain tissue integrity and lung injury was assessed by 
histological examination of paraffin-embedded lung sections stained with hematoxylin 
and eosin.  
 
2.4.24 Statistical analyses (excluding illumina data, see above) 
 
All experiments were performed at least three times unless stated otherwise and each 
treatment done in triplicate and the results are expressed as the mean ± SEM.  Data were 
analysed by a one-way ANOVA with a Student Newman-Keuls multiple comparison 
post hoc test with a 95% confidence interval (multiple conditions) or paired t-test (2 
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3. Results: CDK inhibitor drugs drive neutrophil apoptosis  
 
The CDK inhibitor drug R–roscovitine was shown to drive apoptosis of human 
neutrophils by Rossi et al in their 2006 Nature Medicine paper (Rossi et al. 2006). This 
finding was interesting because, as discussed in the introduction, neutrophils are 
terminally differentiated cells and ought not to have functional cell-cycle machinery. It 
might be expected that cell-cycle inhibiting drugs would have no effect on neutrophils or 
alternatively promote survival as is the case in terminally differentiated neuronal cells 
(Maas, Jr. et al. 1998). The precise mechanisms by which CDK inhibitor drug driven 
neutrophil apoptosis is promoted have not previously been elucidated.  The following 
chapter comprises an investigation of CDK inhibitor drug driven neutrophil apoptosis in 
order to offer mechanistic insight into the inflammation resolving properties of these 
pharmacological agents. It begins with a careful delineation of the time-course and 
pharmacokinetics of CDK inhibitor drug driven neutrophil apoptosis as determined by 
morphological assessment of cytocentrifuge preparations and flow cytometric 
assessment of annexin-V/PI binding and uptake. These same techniques are used to 
compare the effects of CDK inhibitor drugs with known modulators of neutrophil 
apoptosis. Subsequently caspase involvement (western blotting and fluorometric assay) 
and mitochondrial assessment are performed in attempt to dissect the apoptotic pathway 
involved in the process. Confocal microscopy and live cell imaging as well as DNA 
ladder detection are also employed to provide a comprehensive assessment of apoptosis. 
These experiments provide important evidence for the mechanism of action of CDK 
inhibitor drugs in resolution of inflammation by showing why neutrophils are 
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3.1 R-roscovitine promotes neutrophil apoptosis in a time- 
dependent manner 
 
It is important to thoroughly investigate the chronology of apoptosis induction by 
pharmacological agents for a number of reasons. Firstly, it is necessary to establish that 
true apoptosis is induced in the absence of necrosis and that any necrosis detected is 
secondary to apoptosis. Careful time-course experiments assessing both apoptosis and 
necrosis should establish this convincingly. Secondly, some agents (e.g., TNF-(Cross 
et al. 2008;Murray et al. 1997)) can have dual effects on neutrophil longevity by 
promoting apoptosis in an early phase but subsequently prolonging neutrophil lifespan 
or vice-versa (e.g., MG-132 (Derouet et al. 2006;Ward et al. 1999)). Thirdly, there is 
significant variation in the reported rates of constitutive apoptosis in the published 
literature (Sabroe et al. 2004) and therefore carefully controlled experiments are of 
paramount importance.  
 
In figures 3.1 and 3.2, flow cytometry assessment of annexin-V/PI staining and 
morphological assessment of Diff-Quik stained cytocentrifuge preparations were 
performed to document the concentration-dependency and time-course of CDK inhibitor 
drug driven neutrophil apoptosis. Annexin-V binds to PS externalised as one of the 
hallmarks of apoptosis and postulated to play a role in allowing subsequent apoptotic 
cell engulfment by phagocytes. PI binds DNA and is used as a marker of loss of plasma 
membrane integrity and therefore necrosis. 
 
Timeline experiments (Figure 3.2) demonstrate that R-roscovitine promotes a significant 
increase compared to control in the proportion of neutrophils annexin-V positive/PI 
negative by 4-8h (Figure 3.2 iii and iv). The majority of neutrophils treated with R-
roscovitine are annexin-V positive/PI negative by 8h (75.0±2.7%) and by 20h annexin-V 
positive/PI positive cells are the largest population proportionally (60.5±2.1%). Time-
course experiments are shown to demonstrate that cells transition through annexin-V 
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positivity to dual annexin-V/ PI positivity. This indicates that R-roscovitine primarily 
drives apoptosis and that the emergence of a necrotic cell population at late time-points 
(as in figure 3.1) is a secondary phenomenon. Time-lines showing constitutive fate of 
neutrophils (Figure 3.2 i and ii), in our laboratory using our methodology, are shown for 
comparison given the considerable heterogeneity of such data in the literature (Sabroe et 
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Control
R-roscovitine
Figure 3.1a: Representative flow plots and cytocentrifuge 
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Figure 3.1a: Time courses for neutrophil viability and death in the presence of R-roscovitine (20M) as 
assessed by flow cytometric measurement of annexin-V (FL-1)/PI (FL-2) positivity are shown as 
representative flow cytometry plots from each time-point. Flow plots are interpreted as follows: lower left 
quadrant annexin-V-ve/PI –ve (viable), lower right quadrant annexin-V+ve/PI-ve (apoptotic), upper right 
quadrant annexin-V+ve/PI+ve (necrotic) (n=6).  Photomicrographs (x400) of neutrophil morphology at 4 
and 8h for neutrophils cultured alone and with R-roscovitine (20M) treatment. Viable neutrophils have 
multi-lobed nuclei while apoptotic cells have round, densely packed ‘pyknotic’ nuclei. At 8h with R-
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Figure 3.1b: Time-course showing effect of R-roscovitine on 














Figure 3.1b: Neutrophils were cultured at 5x106/ml in IMDM containing 10% autologous serum and R-
roscovitine at a concentration of 20μM. At 4, 8, 12 and 20h samples of cultured neutrophils were removed 
for generation of cytocentrifuge preparations for examination of morphological changes associated with 
apoptosis and for preparation of samples for flow cytometric analysis of Annexin V binding and PI 
staining. Data are presented as a time-course showing the change in untreated neutrophil viability 
(defined as Annexin V-ve/PI -ve) in (i), apoptosis (Annexin V+ve/PI-ve) and necrosis (Annexin 
V+ve/PI+ve) both depicted in (ii) over a 20h time period. The effect of R-roscovitine on the various 
populations as defined above is shown in (iii) and (iv). Lines showing development of apoptosis and 
necrosis are superimposed to demonstrate that necrosis follows apoptosis (secondary necrosis).   
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Figure 3.2: Concentration-dependent effect of the CDK inhibitor, 
















Figure 3.2: Neutrophils were cultured at 5x106/ml in IMDM containing 10% autologous serum and either 
DMSO (vehicle control) or R-roscovitine at concentrations of 2, 10 or 20M. At 20h cultured neutrophils 
were removed for generation of cytocentrifuge preparations for examination of morphological changes 
associated with apoptosis and for preparation of samples for flow cytometric analysis of Annexin-V 
binding and PI staining. Data showing the change in untreated neutrophil viability (defined as Annexin-V-
ve/PI-ve), apoptosis (Annexin-V+ve/PI-ve) and necrosis (Annexin-V+ve/PI+ve) with increasing 
concentration of R-roscovitine. Statistical comparisons are to vehicle control by ANOVA with post-hoc 
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R-roscovitine at 10-20M concentration does significantly decrease the proportion of 
annexin-V negative/PI negative cells compared to control. R-roscovitine 2M had no 
statistically significant effect on any cell population. At a concentration of 10M or 
20M, R-roscovitine did not appear to increase the proportion of annexin-V positive/PI 
negative cells compared to control at 20h (Figure 3.2) but the proportion of annexin-V 
positive/PI positive cells was significantly increased. This suggests either that a 
population of cells are dying primarily by necrosis or that more cells become annexin-V 
positive at an earlier time-point and subsequently become PI positive. The interpretation 
of these findings is either that the dual positive cells are ‘late apoptotic’ (secondary 
necrosis) or that they are primarily necrotic. Interestingly, R-roscovitine appears to have 
a steep effective concentration range with almost no effects at 2M and only slightly 
enhanced efficacy (dual positive cells slightly increased, not statistically significant) at 
20M as compared to 10M. 
  
In order to provide additional evidence and support for the reliability of our flow 
cytometry and cytocentrifuge preparation data, live confocal microscopy imaging of 
neutrophils treated with R-roscovitine and progressively incorporating annexin-V and 
subsequently PI was performed. Stills are shown in figure 3.3 and the video is available 
in appendix 1. In this video neutrophil viability is monitored over 8h by annexin-V/PI 
fluorescence. Annexin-V incorporation occurs 314min post R-roscovitine treatment and 
loss of plasma membrane integrity denoted by PI staining of the nucleus happens at 
415min. This gives a window of approx. 1h 40min to allow phagocyte clearance of the 
apoptotic neutrophil. Live imaging by light microscopy was also performed and is 
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Figure 3.3: Live cell imaging by confocal microcopy of neutrophils undergoing apoptosis and secondary 
necrosis in response to R-roscovitine (20M). Representative stills are shown corresponding to significant 
events in the death process. At 0min the neutrophil is still mobile and alive. At 35min the neutrophil 
rounds up and becomes stationary. At 280min the neutrophil begins the ‘blebbing’ process.  At 314min the 
outer membrane of the neutrophil becomes annexin-V positive demonstrated by green peripheral 
fluorescence. Between 415min and 495min the neutrophil undergoes the process of secondary necrosis  
demonstrated by the red fluorescence of PI in the nucleus. The nuclear membrane expands or becomes 
permeable at 484min. Images made with a Zeiss LSM510 confocal microscope with the use of a POCmini 
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3.2 A comparison of CDK inhibitor drugs and other described 
modulators of apoptosis 
 
A number of pharmacological agents have been demonstrated to modulate neutrophil 
apoptosis and it seemed reasonable therefore to compare the effects of CDK inhibitor 
drugs with these well-described compounds. Both pro-apoptotic and anti-apoptotic 
agents were investigated in order to highlight the extent to which neutrophil fate can be 
influenced by external interventions. A number of compounds were tested including 
dexamethasone (Meagher et al. 1996), cycloheximide (Whyte et al. 1997), db-cAMP 
(Martin et al. 2001), gliotoxin (Ward et al. 1999) actinomycin-D (Whyte et al. 1997) 
(figures 1.4 and 1.5) and a panel of CDK inhibitors (data shown for CDK4 inhibitor and 
DRB), figures 3.6 and 3.7). CDK4 inhibitor had no pro-apoptotic effect within its 
effective concentration range suggesting that this kinase may not be a relevant target in 
terms of neutrophil apoptosis. The effect of R-roascovitine (CDK2, 5, 7, 9 specific) and 
DRB (CDK7, 9 specific) was similar to that observed with the protein synthesis 
inhibitors actinomycin-D and cycloheximide (Whyte et al. 1997) so a time-course 
experiment was performed to further clarify the pharmacological kinetics (figure 3.5). 
In order to examine the impact of CDK inhibitor drugs on neutrophil survival in the 
presence of survival factors known to be abundant at sites of inflammation neutrophils 
were treated with LPS and TNF-in combination with R-roscovitine (figure 3.8). At 
20h the survival effects of these two agents that signal through the key neutrophil 
survival signaling pathway, the NF-B pathway (Ward et al. 1999), were overcome by 
CDK inhibitor drugs. As TNF- is known to have an early pro-apoptotic effect that is 
mediated through activation of the extrinsic ‘death receptor’ pathway of apoptosis 
(Murray et al. 1997) I was keen to investigate the effect of CDK inhibitor drugs on this 
property. Interestingly, R-roscovitine enhanced the early pro-apoptotic effects of TNF- 
in a similar fashion to gliotoxin though co-treatment with both agents promoted more 
significant levels of apoptosis (figure 3.9). 



















































Figure 3.4: Comparison of the effects of various agents on 









Figure 3.4: Neutrophils were cultured at 5x106/ml in IMDM containing 10% autologous serum and R-
roscovitine (20M), dexamethasone (0.1m), db-cAMP (0.2mM), gliotoxin (0.1g/ml) or cycloheximide 
(10M). At 20h samples of cultured neutrophils were removed for generation of cytocentrifuge 
preparations for examination of morphological changes associated with apoptosis and for flow cytometric 
analysis of annexin-V binding and PI staining. Data are presented as a bar chart showing the change in 
untreated neutrophil viability (defined as annexin V-ve/PI -ve). Chart is representative of n=3 experiments 
of 3 separate replicates and are presented as mean+/-SEM.  Statistical significant difference from control 
indicated by p<0.05=* and p<0.01=** by ANOVA with Student Newman-Keuls multiple comparison post 
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Figure 3.5: Time-courses of neutrophil viability following 








Figure 3.5: Neutrophils were cultured at 5x106/ml in IMDM containing 10% autologous serum 
and R-roscovitine (20M) or actinomycin-D (10M). At 4, 8, 12 and 20h samples of cultured 
neutrophils were removed for generation of cytocentrifuge preparations for examination of 
morphological changes associated with apoptosis and for flow cytometric analysis of annexin-V 
binding and PI staining. Data are presented as a time-course showing the change in untreated 
neutrophil viability (defined as annexin-V-ve/PI-ve) over a 20h time period. Data are 





















































Figure 3.6: Comparison of the effects of DRB and R-roscovitine 



















Figure 3.6: Neutrophils were cultured at 5x106/ml in IMDM containing 10% autologous serum 
and R-roscovitine (20M) or DRB (20M). At 4, 8, 12 and 20h samples of cultured neutrophils 
were removed for generation of cytocentrifuge preparations for examination of morphological 
changes associated with apoptosis and for flow cytometric analysis of annexin-V binding and PI 
staining. Data are presented as a time-course showing the change in untreated neutrophil 
viability (defined as annexin-V-ve/PI -ve) over a 20h time period. Data are representative of 
n=3 experiments of 3 separate replicates and are presented as mean+/-SEM.   





















Figure 3.7: Effects of CDK4 inhibitor on neutrophil viability at 12 

















Figure 3.7: Neutrophils were cultured at 5x106/ml in IMDM containing 10% autologous serum 
and CDK4 inhibitor (CDKi4,100nM). At 12 and 20h samples of cultured neutrophils were 
removed for generation of cytocentrifuge preparations for examination of morphological 
changes associated with apoptosis and for flow cytometric analysis of annexin-V binding and PI 
staining. Data are presented as a bar chart showing the change in neutrophil viability (defined 
as annexin V-ve/PI –ve of neutrophils treated with CDK4 inhibitor compared to control 
(untreated). Data are representative of n=3 experiments of 3 separate replicates and are 
presented as mean+/-SEM. No significant difference between CDK 4 inhibitor and control 
(paired t-test).  
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Figure 3.8: CDK inhibitor drugs overcome the survival effects of 
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Figure 3.8: Neutrophils were cultured at 5x106/ml in IMDM containing 10% autologous serum alone as 
control (i) or with R-roscovitine (20μM) (ii), LPS (100ng/ml) (iii), R-roscovitine + LPS (iv), TNF- 
(10ng/ml) (v), or R-roscovitine + TNF- (vi) as indicated above for 20h. Apoptosis was assessed using 
annexin-V/ PI staining and confirmed by morphological examination under light microscopy. Results 
represent n=6, with each experiment being performed in triplicate. Representative flow cytometry plots 
(lower left quadrant is annexin-V-ve/PI-ve, lower right is annexin-V+ve/PI-ve and upper right is annexin-
V+ve/PI+ve) are shown along with examples of neutrophil morphology from the appropriate 
experimental condition. Plots show effect of R-roscovitine on neutrophil viability in the presence of LPS 
(vii) and TNF- (viii). Statistically significant difference to p<0.001 between LPS/TNF- and R-
roscovitine + LPS/ R-roscovitine + TNF- is shown as ***. Statistically significant difference to p<0.001 
between R-roscovitine + LPS/ R-roscovitine + TNF- and control is shown as ### (ANOVA with a 






































































Figure 3.9: R-roscovitine enhances the early pro-apoptotic 










Figure 3.9: Neutrophils were cultured at 5x106/ml in IMDM containing 10% autologous serum alone as 
control or with R-roscovitine (Rosco, 20μM), Gliotoxin (Glio, 0.1g/ml), TNF- (TNF, 10ng/ml), or 
combinations of these agents as indicated above for 2h. Apoptosis was assessed using annexin-V/ PI 
staining and confirmed by morphological examination under light microscopy. Results represent n=3, 
with each experiment being performed in triplicate. Statistically significant difference to control p<0.001 
= *** and between RoscoTNFGlio and GlioTNF/RoscoTNF = ### (ANOVA with a Student Newman-
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3.3 CDK inhibitor drugs promote activation of caspases  
 
Caspases are pivotal enzymes of the apoptotic process and are generally activated by 
two separate, though linked, pathways (Hallett et al. 2008b). Caspase-1 has also been 
implicated in pyroptosis a postulated novel form of cell death related to microbial 
infection (Kepp et al. 2010). 
 In brief (see figure 1 and description in text of introduction for more detail), caspase-8 
can be recruited and activated by death receptor ligand binding (classically TNF- or 
fas-ligand (FasL) resulting in progression through the ‘extrinsic pathway’ of apoptosis. 
Alternatively, cellular stressors (such as genotoxic drugs or UV) can lead to an 
imbalance of pro- vs anti-apoptotic bcl-2 homologues leading to excess pro-apoptotic 
homologues and perturbation of mitochondrial membrane integrity. Loss of 
mitochondrial membrane integrity leads to apoptosome formation and activation of 
caspase-9 in the ‘intrinsic pathway’ of apoptosis. In type II apoptotic cells such as 
neutrophils these pathways are linked by caspase-8 activation of Bid leading to 
mitochondrial membrane integrity loss and signalling via both apoptotic pathways. In 
both pathways the terminal executioner caspase is caspase-3. In order to characterize the 
predominant apoptotic pathway that occurs in response to CDK inhibitor drugs it was 
important to consider this property.  
 
In figure 3.10 I show by western blotting that caspases -3, -8 and -9 are cleaved 
(activated) in response to CDK inhibitor drugs though it proved difficult to separate 
these events chronologically. Figure 3.11, representative images of confocal microscopy 
for caspase-3 cleavage in neutrophils treated with R-roscovitine is supportive of my 
western blotting data. Additionally in figure 3.12 I have used a fluorometric caspase 
activation detection kit (ApoAlertTM kit) in the hope that this might be a more sensitive 
measure of the kinetics of caspase activation in neutrophils. This kit utilizes caspase 
substrates attached to fluorescent linker molecules that emit following successful 
caspase cleavage of substrate. The strongest and most reliable signal was for the 
terminal executioner caspase, caspase-3 which may suggest that initiator caspases need 


















































Figure 3.10: Western blotting for cleaved (active) caspases 3,8 and 9. Neutrophils were incubated with 
appropriate agents (media alone (C), R-roscovitine 20M (R), DRB 20M (D)) in 2ml eppendorfs on a 
shaking heat block at 37oC for 2-4h and subsequently lysed using standard neutrophil lysis buffer. Positive 
control (+ve) was neutrophils left for 24h at 37oC. Blots above are representative of n=3 experiments. 
Non-specific band (40kDa) 
Cleaved caspase-9 (17kDa) 
2.5h 3h 3.5h 4h 
C C C C R R R R
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Figure 3.11: Confocal microscopy of caspase-3 cleavage in 































Figure 3.11: Confocal microscopy of neutrophils labelled for cleaved caspase-3 by indirect 
immunofluorescence. Neutrophils were incubated at 5x106/ml for 4h with R-roscovitine (20M). Upper 
left panel shows transmitted light/bright field image (BF). Upper right panel shows DAPI staining of 
nuclear material. Lower left panel shows staining for cleaved caspase-3 (CC3). Lower right panel is a 
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Figure 3.12: ApoAlert kit- Caspase cleavage in neutrophils in response to treatment with R-roscovitine. 
Neutrophils were prepared as previously described and lysed at times indicated in accordance with 
manufacturers (Clontech)) instructions. Fluorescence was measured on a fluorescent plate reader 
(excitation: 380nm, emission: 460nm). Results represent n=2 experiments (No statistics performed). 
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only be activated to a comparatively lesser degree than the executioner. This seems 
compatible with a model that uses caspases-8 and -9 as triggers whilst caspase-3 is 
functionally important in the successful conclusion of the apoptotic process.  
 
In order to further assess the relevant apoptotic pathways we investigated mitochondrial 
membrane integrity and also Bid cleavage (figure 3.13). If it can be shown that 
mitochondrial outer membrane permeabilisation is present prior to the appearance of the 
morphological features of apoptosis and that Bid cleavage is not detectable it seems 
reasonable to assume (in a type II apoptotic cell) that the critical apoptotic pathway is 
the intrinsic pathway. Mitochondrial permeability was assessed with the use of 
MitocaptureTM dye. The dye accumulates in mitochondria of viable cells and fluoresces 
orange/red whilst in apoptotic cells it leeches out of permeabilised mitochondria into the 
cytoplasm where it fluoresces green. We were able to demonstrate significant induction 
of mitochondrial permeabilisation by R-roscovitine at early time-points (2.5h) where 
there is no evidence of morphological changes of apoptosis. Western blotting for the 
pro-apoptotic protein Bid (figure 3.13) revealed no evidence of cleavage throughout the 
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Figure 3.13: In i) neutrophils were incubated with medium alone or plus R-roscovitine (20M) and 
subjected to standard neutrophil lysis at time-points between 0-6h prior to immunoblotting for full-length 
Bid. In ii) neutrophils were treated with medium alone or plus R-roscovitine (20M) for 2h then incubated 
with MitocaptureTM according to manufacturer’s instructions (30min) and examined by fluorescent 
microscopy (x320). The dye fluoresces red/orange in the mitochondria of viable neutrophils (Solid bars) 
and green in the cytoplasm of neutrophils with loss of mitochondrial transmembrane potential (Striped 
bars). All experiments (n=3). Statistically significant difference in the percentage of cells that have lost 
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3.4 CDK inhibitor drug treatment of neutrophil granulocytes 
leads to classical internucleosomal DNA laddering 
 
A classical measure of apoptosis which is under-represented in recent literature is the 
demonstration of internucleosomal cleavage of DNA at intervals of 200bp resulting in 
the classical ‘DNA ladder’ effect (Wyllie 1980). The process of apoptosis causes DNA 
cleavage in a typical internucleosomal fragmentation pattern by the enzyme Caspase 
activated DNase (CAD) which is normally inhibited by the inhibitor of CAD 
(ICAD)/DNA fragmentation factor (DFF)-45 complex (Widlak et al. 2005). The 
presence of DNA laddering is determined by DNA isolation and gel electrophoresis. 
Figure 3.14 demonstrates a typical DNA ladder from human neutrophils treated with R-
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Figure 3.14: R-roscovitine induces classical DNA laddering in 





































Figure 3.14: Neutrophil DNA (approx. 300ng in 4x sample buffer per lane) isolated as per methods () run 
on 1% agarose gel in TBE for 1.5h. Lane 1 is 100bp marker, Lane 2 is control untreated neutrophils at 6h 
and Lane 3 is neutrophils treated with R-roscovitine (20M) for6h incubation. Image captured with UV 
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3.5 Discussion 
 
In this chapter the mechanisms by which apoptosis proceeds in human neutrophils have 
been investigated. This work adds to the literature characterizing the process of 
apoptosis in these cells and significantly adds to our knowledge of the effects of CDK 
inhibitor drugs on neutrophil apoptosis. 
 
It has been established that CDK inhibitor drugs primarily induce apoptosis in 
neutrophils by careful delineation of the time-line of neutrophil death. This is important 
because it removes any doubt that a population of cells stimulated to undergo apoptosis 
by CDK inihibitor drugs (identified by PS expression visualized by annexin-V binding), 
subsequently undergo secondary necrosis (identified by loss of plasma membrane 
integrity and visualized by PI incorporation to nucleus). Of interest, live-cell imaging 
demonstrates that neutrophils remain apoptotic for 1-2h before undergoing secondary 
necrosis which is illustrative of the demands placed on the mononuclear phagocyte 
system’s clearance capacity by the resolution of significant neutrophilic inflammation. It 
is clear that the time-course for this event may be significantly altered in vivo depending 
on the environmental conditions that the cell is exposed to. However, it is not 
necessarily the case that the time an apoptotic cell can persist without becoming necrotic 
would be shorter in vivo. In this confocal microscopy experiment the cell is periodically 
exposed to lasers to allow visualization of fluorescence (although time-course seems 
comparable to other in vitro data) and the population of cells is probably comparatively 
sparse. There are a number of environmental conditions that may significantly impact on 
neutrophil longevity and that may differ between in vitro and in vivo work including: 
hypoxia (Hannah et al. 1995;Leuenroth et al. 2000a), cell density (Hannah et al. 1998), 
temperature (Pryde et al. 2000), cell-cell contact and adhesion (Coxon et al. 1996;Ginis 
et al. 1997) 
 
To reinforce flow cytometry and cytocentrifuge preparation morphological data with 
regard to CDK inhibitor drug induced neutrophil apoptosis a further 6 techniques 
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(western blotting for caspases (figure 3.10), ApoalertTM assay (figure 3.12), indirect 
immunofluorescence (figure 3.11), live-cell imaging (figure 3.3), mitochondrial outer 
membrane permeabilisation assay (figure 3.13) and DNA laddering (figure 3.14)) are 
employed. It has been recommended by an international committee that the 
demonstration of apoptosis should entail multiple experimental approaches and careful 
use of nomenclature in order to achieve reliable end-points (Galluzzi et al. 
2009;Kroemer et al. 2009). This is because a wide variation in the assessment of 
apoptosis exists in the literature and some features of the apoptotic process are common 
to other modes of cell death. In addition the absence of some key features of apoptosis 
such as caspase cleavage may not necessarily denote cell viability (Kroemer et al. 2005) 
while PS externalisation has been shown to be reversible albeit under very specific 
experimental conditions (Geske et al. 2001). This chapter addresses those concerns with 
the series of experiments it documents. These experiments support apoptosis as the 
primary method of neutrophil death in response to CDK inhibitor drugs and give insight 
into the mechanisms by which apoptosis progresses.  
 
CDK inhibitor drugs disturb mitochondrial membrane potential and activate caspases. 
Although caspase activity has been demonstrated it proved difficult to reliably separate 
the individual elements of the caspase cascade, a failing that is presumably due to the 
rapid procession of this event to conclusion. However, it is clear that an early event in 
CDK inhibitor driven neutrophil apoptosis is mitochondrial outer membrane 
permeabilisation and it is also clear that the pro-apoptotic protein Bid is not cleaved over 
the time-course examined (figure 3.13). As previously discussed, neutrophils are Type II 
apoptotic cells and therefore can link the extrinsic to the intrinsic apoptotic pathway by 
Bid cleavage. Truncated bid which is activated by caspase-8 cleavage can catalyse the 
permeabilisation of the outer mitochondrial membrane (Li et al. 1998). These results 
suggest that this does not occur during CDK inhibitor drug treatment of neutrophils 
which in turn suggests that apoptosis proceeds via the intrinsic pathway. This finding is 
consistent with results from the published literature that investigated CDK inhibitor 
drugs in cancer cell-lines (Lahusen et al. 2003;MacCallum et al. 2005). 
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Additionally, the inflammatory agent TNF-which is known to activate the extrinsic 
pathway of neutrophil apoptosis by signalling through the TNF receptor induces 
apoptosis within 2h of exposure a time-course that is inconsistent with the data for CDK 
inhibitor drugs (Murray et al. 1997). Interestingly the combination of TNF- and R-
roscovitine produces enhanced apoptosis at 2h (figure 3.9) a finding that has previously 
been demonstrated with the NF-B inhibitor gliotoxin (Ward et al. 1999). This result is 
interesting because it suggests that activation of the extrinsic pathway of apoptosis is not 
mediated by R-roscovitine but that inhibition of TNF- induced production of survival 
proteins does occur. This finding has important ramifications for the mechanism of 
action of R-roscovitine that will be discussed in later chapters. At sites of inflammation 
neutrophils have enhanced longevity because they are exposed to agents such as TNF-, 
LPS, fMLP and certain other cytokines (Haslett et al. 1985;Haslett et al. 1991;Lee et al. 
1993). It has been a matter of some debate whether this exposure stimulates enhanced 
transcription of key survival proteins or merely promotes stabilisation of previously 
synthesised proteins. It was even debated (and still is in some quarters) whether 
neutrophils had transcriptional capacity at all or whether following differentiation they 
relied on pre-packaged proteins or perhaps mRNA for their functionality (Cassatella et 
al. 1995;McDonald et al. 1997;McDonald et al. 1998). The relative contribution of 
neutrophils and monocytes/macrophages to the inflammatory milieu in terms of cytokine 
production signalling is still unclear (Cassatella 1995;Cassatella et al. 1997;Cassatella 
1999;Nathan 2006;Sabroe et al. 2004). Whilst monocytes/macrophages undoubtedly 
have greater transcriptional capacity neutrophils often outnumber them so heavily that 
any capacity for signal generation could conceivably tip the balance. The reality under 
physiological conditions is likely to be that these cells don’t work against each other but 
in concert and the outcome of an inflammatory scenario is a balance of their inputs. 
 
In an attempt to mirror the in vivo exposure of neutrophils to inflammatory agents I have 
performed experiments that demonstrate CDK inhibitor drugs can over-ride the effects 
of the survival agents TNF- and LPS to promote neutrophil apoptosis. This is an 
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interesting finding as both these agents stimulate the NF-B signalling system which is 
undoubtedly a central survival pathway for human neutrophils (McDonald et al. 
1997;Ward et al. 1999). Indeed the NF-B pathway has previously been identified as a 
key target of CDK inhibitor drugs in cancer cell-lines (Dey et al. 2008).  In cancer cell-
lines it was shown that R-roscovitine could influence upstream I-kappa-B-kinase (IKK) 
signalling by an unknown mechanism leading to down-regulation of key genes under the 
control of the activated NF-B transcription factor. We have previously investigated the 
relevance of this pathway to CDK inhibitor drug induced neutrophil apoptosis but could 
find no conclusive evidence for any significant, direct involvement (Leitch et al. 2010b). 
Yet it is clear from our data with R-roscovitine and TNF-that an enhanced apoptotic 
effect similar to that seen with the NF-B inhibitor gliotoxin occurs. However, it should 
be noted that co-incubation of these inhibitors with TNF- led to an even greater effect 
on neutrophil apoptosis which to some extent suggests different mechanisms of action. 
 
By comparison of the pharmacokinetic action of R-roscovitine with other agents known 
to influence neutrophil longevity, I have attempted to gain some insight into possible 
mechanism of action. It is known that neutrophils subjected to protein synthesis 
inhibition undergo enhanced apoptosis at early time points (Whyte et al. 1997). This has 
been used as evidence for the central importance of key survival proteins such as Mcl-1 
to neutrophil life-span (Edwards et al. 2004b). R-roscovitine has a similar time-course of 
action to actinomycin-D and cycloheximide and there is a precedent in the literature for 
an effect of CDK inhibitor drugs on the transcription of survival proteins (Kapasi et al. 
2008;MacCallum et al. 2005;McClue et al. 2002). Indeed, it is known that CDK7 (Roy 
et al. 1994) and 9 (Zhu et al. 1997) play important roles in the initiation and elongation 
of selected mRNA transcripts by RNA pol II the key enzyme in human transcriptional 
machinery. Additionally, MacCallum et al have demonstrated that two survival proteins 
of known importance to neutrophils, Mcl-1 and XIAP, are influenced by inhibition of 
CDKs 7 and 9 (MacCallum et al. 2005). It seemed reasonable therefore to further 
investigate both the effect of CDK inhibitor drugs on Mcl-1 and the presence and 
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functionality of CDKs in neutrophils. The results of these investigations are presented in 
the following chapters.  
 
3.6 Summary of Chapter 3 
 
1. CDK inhibitor drugs induce time-dependent apoptosis in 
human neutrophils as demonstrated by flow cytometry assessment 
of annexin-V/PI, morphological assessment, western blotting for 
caspases, DNA laddering, confocal microscopy and assessment of 
mitochondrial membrane potential. 
2. The apoptosis induced by CDK inhibitor drugs proceeds 
via the intrinsic pathway as demonstrated by western blotting for 
tBid and assessment of mitochondrial membrane potential  
3. Apoptosis induced by CDK inhibitor drugs has similar 
kinetics to that of the transcriptional inhibitor 
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4. Results: Mcl-1 down-regulation by CDK inhibitor drugs drives 
neutrophil apoptosis 
 
The previous chapter shows that CDK inhibitor drugs drive classical neutrophil 
apoptosis by the intrinsic pathway. This implicates an important protein family termed 
the ‘bcl-2 homologues’. These proteins have considerable structural homology but are 
split into two groups with directly opposing actions. The pro-apoptotic bcl-2 
homologues such as Bad, Bax and Bim are thought to facilitate loss of mitochondrial 
membrane potential by forming pores in the outer mitochondrial membrane. They are 
counterbalanced by the anti-apoptotic bcl-2 homologues such as Bcl-2, Mcl-1, A1 and 
Bcl-xl that are thought to sequester pro-apoptotic homologues away from mitochondria 
(Brenner et al. 2009). An imbalance in the levels of these opposing groups leads to early 
apoptosis or extended longevity. There is controversy over which are the most relevant 
proteins from this family to neutrophil longevity and apoptosis. It has been stated that 
Bcl-2 is not present in neutrophil granulocytes and there is a large body of work that 
places Mcl-1 in the central role usually occupied by Bcl-2 (Moulding et al. 
2001;Villunger et al. 2003). The most important pro-apoptotic bcl-2 homologues have 
previously been thought to be Bax and Bid but new work seems to indicate that Bim is 
of prime importance (Andina et al. 2009;Cowburn et al. 2010). In this chapter I intend to 
investigate the effects of CDK inhibitor drugs on the bcl-2 homologue family with 
special emphasis on the anti-apoptotic protein Mcl-1. Mcl-1 is assessed by western 
blotting in the presence of factors that are known to alter neutrophil longevity or Mcl-1 
half-life. The effects of preserving Mcl-1 on neutrophil apoptosis are investigated by 
flow cytometry for annexin-V binding and PI incorporation. For comparison protein and 
mRNA levels of other bcl-2 homologue family members are obtained by western 
blotting, proteome profile array, semi-quantitative PCR and illumina gene chip 
technology. The NF-B regulated survival protein XIAP is investigated at the mRNA 
and protein level. 
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It is my contention that Mcl-1 is in the vanguard of apoptotic decision-making in 
neutrophil granulocytes and that CDK inhibitor drugs are capable of profoundly down-
regulating this protein to drive neutrophil apoptosis.  
 
4.1 R-roscovitine down-regulates Mcl-1, circumvents GM-CSF-
mediated protection of Mcl-1 and, in combination with TNF- or 
LPS, enhances Mcl-1 down-regulation. 
 
Edwards and colleagues have previously shown that levels of Mcl-1 protein begin to 
decline by 4h and that the cytokine GM-CSF has a protective effect against Mcl-1 
decline (Derouet et al. 2004). Figure 4.1i) confirms this finding and also demonstrates 
that R-roscovitine further down-regulates levels of Mcl-1 in neutrophils at 4h. This 
figure also demonstrates the ability of R-roscovitine to over-ride the protective effect of 
LPS, TNF- and GM-CSF on Mcl-1 (figure 4.1i). However, when R-roscovitine was co-
incubated with TNF- levels of Mcl-1 were reduced more substantially than with R-
roscovitine alone (Figure 4.1i). 
 
In addition the proteasome inhibitor MG-132 which is known to preserve Mcl-1 in 
untreated neutrophils could also prevent Mcl-1 degradation in neutrophils treated with 
CDK inhibitor drugs. This effect was more significant than that conferred by the pan-






































































































































































Figure 4.1: CDK inhibitor drugs down-regulate the survival 


















Figure 4.1: In i) Neutrophils at 5x106/ml in IMDM containing 10% autologous serum were either lysed 
immediately (time 0) or incubated for 4h in either the absence (control) or presence of GM-CSF 
(50ng/ml), LPS (100ng/ml), TNF- (10ng/ml) or R-roscovitine (20μM) and immunoblotted for Mcl-1 or β-
actin.. In ii), Neutrophils at 5x106/ml in IMDM containing 10% autologous serum were either lysed 
immediately (time 0) or incubated for 2h in either the absence (control) or presence of MG132 (50M), 
zVAD-fmk (100M), R-roscovitine (20μM) or combinations of these agents then lysed and immunoblotted 
for Mcl-1 or β-actin. Blots shown are representative of 3 experiments.   
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4.2 Mcl-1 down-regulation by CDK inhibitor drugs is prevented 
by proteasome inhibition and short-term neutrophil survival 
increased 
 
Induction of neutrophil apoptosis by R-roscovitine (20M) was evident at 4h and by 20h 
the majority of cells had undergone apoptosis and were noted to be secondarily necrotic. 
This process was documented by flow cytometric analysis and confirmed by light 
microscopic morphological examination (Figure 3.1a and b). The effect of R-roscovitine 
was time-dependent.  
 
I hypothesized that if the mechanism of action of R-roscovitine driven neutrophil 
apoptosis was related to an effect on transcription it might be prevented or at least 
delayed by the stabilization of Mcl-1. This might be achieved by 
transfection/transduction but these are difficult techniques to apply to neutrophils. Co-
treatment with a proteasome inhibitor was a simple, if non-specific approach to testing 
the hypothesis which might be further validated by supportive experimental evidence if 
it proved successful. Mcl-1 is an unusual bcl-2 homologue in that it has a PEST domain 
which targets it for degradation in the proteasome in under 2h (Edwards et al. 2004b).  
Figure 4.2 shows that R-roscovitine-mediated annexin-V incorporation can be reversed 
up to 12h by co-incubation with the proteasome inhibitor MG-132 or the pan-caspase 
inhibitor zVAD-fmk. A significant proportion of neutrophils co-treated with zVAD-fmk 
and R-roscovitine were resistant to annexin-V incorporation even at 20h.  
 
In figure 4.3 it can be seen that prevention of annexin-V incorporation with MG-132 was 
only evident if the drug was administered within 2h of R-roscovitine treatment, a time-
course consistent with a transcription-based mechanism of action. By contrast at 4h and 
6h post treatment with R-roscovitine the pan-caspase inhibitor zVAD-fmk is still able to 
preserve some cells from annexin-V incorporation. 
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Additionally, figure 4.4 shows that preservation of Mcl-1 by proteasome inhibition in 
CDK inhibitor treated neutrophils maintains mitochondrial outer membrane integrity 
which accords with the proposed mechanism of action of Mcl-1 (see introduction). By 
contrast despite preventing annexin-V incorporation mediated by CDK inhibitior drugs 
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Figure 4.2: The proteasome inhibitor MG-132 can delay 


































Figure 4.2: Neutrophils were cultured as described previously with no agents (control), R-roscovitine 
(20M), MG-132 (50M) or with a combination of R-roscovitine and MG-132 at the same concentrations. 
Cell viability was subsequently assessed as previously described using flow cytometry for annexin-V/PI 























































Figure 4.3: Delayed proteasome inhibition fails to prevent R-


















Figure 4.3: Neutrophils were cultured as described previously for 8h with no agents (control) or R-
roscovitine (20M). MG-132 (50M) or z-VAD-fmk (100M)  were administered at 0h,2h,4h or 6h in 
order to assess the time dependency of these agents ability to prevent annexin-V incorporation in 
neutrophils treated with R-roscovitine. Cell viability was subsequently assessed as previously described 
using flow cytometry and cytocentrifuge examination. Statistically significant differences are shown as 
p<0.01** and p<0.001=*** compared to combination of R-roscovitine and MG132 or R-roscovitine and 
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Figure 4.4: Proteasome inhibition prevents changes in 























Figure 4.4: Neutrophils were incubated with medium alone (Control) or+ R-roscovitine (20M) alone or 
combined with MG-132 (50M) or zVAD-fmk (100M) for 2h and treated with mitocapture dye according 
to manufacturer’s instructions (30min). The dye fluoresces red/orange in the mitochondria of viable 
neutrophils and green in the cytoplasm of neutrophils where there has been a shift in mitochondrial 
transmembrane potential. Fluorescence microscopy. All experiments (n=3). Statistically significant 
difference compared to control shown as ***, p<0.001 by ANOVA with a Student Newman-Keuls multiple 
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4.3 XIAP is not convincingly down-regulated by CDK inhibitor 
drugs 
 
Given the known importance of the NF-B pathway to neutrophil survival assessment of 
a survival protein known to be directly regulated by NF-B was carried out. XIAP is 
known to inhibit activation of caspases 3, 7 and 9 (Jost et al. 2009). It has recently been 
suggested that XIAP may be the critical discriminator between type I (e.g., lymphocytes) 
and II (e.g., granulocytes) apoptosis (Jost et al. 2009). It has also been implicated in 
neutrophil survival mediated by G-CSF (van Raam et al. 2008) and is degraded in 
oxidant-induced neutrophil apoptosis (Gardai et al. 2004). Unfortunately, no consistent 
results were achieved immunoblotting for XIAP, perhaps because XIAP acts in the final 
stages of apoptosis and results are confounded by the conclusion of this process.  It 
seems that in our system down-regulation of XIAP is more consistent with concluded 
apoptosis. PCR for the XIAP gene demonstrated no significant change in gene 
expression over the treatments studied (figure 4.5) a finding that was backed up by 
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Figure 4.5: RNA extracted from neutrophils treated for 4h with R-roscovitine (20M), LPS (100ng/ml), 
TNF- (10ng/ml) or combination. Gels shown are representative and densitometry is from 3 experiments. 
No statistically significant difference for xiap between R-roscovitine and control, LPS and R-
roscovitine/LPS, TNF- and R-roscovitine/TNF- (ANOVA with a Student Newman-Keuls multiple 
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4.4 Effect of CDK inhibitor drugs on pro-apoptotic Bcl-2 
homologues  
 
In order to support the hypothesis that Mcl-1 is essential to neutrophil survival and that 
its down-regulation by CDK inhibitor drugs leads to apoptosis it was important to show 
that pro-apoptotic bcl-2 homologues were not down-regulated in a similar fashion. Mcl-
1 prevents apoptosis by sequestering or otherwise blocking the ability of pro-apoptotic 
bcl-2 homologues to form pores in the outer mitochondrial membrane leading to 
intrinsic pathway apoptosis via the apoptosome. There has been strong evidence recently 
that the pro-apoptotic bcl-2 homologue Bim is prominent in neutrophil apoptosis and 
that it is especially relevant to apoptosis of cytokine-stimulated (i.e., akin to the 
inflammatory micro-environment) neutrophils (Andina et al. 2009;Cowburn et al. 2010). 
Other bcl-2 homologues previously identified to be of relevance to neutrophil apoptosis 
include Bax, Bid and Bad. We have already assessed Bid by western blotting (figure 
3.13) and have an indirect indication of a predominance of pro-apoptotic bcl-2 
homologues from measured loss (presumably facilitated by pro-apoptotic bcl-2 
homologues) of mitochondrial potential (figure 4.4). Western blotting findings were 
supported by evidence from the use of a proteome profiler kit (figure 4.6) which seemed 
to indicate significant down-regulation of Bad and Bax but demonstrated no significant 
down-regulation of other pro-apoptotic bcl-2 homologues. In addition we have shown 
that Bim protein is preserved throughout a 4h treatment with the CDK inhibitor drug, R-
roscovitine (Leitch et al. 2010b). We performed an illumina gene array for reasons 
which will be discussed in more depth in a later chapter and noted that at gene 
expression level Bim was significantly upregulated while Bax was significantly down-
regulated and other pro-apoptotic bcl-2 homologues remained unaffected (figure 4.7). 
 
 













































































Figure 4.6: Expression of various apoptosis-regulating proteins 











Figure 4.6: Neutrophils were prepared and treated as described previously for 4h with medium alone 
(control) or R-roscovitine (20M). Cells were lysed according to manufacturer’s (R&D) instructions and 
lysates were exposed to proteome profiler array membrane. Bespoke antibodies to apoptosis proteins 
shown above (most relevant to current thesis shown) pre-spotted onto array and streptavidin-HRP, ECL 
detection system used for quantification. Ratio of intensity was calculated by comparing R-roscovitine to 
Control having adusted for background intensity with the use of photoshop software (adobe). No statistics 
shown as n=1 with 2 replicates. Empty bars denote anti-apoptotic proteins, black bars are pro-apoptotic 
proteins and the stripedd bar is an endogenous CDK inhibitor important to apoptosis regulation. 
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Figure 4.7: Effect of CDK inhibitor drugs on gene expression of pro-apoptotic bcl-2 homologues 
measured by Illumina Gene Chip. Neutrophils treated for 4h with media alone, or R-roscovitine (20M), 
were subjected to RNA isolation using Nucleospin kit and Trizol extraction prior to interrogation by 
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4.5 Mcl-1 is down-regulated at the mRNA level 
 
We hypothesized that R-roscovitine was mediating its effects on neutrophil survival by 
influencing production of key survival proteins at the level of transcription. We have 
confirmed this finding with the use of semi-quantitative PCR. R-roscovitine down-
regulates Mcl-1 at the mRNA level even in the presence of survival factors such as LPS 
and TNF- (figure 4.8). By contrast, R-roscovitine did not significantly affect basal 
levels of XIAP mRNA at 4h but did seem to prevent its upregulation by LPS (not quite 
statistically significant when all samples analysed as per methods). TNF- didn’t appear 
to upregulate transcription of XIAP. Illumina gene array findings confirmed >2 fold 
down-regulation of Mcl-1 gene expression after treatment with R-roscovitine even in the 




















































































Figure 4.8: RNA extracted from neutrophils treated for 2h with R-roscovitine (20M), LPS (100ng/ml), 
TNF- (10ng/ml) or combination. Gels shown are representative and densitometry is from 3 experiments. 
Statistically significant difference for mcl-1 between R-roscovitine and control (***), LPS and R-
roscovitine/LPS (+++) and TNF- and R-roscovitine/TNF- p<0.001 (###) (ANOVA with a Student 
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4.6 Discussion 
 
The data presented in Chapter 4 pointed towards a key, short-lived neutrophil survival 
protein being preferentially down-regulated, possibly at a transcriptional level. Mcl-1 
has already been postulated to be the most important survival protein produced by 
neutrophils and there is work suggesting that it is indispensable (Dzhagalov et al. 
2007a;Edwards et al. 2004b). Mcl-1 down-regulation has been implicated in the 
induction of apoptosis by sodium salicylate (Derouet et al. 2006) and TNF-(Cross et 
al. 2008) in neutrophil granulocytes and by dexamethasone (Meagher et al. 
1996;Sivertson et al. 2007) in eosinophil granulocytes. By contrast, stabilisation of Mcl-
1 is implicated in the anti-apoptotic effects of cAMP (Kato et al. 2006), GM-CSF 
(Derouet et al. 2004) and dexamethasone in neutrophils (Meagher et al. 1996;Sivertson 
et al. 2007). In addition Mcl-1 stabilisation is regarded as a key mechanism conferring 
aberrant survival on multiple myeloma cells(Le et al. 2004). We have previously shown 
that the CDK inhibitor R-roscovitine down-regulates Mcl-1 in eosinophil granulocytes 
to promote apoptosis (Duffin et al. 2009). Mcl-1 is increasingly recognised as 
indispensable to neutrophils as a result of the neutropenia evident in the myeloid-
specific mcl-1 knockout mouse (Dzhagalov et al. 2007a). Interestingly, 
macrophage/monocyte cells had normal longevity in this mouse. Mcl-1 is likely to play 
an important role in macrophage function however as it has been implicated in the 
successful resolution of pneumococcal pneumonia in mouse models (Marriott et al. 
2005). Further support for the importance of Mcl-1 to neutrophil survival is given by 
work from two independent groups that have achieved antisense knockdown of Mcl-1 
that induces neutrophil apoptosis (Leuenroth et al. 2000b;Sivertson et al. 2007). This 
effect was shown to overcome the Mcl-1 stabilising effects of dexamethasone and 
hypoxia. 
In the preceding chapter I have attempted by a variety of approaches to demonstrate that 
down-regulation of Mcl-1 at a transcriptional level is central to the pro-apoptotic effects 
of R-roscovitine. Initially, I have demonstrated that Mcl-1 is down-regulated at the 
protein level in the presence of survival agents known to be present at sites of 
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inflammation including GMCSF, LPS and TNF-(figure 4.1i)This is consistent with 
the finding from Chapter 1 that neutrophil apoptosis was promoted even in the presence 
of these same mediators. I have then shown that Mcl-1 can be preserved at protein level 
by co-incubation of neutrophils with the proteasome inhibitor MG-132 an effect that 
isn’t evident with the caspase inhibitor z-VAD-fmk (figure 4.1ii). 
 
MG-132 has previously been used as a surrogate NF-B inhibitor because IB must be 
degraded in the proteasome (Ward et al. 1999). It follows therefore that where IB 
cannot be degraded it must persist and maintain inhibition of NFB. This is not what 
might be regarded as a specific effect but was shown to have an impact on neutrophil 
longevity consistent with the hypothesized mechanism of action (at least at late time-
points). However, it is also known that inhibition of the proteasome prevents 
degradation of the survival protein Mcl-1 and might be expected therefore to have a 
directly opposing effect (Derouet et al. 2006). Of course, it is within the bounds of 
reason that both effects might occur and be observed at different time-points consistent 
with the half-lives of the relevant proteins and the relevant kinetics of transcription and 
alternative methods of degradation attributed to the proteins. I have found that MG-132 
preserves Mcl-1 at the protein level and that this effect translates into enhanced 
neutrophil survival in the presence of CDK inhibitor drugs (figure 4.2). This effect is 
time-limited, so that MG-132 must be administered to CDK inhibitor drug-treated 
neutrophils within 2h whilst the caspase inhibitor zVAD-fmk still confers some survival 
at 4h and 6h administration time-points (figure 4.3). The survival effect persists to 12h at 
which point rapid apoptosis occurs until viability levels are comparable to cells 
incubated with R-roscovitine alone by 20h (figure 4.2). Stabilisation of Mcl-1 by 
proteasome inhibition enhances neutrophil survival in the presence of CDK inhibitor 
drugs in a time-dependent fashion and preserves mitochondrial transmembrane potential 
(figures 4.2 and 4.4). It is difficult to infer what is ultimately responsible for the eventual 
loss of this survival effect but a number of hypotheses may be considered: 1.It is 
possible that proteasome inhibition is time-limited and that Mcl-1 eventually undergoes 
rapid degradation 2. NFB inhibition may over-ride effects of Mcl-1 preservation 3. 
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Mcl-1 may be degraded by other means at this point (e.g. mediated by caspases) 4. Pro-
apoptotic signalling may over-ride limited ability of neutrophil to synthesise more Mcl-
1. 
 
It was important to examine the expression of other pro-apoptotic and anti-apoptotic 
proteins in order to present a comprehensive picture of apoptosis signalling within the 
CDK inhibitor treated neutrophil. I used the proteome profiler kit to examine a wide-
range of apoptosis implicated proteins in neutrophils untreated/treated with R-
roscovitine (figure 4.6). This kit indicated that the general trend was for R-roscovitine to 
promote down-regulation of apoptosis-related proteins regardless of function. In fact the 
only significantly up-regulated protein was the executioner caspase, caspase-3. This 
result is consistent with a mechanism of action that targets transcription as opposed to 
survival signalling more directly. The findings in figure 4.6 were consistent with those at 
the gene expression level where down-regulation was again the general rule (figures 4.7 
and 4.8). The exception to this rule was the pro-apoptotic protein Bim which was 
upregulated at gene expression level (figure 4.7) and appeared to maintain protein level 
(see paper appended, western blot performed by T. Sheldrake)(Leitch et al. 2010b) 
despite R-roscovitine treatment. Bim has come to the fore as the key pro-apoptotic bcl-2 
homologue mediating neutrophil apoptosis (Andina et al. 2009;Cowburn et al. 2010). 
The Bim knockout mouse phenotype was of enhanced neutrophil survival (Bouillet et al. 
1999) and two recent papers have shown Bim upregulation in neutrophils in models of 
inflammation in vitro and in vivo (Andina et al. 2009;Cowburn et al. 2010). Our finding 
is consistent with a critical excess of pro-apoptotic bcl-2 homologues occurring 
following down-regulation of survival proteins (especially Mcl-1) by CDK inhibitor 
drugs and the net result being loss of mitochondrial membrane integrity and apoptosis.   
We have shown that Mcl-1 is down-regulated at the mRNA level by R-roscovitine and 
that this change is readily detected at 2h and is more pronounced at 4h (figure 4.8). We 
believe that Mcl-1 down-regulation precedes and is responsible for the initiation of 
apoptosis because we detect changes in the level of this mRNA/protein at 2h but only 
detect apoptosis by annexin-V binding at 4h and caspase cleavage at 2.5-3h (western 
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blotting and fluorometric caspase assay). By contrast R-roscovitine does not appear to 
decrease basal levels of XIAP but these data are not as clear-cut as the Mcl-1 findings, 
possibly because the half-life of XIAP mRNA is significantly longer than that of Mcl-1 
(Sharova et al. 2009;van Raam et al. 2008). The interpretation of results for TNF- is 
complicated but interesting because of the dual and directly opposing effects of TNF-
on neutrophil apoptosis (Cross et al. 2008;Murray et al. 1997;Murray et al. 2003). 
TNF- both directly activates the extrinsic apoptotic program and enhances transcription 
of key survival proteins via the NF-B pathway. The combination of R-roscovitine and 
TNF- leads to very early initiation of and bias towards the extrinsic apoptotic program 
detectable by annexin-V binding at 2h (data not shown). XIAP is upregulated and 
stabilised in response to caspase cleavage so it might be expected that we would find 
enhanced mRNA/protein levels of XIAP. However, there is no detectable upregulation 
as measured by PCR which probably represents a degree of upregulation in response to 
the early initiation of apoptosis that is balanced by inhibition of transcription by R-
roscovitine.  We have shown that de novo transcription of XIAP as stimulated by LPS is 
prevented by R-roscovitine.  
 
By demonstrating that the important survival protein Mcl-1 is down-regulated at the 
level of transcription (figure 4.8), we corroborate our finding that direct inhibition of 
NF-B is not responsible for CDK inhibitor driven neutrophil apoptosis (Leitch et al. 
2010b). We hypothesise that a more central, generalised effect on neutrophil 
transcription is responsible for the induction of apoptosis. This effect is particularly 
evident in granulocytes because of the importance of rapidly transcribed and degraded, 
short-lived protein Mcl-1 to their survival. Pro-apoptotic bcl-2 homologues have much 
longer half-lives and in excess drive neutrophil apoptosis via the intrinsic 
(mitochondrial) pathway.  In addition the pro-apoptotic bcl-2 homologue Bim appears to 
be upregulated at gene level in response to CDK inhibitor drug treatment. Our work adds 
to the literature suggesting the fundamental importance of these proteins to neutrophil 
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survival and further illuminates the mechanism of action of the CDK inhibitor drug, R-
roscovitine. 
 
4.7 Summary of Chapter 4 
 
1. The key neutrophil survival protein, Mcl-1, is down-
regulated by CDK inhibitor drugs as assessed by western 
blotting 
2. Inhibition of the proteasome prevents Mcl-1 degradation 
and delays CDK inhibitor drug induced apoptosis as 
assessed by western blotting and flow cytometry for annexin-V/PI 
3. Mcl-1 is down-regulated at the level of transcription as 
assessed by semi-quantitative PCR and illumina gene-chip technology 
4. Pro-apoptotic bcl-2 homologue Bim is up-regulated by 
CDK inhibitor drugs as assessed by western blotting and illumina 
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5. Results: CDKs and cyclins are present in neutrophils 
 
The presence, distribution and functionality of CDKs, their cyclin binding partners and 
endogenous inhibitors has not previously been subjected to detailed analysis in 
neutrophils. It has presumably been felt that any detection of these proteins would 
merely be the cataloguing of vestigial remnants of the differentiation process from 
myeloid precursors. With the discovery that inhibitors of CDKs can significantly 
influence cell viability it may be inferred that these kinases contribute something 
important if not irreplaceable to terminally differentiated neutrophils. I have already 
discussed at some length in the introduction the different functionalities of CDKs in 
other cells and cell-lines. In this chapter I intend to establish the existence of key CDKs, 
cyclins and endogenous inhibitors in neutrophils, to document their responsiveness to 
known neutrophil survival factors and to investigate the impact of CDK inhibitor drugs. 
This will be achieved by a combination of western blotting with differential 
nuclear/cytoplasmic lysis, illumina gene chip technology and confocal microscopy. The 
function of the key CDKs 7 and 9 is assessed by western blotting for phosphorylation of 
the transcription enzyme RNA pol II. 
 
5.1 Identification of CDKs and cyclins at protein level in human 
neutrophils 
 
CDKs were identified at protein level by western blotting (figure 5.1). Western blotting 
of nuclear and cytoplasmic lysates from neutrophils was performed to investigate the 
sub-cellular distribution of CDK proteins. We initially concentrated on CDKs known to 
be within the specificity of our nominated inhibitor R-roscovitine (i.e., CDKs 2,5,7 and 
9).  
 
CDK2 was difficult to detect and despite attempts with two different primary antibodies 
at a range of primary and secondary antibody concentrations with various blocking 
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solutions it was only detectable as a faint band on prolonged exposure. This is in 
keeping with previous findings from our group (Rossi et al. 2006). CDK2 appeared to be 
largely cytoplasmic in distribution although there is some detected in the nuclear 
fraction when cells are stimulated with LPS (figure 5.1).  
 
CDK5 was easily detected and was distributed between the cytoplasmic and nuclear 
fractions with the cytoplasmic fraction predominating. There appears to be some 
increase in the nuclear fraction of CDK5 or perhaps just an increase in total CDK5 
protein on stimulation with LPS that is blocked by co-treatment with R-roscovitine 
(figure 5.1).  
 
CDK7 was again easily detected and in a similar distribution to CDK5 though R-
roscovitine appeared to have less impact on the ability of LPS to upregulate protein 
levels generally and/or to enhance nuclear translocation (figure 5.1). 
 
Two distinct isoforms of CDK9 have previously been described in the literature and both 
of these were easily detected for the first time in neutrophils. The 55kDa isoform was 
equally distributed between nuclear and cytoplasmic fractions while the 43kDa isoform 
appeared predominantly in the nuclear fraction. There was no obvious effect of LPS 
stimulation or R-roscovitine treatment (figure 5.1). 
 
The binding partner cyclins of CDKs 7 and 9 (cyclin H and cyclin T1) were identified as 
these CDKs seemed targets of particular interest from the published literature with 
regard to R-roscovitine. The cyclin proteins were predominantly expressed in the 
nuclear fraction which is consistent with the published literature. There appeared to be 
minimal impact of LPS stimulation or R-roscovitine treatment (figure 5.1).  
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Figure 5.1: Presence of selected CDKs and cyclin binding 
partners in neutrophil granulocytes and response to stimulation 





Figure 5.1: Western blotting for CDKs known to be inhibited by R-roscovitine and cyclin binding partners 
of CDKs 7 and 9. Neutrophils were incubated as previously indicated for western blotting with agents as 
indicated above at the following concentrations: R-roscovitine 20M, LPS 100ng/ml. At 4h cells were 
lysed using neutrophil nuclear/cytoplasmic lysis buffers and technique (see methods). Lysates were run on 
10% pre-cast gels and protein identified by marker analysis. All gels are representative of n=3 
experiments.C=Cytoplasmic fraction , N=Nuclear fraction. 
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In order to confirm the data accumulated by western blotting confocal microscopy of 
neutrophils labelled by indirect immunofluorescence was performed (figures 5.2 and 
5.3). Freshly isolated neutrophils were transferred onto glass cover-slips, fixed, 
permeabilised and labelled with the primary antibody of interest. Secondary fluorescent 
antibodies were alexa-fluorTM with an excitation maximum of 647nm (far-red spectrum) 
to minimise the potential for interaction with a high degree of auto-fluorescence 
generated by granulocyte cells. Cells were also stained with DAPI to allow estimation of 
nuclear co-localisation.  
CDKs 7 and 9 were identified within the nucleus and cytoplasm of neutrophils and 
confocal imaging indicated that CDK7 and was strongly expressed in the nucleus in a 
constitutive manner and appears in an inverse nuclear pattern to DAPI (figure 5.2). 
DAPI staining is greatest at the nuclear periphery as this is where chromatin is most 
condensed. CDK7 appears more centrally within the nucleus. It has been suggested that 
transcriptionally active chromatin is less condensed (Bartova et al. 2001;Bartova et al. 
2002;Yerle-Bouissou et al. 2009). CDK9 appeared to be predominantly expressed in the 
cytoplasm and though there was evidence of nuclear co-localisation it was less striking 
than that observed with CDK7 (figure 5.3). It was difficult to reliably identify CDKs 2 
and 5 by confocal microscopy despite careful investigation. This is in keeping with the 
western blotting data for CDK2 but not for CDK5 where protein was easily detected. 
The main problem with confocal microscopy for CDK5 was significant background and 
it may be that the gentler washing steps required to maintain cell integrity in confocal 
microscopy were not sufficient to discriminate between specific antibody binding and 
background. 
 In addition there were differences in the apparent levels of nuclear CDK as measured by 
western blotting and confocal microscopy. CDK7 appeared to be predominantly 
cytoplasmic by western blotting but nuclear by confocal microscopy. Western blotting, 
especially nuclear/cytoplasmic lysis is complicated in neutrophils by the excessive levels 
of proteases generated by these cells. There is great potential to lose protein despite 
careful handling. Although protein levels were assessed by BCA assay and cytoplasmic 
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fraction was diluted accordingly it is still possible that there was comparatively more 
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Figure 5.2: Confocal microscopy of CDK7 in neutrophils by indirect immunofluorescence. Upper left 
panel shows transmitted light/bright field (BF), upper right panel shows DAPI nuclear staining (blue), 
lower left panel shows CDK7 staining (red), lower right panel shows merged image (MERGE) 
demonstrating nuclear colocalisation (pink). Leica SP confocal microscope x630 oil immersion. 
Representative image of at least n=3 experiments. 
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Figure 5.3: Confocal microscopy of CDK9 in neutrophils by indirect immunofluorescence. Upper left 
panel shows transmitted light/bright field (BF), upper right panel shows DAPI nuclear staining (blue), 
lower left panel shows CDK9 staining (red), lower right panel shows merged image (MERGE) 
demonstrating nuclear co-localisation (pink). Leica SP confocal microscope x630 oil immersion. 
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5.2 Sub-cellular distribution of CDK7 and 9 in neutrophils 
following stimulation with LPS by confocal microscopy  
 
In order to investigate a functional role for the sub-cellular distribution of CDKs in 
neutrophils I again utilised western blotting (figure 5.1) and confocal microscopy (figure 
5.4 and 5.5) to detect changes in the sub-cellular localization of CDKs on stimulation 
with LPS and in the presence of CDK inhibitor drugs. Confocal microscopy for CDK7 
in neutrophils stimulated with LPS allowed easier detection of the protein presumably 
because there was more CDK7 protein to detect in stimulated cells (figure 5.4). CDK9 
appears in an inverse nuclear pattern to DAPI staining following LPS stimulation. 
(figure 5.5). It might be inferred that LPS stimulation drives recruitment of CDK9 to 
decondensed chromatin or that LPS stimulation drives chromatin decondensation 
allowing CDK9 recruitment. The sub-cellular distribution of CDKs 7 and 9 was 
unaffected by CDK inhibitor drug treatment though it was noticeable that CDK7 
fluorescence was less intense following co-incubation of neutrophils with LPS and R-
roscovitine compared to LPS alone and more akin to the intensity observed constituively 
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Figure 5.4: Confocal microscopy of neutrophils stimulated by LPS (100ng/ml) and probed for CDK7 by 
indirect immunofluorescence. Upper left panel shows transmitted light/bright field (BF), upper right panel 
shows DAPI nuclear staining (blue), lower left panel shows CDK7 staining (red), lower right panel shows 
merged image (MERGE) demonstrating nuclear colocalisation (pink). Leica SP confocal microscope x630 
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Figure 5.5: Confocal microscopy in neutrophils stimulated with LPS (100ng/ml) and probed for CDK9 by 
indirect immunofluorescence. Upper left panel shows transmitted light/bright field (BF), upper right panel 
shows DAPI nuclear staining (blue), lower left panel shows CDK9 staining (red), lower right panel shows 
merged image (MERGE) demonstrating nuclear co-localisation (pink). Leica SP confocal microscope 
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5.3 Identification of CDKs, endogenous CDK inhibitors and 
cyclins at gene level in human neutrophils 
 
Using Illumina genechip technology we identified CDK gene expression levels in 
untreated/unstimulated neutrophils and compared this with neutrophils stimulated with 
LPS and either treated with R-roscovitine or not (figure 5.6). Neutrophils were incubated 
as previously described and purity of the cell population obtained by gradient method 
was checked by cytospin and flow cytometry. Granulocytes accounted for 99.3% of the 
cell population using this methodology and eosinophils less than 2% of the granulocyte 
population. Once neutrophil purity was confirmed RNA isolation was performed by 
Trizol extraction. RNA purity and quantification were initially performed with the use of 
a nanodrop 100. RNA was further quantified and assessed with the use of an Agilent 
Bioanalyser before the gene-chip assay was performed. The most strongly expressed 
CDKs appeared to be CDKs 2, 7 and 9 (figure 5.6). Interestingly, there was an induction 
of gene expression of CDKs 2 and 7 in neutrophils stimulated with LPS (figure 5.6). 
This induction appeared to be inhibited by over 50% when LPS-stimulated cells were 
co-treated with R-roscovitine.  
 
The cyclin binding partners of CDK7 and 9 (cyclin H and cyclin T1 respectively) were 
expressed at higher levels than other cyclins (cyclin D1 shown for comparison) (figure 
5.7). Cyclin H expression was negatively regulated to a statistically significant degree by 
R-roscovitine treatment. MAT1 another binding partner of CDK7 as part of the 
transcription factor complex TFIIH was expressed at low levels that were unaffected by 
treatment or stimulation. 
 
Endogenous CDK inhibitors, p21 and p27 were significantly expressed at gene level by 
neutrophils and p21 variant (v) 1 was upregulated by LPS treatment (figure 5.8). By 
comparison p21v2 was only minimally expressed. p21v1 is known to be regulated by 
LPS but it was interesting to note that R-roscovitine significantly blocked the ability of 
LPS to upregulate p21 gene expression by approx. 30%. 
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Figure 5.6: Illumina Gene Chip expression levels of neutrophil CDKs. Neutrophils treated for 4h with 
media alone, R-roscovitine (20M), LPS (100ng/ml) or a combination were subjected to RNA isolation 
using Nucleospin kit and Trizol extraction prior to interrogation by microarray. Result shows gene 
expression levels of CDK 1-10 genes as mean+/- SEM. Significant differences p<0.001 between Control 
and R-roscovitine are shown as * and between LPS and R=roscovitine/LPS as  # by ANOVA with post hoc 
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Figure 5.7: Illumina Gene Chip expression levels of neutrophil cyclins and binding partners. Neutrophils 
treated for 4h with media alone, R-roscovitine (20M), LPS (100ng/ml) or a combination were subjected 
to RNA isolation using Nucleospin kit and Trizol extraction prior to interrogation by microarray. Result 
shows gene expression levels of cyclin and MAT1 genes as mean+/- SEM. Significant differences p<0.001 
between Control and R-roscovitine are shown as * and between LPS and R=roscovitine/LPS as # by 
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Figure 5.8: Illumina Gene Chip expression levels of neutrophil endogenous CDK inhibitors. Neutrophils 
treated for 4h with media alone, R-roscovitine (20M), LPS (100ng/ml) or a combination were subjected 
to RNA isolation using Nucleospin kit and Trizol extraction prior to interrogation by microarray. Result 
shows gene expression levels of endogenous CDK inhibitor genes as mean+/- SEM. Statistically 
Significant differences p<0.001 between LPS and Control shown as * by ANOVA with post hoc 
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5.4 RNA polymerase II is present in phosphorylated and 
unphosphorylated forms in neutrophils and the process of 
phosphorylation is modulated by CDK inhibitor drugs 
 
It has previously been argued that neutrophils have no transcriptional capacity and that 
any RNA isolated from these cells is pre-packaged having been assembled earlier in the 
differentiation process. This theory has subsequently been discounted by a number of 
groups that have found evidence for de novo transcription in a variety of circumstances 
(Cassatella 1995;McDonald et al. 1998). 
 
The aim of this experiment was to identify evidence for previously unidentified 
neutrophil transcriptional machinery and to examine evidence for the involvement of 
CDKs 7 and 9 in the regulation of transcription. Additionally, phosphorylation of the 
CTD of RNA pol II which consists of 52 repeats of heptapeptide Tyr1-Ser2-Pro3-Thr4-
Ser5-Pro6-Ser7 (YSPYSPS) provides a functional assay for CDK7 and 9 activity. CDK7 
is known to phosphorylate RNA pol II serine 5 whilst CDK9 is known to phosphorylate 
predominantly serine 2 (though it can phosphorylate both under certain conditions in 
different cell types).  
 
In figure 5.9 the total RNA polymerase protein complex (Poltot) and RNA polymerase 
phosphorylated on key serine residues at position 2 (PS2) and 5 (PS5) are identified by 
western blotting with densitometry quantification. Phosphorylation on these serine 
residues is of known importance to the regulation of transcription by CDKs 7 and 9. 
Significant time-dependent loss of phosphorylation at serine residues 2 and 5 when 
neutrophils are incubated with the CDK inhibitor R-roscovitine is shown (figure 5.9). In 
addition the RNA pol II protein is identified by indirect immunofluorescence detected 
by confocal microscopy (figure 5.10 and 5.11). Confocal microscopy reveals the inverse 
DAPI staining pattern previously seen with stimulated neutrophils stained for CDK7 and 
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9 and is consistent with RNA pol II being present at sites of active gene transcription. 
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Figure 5.9: RNA polymerase II phosphorylation in presence and 



















Figure 5.9: Western blotting for RNA polymerase II total (Pol tot), phosphorylated on serine 2 (PS2) and 
phosphorylated on serine 5 (PS5). Neutrophils incubated as previously described with media (Control) or 
R-roscovitine (Rosco) (20m). Nuclear/cytoplasmic lysis protocol was used to optimize protein retrieval 
and lysates were run on 4% acrylamide gels. Blots shown are representative of 3 experiments and 
densitometry is data from 3 experiments shown as mean +/- SEM. Statistical significance compared to 
relevant time-point control p<0.001 is shown as ** and p<0.05 * by ANOVA with post hoc multivariate 
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Figure 5.10: Confocal microscopy of neutrophils probed for 
































Figure 5.10: Confocal microscopy of RNA pol II (total) in neutrophils by indirect immunofluorescence. 
Upper left panel shows transmitted light/bright field (BF), upper right panel shows DAPI nuclear staining 
(blue), lower left panel shows RNA pol II (total) staining (red), lower right panel shows merged image 
(MERGE) demonstrating nuclear colocalisation (pink). Leica SP confocal microscope x630 oil 
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Figure 5.11: Confocal microscopy of neutrophils stimulated 






























Figure 5.11: Confocal microscopy of neutrophils stimulate with LPS (100ng/ml) probed for RNA pol II 
(total) by indirect immunofluorescence. Upper left panel shows transmitted light/bright field (BF), upper 
right panel shows DAPI nuclear staining (blue), lower left panel shows total RNA pol II (RNApol tot) 
staining (red), lower right panel shows merged image (MERGE) demonstrating nuclear colocalisation 
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5.5 Down-regulation of RNA polymerase II phosphorylation by 
CDKs 7 and 9 has specific effects on gene transcription 
 
In figure 5.12 global effects on gene expression assessed by illumina gene chip 
technology for neutrophils treated with R-roscovitine are illustrated by representative 
bar-graphs and a heat map. The heat map shows the genes most significantly up- and 
down-regulated across all four treatment conditions (untreated neutrophils (C), R-
roscovitine-treated (R), LPS-stimulated (L) and LPS/R-roscovitine co-treatment (RL)). 
In total of genes detected: 1656 genes were down-regulated, 886 were upregulated and 
1359 weren’t significantly affected following treatment with R-roscovitine for 4h. 
Interestingly, though perhaps not surprisingly genes related to transcription were highly 
represented in terms of differential regulation following R-roscovitine treatment. In 
figure 5.13 you can see the impact on transcription related genes as well as data for 
further gene types of specific interest to this thesis (apoptosis, inflammation, cell-cycle). 
The general trend is of down-regulation of genes. Using gene ontology cluster analysis 
(figure 5.14) it is possible to identify clusters of genes that are most affected by R-
roscovitine treatment (in terms of both up- and down-regulation of expression). Those 






















































Figure 5.12: Illumina gene chip effect of CDK inhibitor drugs on the neutrophil transcriptome and 
specifically on genes involved in transcription. Neutrophils treated for 4h with media alone orR-
roscovitine (20M) were subjected to RNA isolation using Nucleospin kit and Trizol extraction prior to 
interrogation by microarray. Bar graph above shows genes down-regulated >2 fold by R-roscovitine 
compared to control (-), genes up-regulated >2 fold by R-roscovitine treatment compared to control (+) 
and genes unaffected. Heat map shows gene expression most changed (upregulated and downregulated) 
across the four treatment groups (R-roscovitine (R), R-roscovitine/LPS (RL), Control(C) and LPS alone 










































































Genes 196 72 78 25 27 16
Apoptosis - Apoptosis + Cell cycle- Cell cycle+ Inflammation - Inflammation +





































Figure 5.13: Illumina gene chip effect of CDK inhibitor drugs on specific clusters of genes relevant to this 
thesis. Neutrophils treated for 4h with media alone or R-roscovitine (20M) were subjected to RNA 
isolation using Nucleospin kit and Trizol extraction prior to interrogation by microarray. Results show 
genes down-regulated >2 fold by R-roscovitine treatment compared to control (-) and genes up-regulated 
>2 fold by R-roscovitine compared to control(+). Gene families assessed include: transcription, 
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Figure 5.14: Gene ontology (GO) terms over-represented in 






Figure 5.14: Over-represented gene ontology terms in genes significantly up and down-regulated (up and 
down-regulation >2-fold, R-roscovitine compared to control with significance of p<0.001) R-
roscovitine:Control. 
 Downregulated genes (>2 fold p<0.01) Upregulated genes (>2 fold p<0.01) 
1 nucleobase, nucleoside, nucleotide and nucleic 
acid metabolic process 
 translational elongation  
2 cellular metabolic process cellular protein metabolic process 
3 cellular catabolic process ribosomal small subunit biogenesis 
4 positive regulation of I-kappaB kinase/NF-
kappaB cascade 
attachment of GPI anchor to protein 
5 response to unfolded protein immune response 
6 protein transport rRNA processing 
7 regulation of programmed cell death generation of precursor metabolites and 
energy 
8 regulation of primary metabolic process leukocyte activation during immune 
response 
9 protein modification by small protein conjugation 
or removal 
lysosomal transport  
10 modification-dependent protein catabolic process negative regulation of interleukin-8 
biosynthetic process 
11 regulation of macromolecule metabolic process positive regulation of pinocytosis 
12 regulation of transcription from RNA 
polymerase II promoter 
defense response to fungus 
13 positive regulation of nitrogen compound 
metabolic process 
leukocyte activation 
14 positive regulation of biosynthetic process regulation of translation 
15 protein localization phospholipid biosynthetic process 
16 positive regulation of biological process antigen processing and presentation 
17 cell cycle negative regulation of peptidase activity 
18 RNA splicing programmed cell death 
19 small GTPase mediated signal transduction glycerolipid biosynthetic process 
20 mRNA processing biosynthetic process 
21 cellular protein localization lymphocyte differentiation 
22 transcription initiation from RNA polymerase 
II promoter 
T cell activation 
23 positive regulation of transcription NADPH regeneration 
24 induction of apoptosis via death domain 
receptors 
regulation of macrophage activation 
25 RNA biosynthetic process cellular macromolecule biosynthetic process 
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5.6 Discussion 
 
The discovery that neutrophils could be driven to undergo apoptosis by pharmacological 
inhibitors of elements of the cell-cycle machinery termed cyclin-dependent kinases 
(CDKs) has established a major research track for our group (Duffin et al. 2009;Leitch et 
al. 2009;Leitch et al. 2010b;Rossi et al. 2006). This finding was unexpected given the 
cell-cycle status of neutrophils as the only other terminally differentiated cell type 
(neurons) studied with these pharmacological agents, prior to our work, demonstrated 
enhanced longevity (Maas, Jr. et al. 1998). Additionally it had been shown that some 
CDKs were progressively down-regulated as myeloid lineage cells matured (Klausen et 
al. 2004). Myeloid lineage cells differentiate in the following order: myeoblast, 
promyelocyte, myelocyte, metamyelocyte, band cell, segmented cell, neutrophil. 
Klausen et al., using primary human bone-marrow cells from healthy volunteers 
described progressive loss of CDKs 2, 4 and 6 which began at the 
myelocyte/metamyelocyte stage and was almost complete by full maturation (Klausen et 
al. 2004). This occurrence coincided with upregulation of the endogenous CDK inhibitor 
p27kip1 and both results were shown at the mRNA and protein level. No consistent 
finding with regard to the up or down-regulation of the CDK binding partners, termed 
cyclins, was obtainable illustrating the complexity of regulation involved in this system. 
This finding was important as other works on granulopoiesis had utilised a variety of 
cell-lines and discovered, perhaps unsurprisingly, a variety of CDK/CDK binding 
partner expression patterns. It also suggested that p27kip1 might be more important than 
the commonly implicated endogenous CDK inhibitor, p21. Interestingly, p21 has come 
to the fore recently as a novel modulator of the response to LPS made by inflammatory 
macrophages (Lloberas et al. 2009;Scatizzi et al. 2009).  
 
The previous chapters have characterised the molecular mechanism by which CDK 
inhibitor drugs drive neutrophil apoptosis (Chapter 3) and identified functional CDKs 
and transcriptional machinery in neutrophils (Current Chapter). In addition they have 
identified specific transcriptional effects of CDK inhibitor drugs on neutrophils. The 
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evidence gathered so far has shown that apoptosis proceeds via the intrinsic pathway, 
that short-lived, responsive mRNAs are selectively affected by CDK inhibitor drugs and 
that proteins involved in apoptosis are amongst that cluster of transcripts. 
I have identified at gene and protein level the expression of CDKs, their binding partners 
and endogenous inhibitors in neutrophils. Perhaps unsurprisingly given the terminally 
differentiated state of these cells the most significantly expressed CDKs, CDKs 7 and 9, 
have no role in the cell cycle/proliferation but are essential for transcription of a key 
subset of genes (Roy et al. 1994;Zhu et al. 1997). Gene expression is the end-product of 
a number of different processes (transcription, mRNA elongation/splicing/capping, 
translation, degradation) but transcription regulated by a variety of transcription factors 
is often the most important contributor. The standard model of transcription from a 
promoter involves the binding and formation of a pre-initiation complex composed of 
RNA pol II and various TATA box binding proteins, kinases and ubiquitin ligases. This 
is termed the RNA pol II holoenzyme and is responsible for the majority of RNA 
transcription in mammalian cells. The pre-initiation complex requires further input 
before full-length, viable mRNA can be produced. It is at this stage that regulation from 
signalling cascades such as those activated in the presence of inflammatory stimuli is 
integrated into the system. Signalling cascades may promote the subcellular 
redistribution of transcription factors (e.g. NF-B) or may activate kinase cascades by 
dimerisation or ligand-binding. It is the subsequent binding and activation of the pre-
initiation complex by pathway-specific transcription factors and coactivators as well as 
phosphorylation by dedicated kinases that determines the level and variety of gene 
expression.  In highly inducible genes such as those involved in inflammatory signalling 
or apoptosis RNA polymerase II recruitment and activation occur simultaneously. These 
genes appear to be heavily dependent on the positive transcription elongation factor b 
(P-TEFb) complex. P-TEFb is a heterodimer of CDK9 and cyclin T1 that can 
phosphorylate serines 2 and 5 within the 52 repeats of heptapeptide YSPTSPS on the 
CTD of RNA pol II. Interestingly, it has been shown that NF-B dependent genes are 
dependent on P-TEFb activity and that there may be a physical interaction between NF-
B and P-TEFb (Barboric et al. 2001;Nowak et al. 2008). Phosphorylation of serine 2 is 
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known to be important for transcriptional elongation of highly inducible genes. CDK7, 
cyclin H and the cofactor MAT1 are part of the transcription factor IIH complex (TFIIH) 
which is known to be important for the initiation of transcription. Interestingly, it 
appears that LPS stimulation enhances transcription of the CDK7 gene suggesting that 
enhanced transcription directly drives production of the machinery of transcription 
(figure 5.4). This process is down-regulated by the CDK inhibitor drug, R-roscovitine. 
Additionally LPS stimulation appears to enhance CDK9 and RNApol II recruitment to 
decondensed/transcriptionally active chromatin within the nucleus, a process that is 
unaffected by CDK inhibitor drug treatment.  
 
 It is my contention that it is inducible genes: short-lived, rapidly upregulated, 
responsive and dependent on CDK activation that confer the phenotype that allows 
neutrophils to be an effective early arm of immune defence. The gene clusters that fit 
this description include those involved in transcription, apoptosis, signalling and 
chemokine production (figure 5.10).  To support this contention I have demonstrated 
that RNA polymerase II is both present in neutrophils and phosphorylated by CDKs 7 
and 9 in order to enhance transcriptional capacity (figure 5.7). Inhibition of CDKs 7 and 
9 leads to dephosphorylation of this enzyme and downregulation of transcription. As I 
have previously discussed the transcriptional capacity of neutrophils has been a matter 
of some controversy. Work by Cassatella and MacDonald et al (Cassatella 
1995;McDonald et al. 1998) suggested that neutrophils do indeed have the capacity for 
de novo transcription. Here I describe the machinery by which they achieve this 
functionality and a method by which it may be selectively altered to enhance apoptosis 
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 Summary of Chapter 5 
 
1. CDKs 2,5,7,9 present in human neutrophils as assessed by 
western blotting, illumina gene chip technology and confocal microscopy 
2. CDKs intracellular localisation can be dictated by known 
neutrophil survival factors 
3. RNA polymerase II is present and functional in human 
neutrophils  as assessed by western blotting and confocal microscopy 
4. CDK inhibitors can prevent phosphorylation of RNA 
polymerase II by CDKs 7 and 9 as assessed by western blotting 
5. Gene expression in human neutrophils is specifically 
regulated by CDK inhibitor drug treatment as assessed by 
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6. Results: A molecular biology strategy to corroborate data 
generated with regard to pharmacological CDK inhibitor drugs 
 
In order to strengthen our hypothesis that CDKs 7 and 9 are of key importance in the 
promotion of neutrophil apoptosis by CDK inhibitor drugs we aimed to develop a 
molecular biology knockdown strategy that would be successful in human neutrophils. 
 
Human neutrophils are notoriously difficult to influence by techniques such as antisense, 
siRNA and viral vector transfection that have become established standards in other cell-
types. This is because neutrophils have a constitutive life-span of approximately 24h that 
can be extended in response to infection/inflammation and certain pharmacological 
agents (dexamethasone, db-cAMP). This doesn’t leave a satisfactory window for 
achieving cell transfection and gene of interest knockdown. However, antisense has been 
used to knockdown the key survival protein Mcl-1 in neutrophils subject to enhanced 
longevity because of dexamethasone (Sivertson et al. 2007) treatment or hypoxia 
(Leuenroth et al. 2000b) and recently Sabroe et al have demonstrated that a lentiviral 
strategy can be used successfully to knockdown the NF-B pathway (Dick et al. 2009). 
Certain publications have described the use of siRNA in neutrophils but these data are 
controversial in my opinion (Azuma et al. 2007;Ernens et al. 2006). In the first 
publication phospholipase-D is knocked down in rat neutrophils over a 24h period 
before cells are stimulated with fMLP (Azuma et al. 2007). In my experience the 
interpretation of these data would be rendered difficult by a high degree of cell death, 
both apoptotic and necrotic at this time-point. The second paper describes gene 
knockdown in human neutrophils over a 48h period prior to stimulation with adenosine 
and fMLP (Ernens et al. 2006) which requires an in vitro neutrophil life-span not 
compatible with the majority of literature dedscribing unstimulated neutrophils. It may 
be the case that the siRNA process significantly extends neutrophil lifespan through off-
target effects (e.g., described effects on the JAK/STAT pathway (Sledz et al. 2004)) but 
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in that case the experiment requires significantly better design and control to justify its 
use let alone conclusions. 
 
The most consistently employed knockdown strategy in neutrophils (and eosinophils) is 
the HIV-tat transduction method (Gump et al. 2007). This bypasses the necessity for 
knockdown at the intracellular gene transcription level by delivering a pre-synthesised 
protein direct to the cell. The tat protein is an HIV virulence factor that promotes cell-
membrane entry probably by a novel process (Gump et al. 2007). Small peptides to large 
proteins can be coupled to a short peptide sequence of the tat protein and efficiently 
transduced into a variety of cell types.  
 
I chose to use the HIV-tat transduction system to deliver dominant negative CDK 7 and 
9 proteins to human neutrophils in order to test our hypothesis that CDK7 and 9 were 
important targets of CDK inhibitor drugs in neutrophil apoptosis and the resolution of 
inflammation.  
 
6.1 Cloning of HIV-tat dominant negative CDKs 7 and 9  
 
In order to generate HIV-tat dominant negative (dn) CDKs 7 and 9 protein it was 
necessary to generate a DNA sequence that combined both HIV-tat, dnCDK 7 or 9 and a 
His-tag sequence to allow affinity purification of the protein later in the process. HIV-tat 
plasmids (plasmid sequence in figure 6.1) were a generous gift from Dr Steven Dowdy 
(UCSD) and CDK7dn and 9dn (plasmid maps in figure 6.2) were bought (for a nominal 
fee) from Addgene with the permission of the Fujinaga lab. The CDKdn DNA was sub-
cloned into the HIV-tat plasmid as described on page 82 (methods section). The success 
of this process was confirmed by restriction enzyme digest which released an 
appropriately sized fragment (figure 6.3i), PCR for relevant CDKdn (figure 6.3ii) and 
finally by definitive sequencing using 5 sets of primers (named CDK FOR 1 and 2, CDK 
REV 1 and 2 and T7- see materials for sequences). Figure 6.4 shows key sections of the 
obtained sequence which fully aligned with known sequences for the tat plasmid and the 
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CDKdn. In addition it was possible to confirm that the one amino acid substitution 
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Figure 6.1: Plasmid sequence for pET-tat 2.1 provided by Dr Steve Dowdy (UCSD). 
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Figure 6.3: In i) Cloning of CDK9-dn to tat plasmid is confirmed by PCR using primers FOR1 and REV1 
(see materials page 74) Lane 1 is marker, lane 2 is TopoXL vector with CDK9dn and lane 3 is tat vector 
CDK9dn . In ii) a restriction enzyme digest using EcoRI/NotI was performed to release the CDK9dn 
fragment which had been cloned in with the use of these restriction sites. In lane 1 is marker, lane 2 is 
uncut tat plasmid, lane 3 is plasmid cut with restriction enzymes and lane 4 is marker. 
Lane 
Lane 
1 2 3 
2 3 1 4 
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Figure 6.4: Sequencing of tat-CDK9dn plasmid 
i) Inactivating enzymatic domain of CDK9: GAC-AAC(D-N) = Aspartic acid 
to asparagine   
 
 


















Figure 6.4: Excerpts from sequencing results for Tat-CDK9-DN DNA. Full sequencing was performed for 
both Tat-CDK-DN DNA and representative images for CDK9-DN are shown. In i) the dominant negative 
amino acid substitution is identified, in ii) tat vector followed by the EcoRI restriction enzyme sequence 
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6.2 Production of HIV-tat dominant negative CDK7 and 9 
proteins 
 
HIV-tat proteins were produced by transformation of BL21(DE3)plysS E.coli bacteria. 
A variety of conditions were investigated to establish whether it might be possible to 
produce soluble protein without the use of denaturing conditions. E.coli were induced to 
produce protein at temperatures of 20oC, 30oC, 37oC over time periods from 2-24 hrs 
and in the presence/absence of glucose. All experiments were carried out under the 
selection pressure of kanamycin (HIV-tat-dnCDK7/9 confer resistance). It appeared that 
regardless of the above conditions the majority of protein was contained in insoluble 
inclusion bodies (as has previously been found by Zhao et al). It was determined that in 
order to produce enough protein to allow for losses incurred in purification steps 
denaturing conditions would have to be used. CDK7 and 9 tat proteins were solubilised 
and then subjected to His-tag affinity purification using batch metal affinity 
chromatography (TalonTM Cobalt resin) as shown in coomassie stained gel in figure 6.5.  
 
During batch isolation E.coli lysates were solubilised in 8M urea or 6M Guanidium HCl 
and bound to cobalt metal affinity resin using conditions described in method. Proteins 
were eluted with the use of 150mM to 1M imidazole and checked by coomassie staining 
and western blotting for both CDK7/9 and His-tag. Figure 6.6 shows representative 
images of western immunoblotting for His-tag and CDK9 (for example).  
 
It was confirmed that dn-CDK7 and 9 tat proteins had been produced. However 
subsequent HPLC purification and salt exchange steps demonstrated that the majority of 
tat protein produced aggregated or degraded on introduction of non-denaturing buffer. 
This was despite the use of various strategies employed to produce pure protein in cell 
compatible buffer including: spin column dialysis, overnight dialysis by slide-a-
lyzer/snakeskin tubing, HPLC on column refolding (various buffers and strategies), 
HPLC gel filtration and ion exchange chromatography. 
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Figure 6.5: Coomassie protein stain of gel showing batch isolation process. Protein was produced by 
BL21 E.Coli induced (I) with the use of IPTG (1mM). Uninduced (UI) BL21 E.coli protein lysate is shown 
for comparison. Protein was bound to cobalt resin using a batch method and the resin was subsequently 
washed 3x (W1-3) in wash buffer prior to elution (E) with imidazole (150mM) buffer. Elution was 
repeated 4 times (E1-4). FT represents flow through following binding of initial protein sample to resin. 
tat-CDK9dn 
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Figure 6.6: Western blots for His-tag (His) and CDK9. Loaded samples are the same as those shown in 
figure 6.5 (Coomassie stain). Positive control for CDK9 is A549 lysate. Protein was bound to cobalt resin 
using a batch method and the resin was subsequently washed 3x in wash buffer, washes 1 and 2 (W1+2) 
are shown. Elution (E) samples E1 and E2 from previous figure are probed for His-tag and E2 is 
subsequently probed for CDK9.  
W1
50kDa 
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6.3 Isolation and purification of HIV-tat dominant negative CDK7 
and 9 
 
HPLC affinity purification using nickel and cobalt IMAC columns was attempted but 
was unsuccessful. For reasons that I have been unable to determine His-tag binding was 
not of strong enough affinity to allow the wash steps required for HPLC purification. 
The chromatograph shown in figure 6.7 shows no protein peak as determined by UV 
trace. The peak in the latter stages represents the change in trace related to imidazole 
content of elution buffer (Absence of protein of interest was confirmed by agarose gel 
electrophoresis of eluted samples followed by coomassie staining). Coomassie staining 
of agarose gel electrophoresis of samples from various stages of process demonstrated 
that the majority of protein was lost during the wash stage. This seemed to occur with 
cobalt and nickel metal ion columns, independently of buffer conditions (guanidium, 
urea or NDSB-201, pH, imidazole content, salt content) and time of contact of protein 
sample with resin. In order to proceed without returning to DNA level I attempted to 
batch purify protein using metal affinity followed by clean-up using HPLC gel filtration 
and ion exchange.  Although adequate sample was obtained by batch purification, clean-
up stages were complicated by significant loss of protein to aggregation and insolubility.  
Figures 6.7 and 6.8 show chromatograms of attempted clean-up steps. The protein of 
interest should have appeared between 50 and 60ml (as compared with known protein 
standards) by gel filtration but appeared earlier in aggregate forms as detected by UV 
trace and agarose gel electrophoresis. In this experiment the protein came out of solution 
when it was filtered directly into non-denaturing buffer but in a repeat using a gradient 
of denaturing to non-denaturing buffer the protein also came out of solution (Gu et al. 




















































































































Figure 6.7:  UV traces from HPLC tat-CDK9dn protein isolated from E.coli lysates. In i) protein was 
bound to a Cobalt IMAC column according to method 1 (see materials and methods). Trace shows no 
purified protein peak. In ii) protein isolated from E.coli lysates was subjected to HPLC gel filtration 
through a buffer gradient as per method 2. The protein peak should appear between 50 and 60mls (by 




























































































































































Figure 6.8: HPLC purification of tat-CDK9dn by gel filtration and 






















Figure 6.8:  UV traces from HPLC tat-CDK9dn protein isolated from E.coli lysates. In i) protein isolated 
from E.coli lysates was subjected to HPLC gel filtration into refolding buffer as per method 3. The protein 
peak should appear between 50 and 60mls (by comparison with known standards but instead appears 
earlier (0-10mls) suggesting protein aggregation. In ii) protein purification by ion exchange 
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6.4 Transduction of neutrophils by HIV-tat dominant negative 
CDK7 and 9 
 
I decided to test the ability of the small amounts of tat protein produced in soluble form 
to transduce into human neutrophils as a proof of concept experiment. A quantity of 
protein was labelled with FITC which allowed assessment of cellular location by 
confocal microscopy and flow cytometry. In parallel assays for neutrophil apoptosis 
were performed with unlabelled protein. It was clear that FITC labelled protein could 
transduce human neutrophils figure 6.9 and 6.10. It was also demonstrated that proteins 
significantly activated human neutrophils (see figure 6.9 and compare morphology of 
cells between free FITC treated and FITC labelled tat-CDK9dn) which made 
interpretation of flow cytometry assay for neutrophil viability difficult (data not shown). 
It was subsequently established by limulus assay that this was related to LPS 
contamination of the protein associated with the batch method of protein purification. It 
was determined that further purification of tat proteins by HPLC is required before they 
can be successfully used in human neutrophils. An endotoxin affinity column was used 
to promote removal of this important bacterial product. The protein of interest bound 
strongly to the endotoxin column along with LPS and could not be eluted in sufficient 
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Figure 6.9: HIV-tat transduction of human neutrophils using 





Figure 6.9: tat-CDK9dn protein was labelled with FITC and labelled protein was purified by buffer 
elution from PD-10 gel filtration column. Human neutrophils isolated as previously described were 
exposed to FITC-labelled tat-CDK9dn protein or free FITC for 30min in a 2ml eppendorf at 37oC, 5% 
CO2. Cells were subsequently spun down and washedx3 in medium + 10% autologous serum. After 
washing cells were transferred to coverslips and prepared for confocal microscopy (Zeiss LSM meta 510, 
488nm laser, x400 oil immersion). 
Control free FITC 
Tat-CDK9-FITC 
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Figure 6.10: HIV-tat transduction of human neutrophils using 










Figure 6.10: tat-CDK9dn protein was labelled with FITC and labelled protein was purified by buffer 
elution from PD-10 gel filtration column. Human neutrophils isolated as previously described were 
exposed to FITC-labelled tat-CDK9dn protein or free FITC for 30min in a 2ml eppendorf at 37oC, 5% 
CO2. Cells were subsequently spun down and washedx3 in medium + 10% autologous serum. After 
washing cells were analysed by confocal microscopy for shift in FL-1 indicating incorporation of FITC 
dye. Two concentrations of labelled  tat-CDK9dn protein are shown (50nm and 100nm) and compared to 
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6.5 Discussion of Chapter 6 
 
The HIV-tat transduction system has been successfully used to deliver peptides and 
large proteins to both neutrophil and eosinophil granulocytes (Fujihara et al. 2002;Han et 
al. 2003;Kilpatrick et al. 2010a;Kilpatrick et al. 2010b;Vidarsson et al. 2006). The 
advantage of this method is that it delivers a pre-formed peptide/protein to the cell 
without the extra steps of gene knockdown required by techniques like lentiviral 
transfection, antisense knockdown and siRNA. Theoretically it should also be possible 
to deliver the protein of choice without recourse to transfection agents that might have 
negative effects on cell longevity (there is a degree of cell-toxicity associated with most 
transfection protocols). This is important when a major read-out of the experiment is the 
promotion of cell death. The numerous examples of successful transduction of 
granulocytes and the theoretical advantages detailed above led me to pursue an HIV-tat 
transduction strategy for the knockdown of CDK 7 and 9 function in human neutrophils.  
 
Dominant negative CDKs 7 and 9 are described in the literature and have been used to 
successfully knockdown the functions of these proteins including there effects on 
transcription (Garriga et al. 1998;Garriga et al. 2004;Garriga et al. 2009;Zhu et al. 1997). 
The experimental plan was to produce tat-linked CDKdn and then to transduce 
neutrophil granulocytes and repeat the experiments already described using 
pharmacological CDK inhibitors. In short, we planned to perform assessments of 
neutrophil viability over a time-course following transduction (flow cytometry for 
annexin-V/PI and morphological assessment by cytocentrifuge preparation), to measure 
RNApol II phosphorylation (western blotting) and Mcl-1/Bim levels (PCR and western 
blotting). An initial preparatory experiment would have been to FITC label tat-CDKdn 
and ensure it had entered cells by flow cytometry assessment and fluorescence 
microscopy. In addition we planned to perform western blots for His tag and CDK (it 
might be expected that native and recombinant protein would have different molecular 
weight because of the His and tat tags) in transduced cells to confirm protein 
internalisation.  
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The decision to attempt IMAC purification of tat-CDKdn protein was made because this 
technique had previously been utilised by other groups (Zhang et al. 2009;Zhao et al. 
2007) and because the tat-plasmid has a His-tag sequence built in (see figure 6.1). For 
reasons we haven’t been able to identify but presumably related to the properties of 
CDK proteins this method was only partially successful. The affinity of the His-tag for 
the IMAC column appeared to be significantly decreased and only batch purification by 
metal ion resin proved possible and even by this method there was still significant 
protein loss in the washing stages.  Batch-purified protein was found to be significantly 
contaminated by LPS (proven by LAL assay and see figure 6.7) but was capable of 
transducing human neutrophil granulocytes (as proven by FITC labelling, confocal 
microscopy and flow cytometry).  
 
HPLC purification of the protein was attempted by gel filtration (size exclusion) and ion 
exchange chromatography. Despite using various well-described buffers and methods 
(see materials and methods) refolded protein in monomeric form wasn’t obtained in 
sufficient quantities for experimental use. 
 
This experimental line has not been exhaustively investigated however and there are still 
numerous approaches that could be used to overcome the problems encountered. It has 
been noted that different proteins require specifically tailored purification strategies 
though the means to achieve this consistently without resorting to trial and error has not 
been developed (Buckle et al. 2005). It has been estimated that only 13% of human 
proteins are isolated in soluble form from genetically modified bacteria (Braun et al. 
2002). There are a number of variations on the gel filtration/ion exchange strategies that 
I have not been able to attempt that might potentially allow good yield and acceptable 
purity. In addition, the use of an ATP-binding column is a strategy often used in the 
isolation of kinase-type proteins and this strategy has been used to successfully isolated 
CDK proteins previously. Alternatively, it would be possible to start again with a 
different expression vector in order to avoid some of the contamination issues associated 
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with bacterial expression. Other potential expression strategies might include 
baculovirus, mammalian, plant or yeast expression (Demain et al. 2005). Given the 
inefficiency of the his-tag the introduction of a different tag isolation method such as 
GST, CBP, CYD (covalent yet dissociable NorpD peptide), Strep II, FLAG or HPC 
might be contemplated (Lichty et al. 2005). 
 
Additionally, it might be possible to subject stimulated (and therefore longer-lived) 
neutrophils to lentiviral knockdown in a carefully controlled experiment akin to that 
recently achieved by Sabroe et al (Dick et al. 2009). 
 
 
6.6 Summary of Chapter 6 
1. Cell-delivery peptides coupled to dominant negative 
CDKs 7 and 9 have been produced but require further 
purification 
2. Future approaches for the production of highly purified 
proteins may involve alternative protein 
production/isolation techniques 
3. Lentiviral/siRNA transduction of stimulated neutrophils 
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Chapter 7: CDK inhibitor drugs and the bleomycin lung injury 
model 
 
7.1 CDK7/9-specific inhibitor DRB drives resolution of 
inflammation in the bleomycin lung injury model 
 
In order to enhance our previous work with the CDK inhibitor, R-roscovitine in the 
resolution of neutrophil-dominant lung injury (Rossi et al. 2006) we attempted to refine 
the specificity of the pharmacological agent used. There are a number of different 
classes of CDK inhibitor drug that show varying specificities for different CDKs. At 
high concentrations these specificities disappear but by careful use within designated 
concentration ranges it ought to be possible to target defined CDKs. The CDK inhibitor 
drug DRB has been described as a CDK7/9 specific inhibitor and its utility in this regard 
has been described in numerous publications in the literature (Lee et al. 2001;Luecke et 
al. 2005;Marshall et al. 1996;Peng et al. 1998). It has also been used as an inhibitor of 
transcription, a function it has been shown to perform by the inhibition of CDKs 7 and 9 
(Lee et al. 2001;Luecke et al. 2005;Marshall et al. 1996;Peng et al. 1998). In this thesis 
DRB has been shown to drive human neutrophil apoptosis with equal efficacy and 
similar pharmacokinetics to R-roscovitine (figure 3.6, page 101) and to activate caspases 
(figure 3.10, page 108). In addition, we have shown that DRB drives apoptosis of mouse 
bone-marrow derived neutrophils in vitro (data not shown). 
 
The model of neutrophil-dominant lung injury we chose to investigate was the acute-
phase of bleomycin-induced lung injury. This model has been the gold-standard for 
investigation of the lung inflammation and fibrosis associated with IPF and has been 
shown to be reproducible and similar to human disease pathology (It causes acute 
alveolar/interstitial inflammation with subsequent development of epithelial cell death 
and basement membrane damage leading to predominantly bronchiolocentric fibrotic 
changes (Moeller et al. 2008;Moore et al. 2008)). The initial phase of the injury up to 
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Day 7 resembles the histopathology of acute exacerbation of IPF or even ARDS/ALI 
and it is therefore a useful model for the investigation of neutrophil-dominant 
inflammation. 
 
I investigated the ability of DRB to resolve neutrophilic inflammation associated with 
the bleomycin lung injury model. This seemed a logical approach because of our 
previous research finding that R-roscovitine could promote resolution of the neutrophil-
dominant inflammation associated with this model. In that experiment mice were given 
i.t. bleomycin on Day 0, R-roscovitine was administered i.p. at a dose of 100mg/kg on 
day 2 and mice were killed on day 7. Histological evidence of neutrophil-dominant 
inflammation was clear in control animals but in R-roscovitine-treated animals, 
inflammation had almost entirely resolved.  
 
To increase the novelty of this essentially mechanistic experiment and to further assess 
the potential of CDK inhibitor drugs to translate to clinical entities we used an i.t. 
aspiration model to mimic the delivery of standard inhaled therapies. This allowed us to 
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Figure 7.1: In vivo experimental plan for assessment of 

































Read-outs:   
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Mice treated with bleomycin at day 0 develop a significant neutrophil-predominant 
infiltrate after 24h. This usually persists to 7 days (figures 7.2A, C and 7.3) and is 
associated with significant damage to the epithelium which eventually results in collagen 
deposition and fibrosis. Mice treated with DRB or R-roscovitine on days 2 and 4 clear 
the bleomycin-induced multifocal inflammatory cell infiltration from the alveoli, peri-
bronchiolar and peri-vascular areas by day 7 and their lungs remain architecturally intact 
with only minimal histological evidence of inflammation (figure 7.2B and D). This is in 
contrast to untreated mice where neutrophils persist and significant architectural 
disturbance occurs resulting in fibrosis.  
 
Mice subjected to bleomycin injury develop significant BAL neutrophilia (figure 7.3) 
and additionally a measurable increase in BAL protein (figure 7.4) suggestive of 
inflammatory injury. By contrast mice subjected to bleomycin injury but treated with the 
CDK7/9- specific inhibitor DRB or R-roscovitine have less neutrophils in BAL with no 
detrimental effect on macrophage numbers (figure 7.3). Additionally, there is 
significantly less protein in BAL of these mice compared to vehicle control (figure 7.4). 
There is an apparent trend towards less LDH in BAL of treated mice that is statistically 
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Figure 7.2: Representative histology from Bleomycin acute lung injury model experiment. Images are at 
magnification x100 (Size bar m). 
DRB  
R-roscovitine vehicle R-roscovitine  
DRB vehicle 
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Figure 7.3: DRB reduces BAL neutrophil count with no 





Figure 7.3: Differential white cell counts from broncho-alveolar lavage of mice subjected to bleomycin 
injury and treated according to the schedule in figure 7.1. Statistically significant difference compared to 
vehicle control shown as ** p<0.01 or *** p<0.001 by ANOVA with a Student Newman-Keuls multiple 



















































































Figure 7.4: DRB reduces protein levels with no significant effect 






















Figure 7.4: Total protein and LDH levels from BAL of mice subjected to bleomycin injury and treated 
according to the schedule in figure 7.1 Statistically significant difference compared to control shown as 
*** p<0.001 by ANOVA with a Student Newman-Keuls multiple comparison post hoc test with a 95% 
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7.2 Discussion of Chapter 7 
 
We have previously shown that a CDK inhibitor drug, R-roscovitine, can resolve 
bleomycin-induced lung injury by promotion of neutrophil apoptosis. We were keen to 
incisively investigate the mechanism responsible for this effect by knocking down 
specific, individual CDKs in neutrophils in vivo. We had planned to achieve this by 
producing dominant negative CDK proteins coupled to the tat cell penetrating peptide.  
The production of these proteins encountered various difficulties (we are still confident 
we will be able to produce these proteins) and we therefore utilised the CDK7 and 9-
specific pharmacological inhibitor DRB. The experiment we performed (as detailed in 
the schematic in figure 7.1) aimed to compare the impact of DRB and R-roscovitine 
(CDK2, 5, 7 and 9 specific) on the early (first week) neutrophil-dominant inflammation 
induced in mouse lungs by i.t. administration of bleomycin. Additionally we attempted a 
local delivery of CDK inhibitor drugs by i.t. administration in an attempt to mimic the 
aerosol administration of inhaled/nebulised therapy in use in respiratory disease such as 
COPD/asthma. I.t. administration allowed us to reduce the dose of drug given to the 
animals ten-fold (100mg/kg to 10mg/kg). We expect that local delivery of a reduced 
drug-dose may help to attenuate some of the side-effects encountered in humans when 
these drugs are used as cancer therapeutics. 
 
BAL and lung tissue were retrieved and cell-counts and histology revealed effective 
neutrophil depletion in BAL and tissue. Macrophage numbers remained constant in 
BAL. We are confident that neutrophil apoptosis is induced in vivo rather than, for 
example, an inhibition of neutrophil recruitment because neutrophil-dominant 
inflammation is already established by the time we administer CDK inhibitor drugs. In 
addition we observe neutrophil debris and apoptotic bodies within macrophages in 
mouse BAL and tissue from animals treated with CDK inhibitor drugs. 
 
Additionally, there is evidence of resolution of bleomycin-induced inflammatory injury 
by CDK inhibitor drugs in the form of reduced protein leak measured in BAL. No 
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significant difference in measured LDH levels was detected though there was a trend 
towards less LDH in in CDK inhibitor treated mice. This probably reflects the use of a 
model of established neutrophilic inflammation where a degree of cell damage has 
already occurred by the time we institute treatment. We would hypothesise that levels of 
LDH would fall at later time-points as resolution is allowed to progress whereas they 
might be expected to be maintained in untreated animals. 
 
 
Summary of Chapter 7 
 
1. The CDK7 and 9-specific inhibitor, DRB can resolve 
bleomycin-induced, neutrophil-dominant lung injury. 
2. CDK7 and 9 are potential targets for pro-resolution of 
inflammation therapeutics in the treatment of lung 
disease 
3. Macrophage numbers are not adversely affected by CDK 
inhibitor drug therapy 
4. Local (i.t.) administration of CDK inhibitor drugs is an 








                                                                                                                                           181
8 General Discussion 
 
Inflammation is recognised as central to the pathogenesis of a number of disease entities 
including: cancer, atherosclerosis, arthritis, glomerulonephritides, asthma and smoking-
related lung disease (Hallett et al. 2008b;Rossi et al. 2007;Serhan et al. 2007). 
Consequently, it is an important target for the design of new therapeutics. These 
therapeutics have traditionally targeted the initiation and propagation phases of 
inflammation. Important examples include NSAIDs which target COX the enzyme that 
drives production of prostaglandins which are key mediators in the early stages of 
inflammation and glucocorticosteroids which work through a variety of effects at the 
molecular level including enhancement of anti-inflammatory and repression of pro-
inflammatory gene transcription (Newton 2000). They are very successful at treating 
eosinophil-dominant inflammatory disease such as asthma while they have had more 
modest (possibly arguable) success with neutrophil-dominant disease. It is now known 
that glucocorticoids promote eosinophil apoptosis but actually prolong neutrophil 
survival (Heasman et al. 2003;Sivertson et al. 2007;Ward et al. 1999). The latter effect 
is, presumably, partially compensated by glucocorticoid-mediated, enhanced 
macrophage phagocytosis of apoptotic neutrophils (Heasman et al. 2003). Additionally, 
designer anti-cytokine therapies like the anti-TNF- agents have aimed to remove the 
main constituents of ongoing inflammation. More recently, a movement towards 
specifically targeting the resolution phase of inflammation has been evident (Serhan et 
al. 2007). The key determinants of appropriate resolution of inflammation include 
removal of the inciting stimulus, controlled death (usually by apoptosis) of inflammatory 
leucocytes and removal of dead cells and debris by phagocytic cells. Indeed, the 
compound RX-10045 (a therapeutic based on the lipid mediator resolvin) which has 
multiple pro-resolution properties is likely to translate into routine clinical usage in the 
near future (www.resolvyx.com).   
 
The death by apoptosis of the early-responding and most abundant inflammatory 
leucocyte, the neutrophil, has been identified as a key step in the resolution of 
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inflammation (Hallett et al. 2008b;Haslett 1999). It is a key step not just because it 
removes a potentially injurious cell population (Kobayashi et al. 2003;Koedel et al. 
2009) but because a pro-resolution signal is sent by both the process of apoptosis 
(Perretti et al. 2004;Scannell et al. 2007a;Voll et al. 1997) and the phagocytic removal of 
apoptotic cells (Fadok et al. 1998;Voll et al. 1997). The proof of concept experiment, 
delivery of apoptotic cells to mice subjected to LPS-induced inflammation as a pro-
resolution therapeutic powerfully demonstrated the potential for treatment of 
inflammation driven disease (Huynh et al. 2002;Ren et al. 2008). 
 
In keeping with this finding CDK inhibitor drugs were shown to drive neutrophil 
apoptosis and to promote resolution of inflammation (Rossi et al. 2006). These drugs 
were developed as anti-cancer therapeutics as they inhibit CDKs which are master-
regulators of the cell-cycle (Knockaert et al. 2002;Senderowicz 2003). This mechanism 
of action was not directly translatable to neutrophils as they are non-proliferating, 
terminally differentiated cells. Indeed, the only other terminally differentiated cells 
treated with these drugs, neuronal cells, have been shown to respond with enhanced 
longevity (Blondel et al. 2007). The over-arching aim of this thesis is to determine the 
mechanism by which cyclin-dependent kinase inhibitor drugs promote neutrophil 
apoptosis. 
 
The first results chapter (chapter 3) addresses the pharmacokinetics of CDK inhibitor-
driven neutrophil apoptosis and investigates established molecular mechanisms of 
neutrophil apoptosis in order to provide a framework for further characterisation of 
underlying mechanism. In this chapter I have determined the concentration of CDK 
inhibitor drug which will be investigated in the remainder of the thesis and have 
characterised the time-line of neutrophil death both constitutively and in the presence of 
CDK inhibitor drugs. This chapter shows conclusively that apoptosis is the primary 
mode of cell death induced by CDK inhibitor drugs and that necrosis only occurs after a 
time-delay as a secondary process. These findings are clearly demonstrated in figures 
3.1-3.3. I have implicated the caspase machinery in CDK inhibitor driven neutrophil 
                                                                                                                                           183
death and have shown that a key early step in this process is the loss of mitochondrial 
membrane integrity. Surprisingly given our earlier work which showed that direct 
inhibition of the key neutrophil survival signalling pathway NF-B was not applicable to 
the CDK inhibitor drug effect (Leitch et al. 2010b), I show that early apoptosis driven by 
TNF-is enhanced by CDK inhibition (figure 3.8). This finding along with loss of 
mitochondrial membrane integrity (figure 3.13), similar kinetics of apoptosis to protein 
synthesis inhibitor drugs (figure 3.5) and relevant findings in the literature implicated the 
down-regulation of a survival protein in the mechanism of apoptosis. 
 
The fourth chapter of this thesis pursues the hypothesis that a key survival protein is 
down-regulated in order to allow neutrophil apoptosis to proceed. It is already 
established in the literature that the pre-eminent neutrophil survival protein is the bcl-2 
homologue Mcl-1 (Dzhagalov et al. 2007a;Edwards et al. 2004b). In this chapter it is 
demonstrated that Mcl-1 is down-regulated by CDK inhibitor drugs even in the presence 
of inflammatory pro-survival signals. These data complement the chapter 3 finding that 
the enhancement of neutrophil longevity by pro-survival agents is overcome by CDK 
inhibitor drugs. In the reverse of this experiment preservation of Mcl-1 by 
pharmacological means (proteasome inhibition) delays the onset of CDK inhibitor drug 
induced apoptosis. It is shown that the balance of bcl-2 homologue signalling is tipped 
towards apoptosis by the persistence of key pro-apoptotic homologues (especially Bim) 
even in the presence of CDK inhibitor drugs. PCR for MCL-1 demonstrates that it is 
down-regulated at the level of transcription by CDK inhibitor drugs. This finding 
coupled with the similar kinetics of apoptosis of protein synthesis inhibitor drugs and 
pertinent findings in the literature related to the transcriptional roles of CDKs 2, 7 and 9 
instigated the investigation of an effect of CDK inhibitor drugs at the level of 
transcription in chapter 5. 
 
This chapter covers the identification and characterisation of the sub-cellular distribution 
of CDKs and binding partners within neutrophil granulocytes. CDKs are known to be 
subject to complex layers of regulation. This includes activation by binding partner 
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cyclins, inhibition by endogenous CDK inhibitors, phosphorylation by activating CDKs 
and other kinases, inhibitory binding and sequestration (7SK etc) and nucleo-
cytoplasmic shuttling. Initially the CDKs and cyclin binding partners known to fall 
within the well-characterised pharmacological specificity of R-roscovitine (the most 
extensively studied CDK inhibitor drug) are identified at protein and gene expression 
levels. The data generated in Chapter 2 and the expression data with regard to CDKs 7 
and 9 suggest that these may be key targets because of their known role in the process of 
transcription. These CDKs regulate transcription by phosphorylation of the C-terminal 
domain of RNA polymerase II. CDK7 phosphorylation at the key serine 2 residue allows 
transcription initiation to proceed while CDK9 phosphorylation at serine 2 and 5 allows 
transcript elongation. This is the first time the fundamental regulation of the key enzyme 
of eukaryotic mRNA transcription RNA polymerase II has been investigated in 
neutrophils. This provides evidence that the most important target of the CDK inhibitor 
R-roscovitine in the promotion of neutrophil apoptosis is the inhibition of the 
transcriptional role of CDKs 7 and 9. In order to further investigate this novel finding an 
assessment of the neutrophil transcriptome is performed at the constitutive level and in 
the presence of R-roscovitine. The gene expression data support the idea of CDK 
inhibition down-regulating transcription through effects on RNA polymerase II. In 
addition it appears that the transcripts regulated by CDK7 and 9 are signalling 
responsive, rapidly up/down-regulated genes many of which have key roles in 
transcription, apoptosis and inflammation. Additionally, this experiment increases the 
weight of evidence for a critical differential at the level of mRNA and protein between 
Mcl-1 and Bim that would shift neutrophil fate towards apoptosis.  
 
In Chapter 6 an attempt is made to devise a molecular biology strategy that would allow 
specific targeting of CDKs 7 and 9 in neutrophils to establish an alternative to 
pharmacological knockdown and to support the hypotheses and results generated in 
chapters 1-3. After consideration of the currently available strategies for targeted 
knockdown of proteins an attempt is made to develop a cell-delivery peptide based 
experiment where dominant-negative CDKs would be introduced into neutrophils. This 
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strategy was the most appealing because of the time-constraints imposed by limited 
neutrophil life-span and the known (and demonstrated) toxicity of lipid-based delivery 
agents. The production of HIV tat linked dominant negative CDKs proved a time-
consuming and difficult process. It was considerably hampered by the difficulties 
involved in isolating functional, pure protein from insoluble pellet fractions. It remains a 
work in progress. 
 
In Chapter 7 a more specific pharmacological inhibitor of CDKs 7 and 9 is shown to 
resolve neutrophil-dominant inflammation in the murine bleomycin lung injury model. 
This finding supports the in vitro data generated in chapters 1-3 that suggest the most 
important targets of the CDK inhibitor R-roscovitine are CDKs 7 and 9. In addition the 
use of i.t. administration demonstrates that a ten-fold reduction in dose is possible by a 
delivery method that is easily translatable to human therapeutics (e.g., inhalers, 
nebuliser). 
 
This thesis has added to the published literature on apoptotic mechanisms pertinent to 
neutrophil granulocytes by highlighting the importance of the anti-apoptotic bcl-2 
homologue survival protein Mcl-1 and the pro-apoptotic bcl-2 homologue Bim. This 
thesis increases the weight of evidence suggesting not only that neutrophil granulocytes 
are capable of de novo transcription but that this facility is indispensable to both 
constitutive and stimulated neutrophil survival. It is the first work to characterise the 
CDK machinery involved in the regulation of transcription by RNA polymerase II and to 
identify the presence and modulation by phosphorylation of this important holoenzyme 
in neutrophil granulocytes. In addition this thesis highlights the potential for selective 
modulation of transcriptional machinery towards the promotion of pro-resolution 
phenotypes not just in neutrophils but across a range of cell types. In particular the thesis 
shows how rapidly signal-responsive, upregulated genes involved in immune response, 
apoptosis and transcription can be down-regulated by inhibition of components of the 
transcriptional machinery. The thesis confirms that such specific inhibition of 
transcriptional machinery can promote resolution of inflammation in a murine model 
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without deleterious off-target effects.  In addition, the specific transcriptional effects 
demonstrated may explain the limited side effects associated with systemic delivery of 
CDK inhibitor drugs. Regardless, efficacious i.t. delivery in our murine experiments 
suggests that there is potential for the local delivery of CDK inhibitor drugs to sites of 
inflammation including the lungs via inhalation.  
 
The potential future application of CDK inhibitor drugs to the treatment of human 
inflammatory disease is a realistic prospect. The suitability of these agents for translation 
is in part shown by data in this thesis but also by the known side-effect profile that has 
emerged from their use in human clinical trials as cancer therapeutics. Our group has 
begun an experimental medicine trial of a CDK inhibitor drug in patients with IPF which 
will investigate multiple parameters of anti-inflammatory response including: reduction 
of BAL neutrophilia and change in PET signal as well as clinical parameters such as 
pulmonary function tests and exacerbation frequency. It is important in the assessment 
of potential anti-inflammatory agents that the anti-inflammatory/pro-resolution effects 
observed in animal models are achieved in humans (e.g., reduction in BAL neutrophil 
count) as well as assessing traditional measures of disease activity to allow a correct 
evaluation of the agent studied (Katharine et al. 2009). Other conditions that might 
benefit from clinical trial of these drugs include vasculitides (Gomez-Puerta et al. 2009) 
and resistant eosinophilic disorders (Duffin et al. 2009;Roufosse et al. 2010) where there 
is multi-system granulocyte-dominant inflammation. In these conditions 
immunosuppressive agents are already established as gold-standard therapies. A more 
controversial but potentially extremely rewarding use of these agents might be in the 
treatment of severe infections unresponsive to antibiotics and especially where ARDS 
supervenes. There is a precedent for the use of a CDK inhibitor drug as an apoptosis-
inducing agent in an infective condition provided by the study of bacterial meningitis by 
Koedel et al where R-roscovitine and an antibiotic were shown to promote better 
resolution of pathology than an antibiotic alone (Koedel et al. 2009). 
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This thesis highlights the difficulty inherent in the application of ‘standard’ molecular 
biology approaches to in vitro neutrophil experimentation. Further work will be required 
to successfully develop and utilise cell-permeable peptide delivery agents in the 
investigation of potential resolution of inflammation targets. In addition the development 
of lentiviral/siRNA tools for the manipulation of stimulated and hence longer-lived 
neutrophils may be a succesful alternative strategy. 
 
Further experiments that will enhance the work contained within this thesis will include:  
 
1. The application of models of inflammation to the myeloid MCL1-/- mouse. The 
MCL-1-/- mouse is relatively neutropenic and those neutrophils that are 
produced are short-lived. These experiments will determine the importance of 
Mcl-1 to neutrophils under inflammatory conditions. They will also afford the 
opportunity to dissect out the role of long-lived, activated neutrophils in causing 
inflammatory damage. 
2. An assessment of CDK inhibition on macrophage signalling and on the 
macrophage transcriptome using a bioinformatics based approach 
3. An assessment of CDK inhibition on fibroblast signalling and on the fibroblast 
transcriptome with a view to the investigation of models of aberrant wound 
healing/fibrogenesis (e.g. late-stage bleomycin lung injury) 
4. Alternative methods for generation of CDK-dn peptides- including mammalian 
cell based production and alternative isolation tags  
5. Alternative molecular biology techniques including lentiviral, siRNA 






                                                                                                                                           188
9 Concluding remarks 
 
This thesis identifies the key targets of the CDK inhibitor drugs to be CDKs 7 and 9 
which are responsible for the regulation of specific genes transcribed by RNA 
polymerase II, in particular the survival protein Mcl-1 which is critical for neutrophil 
survival (figure 8). Consequently, the thesis emphasises the importance of neutrophil 
apoptosis to the resolution of inflammation and supports the therapeutic trial of CDK 
inhibitor drugs in inflammatory disease. The potential for translation of these drugs or 
other targets identified in their investigation is exemplified by an experimental medicine 
trial of a CDK inhibitor drug for the treatment of patients with idiopathic pulmonary 
fibrosis which is in progress in our institute. The data in this thesis would support further 
application to neutrophil-dominant diseases that would include: ALI, exacerbation of 
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Figure 8: Model of CDK inhibitor drug inhibition of neutrophil 

























Figure 8: Survival signals promote CDK7 and 9 -dependent transcription of inflammatory cytokines and 
the survival protein, Mcl-1. Mcl-1 sequesters Bim in an inactivated state preventing apoptosis. When CDK 
inhibitor (CDKi) is present Bim is upregulated, Mcl-1 is no longer transcribed and Bim is able to activate 
Bax which leads to intrinsic pathway apoptosis with mitochondrial outer membrane permeabilisation in 
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